Anal Cancer, Bladder Cancer, Bone and Joint Cancer, Breast Cancer, Cancer, Chronic Pancreatitis, Diabetes, Epilepsy, Nervous System Cancer, Pain, Neuropathic, Pancreatic Cancer, Penis Cancer, Renal Cancer, Renal Cell Carcinoma, Renal Pelvis Cancer, Stomach Cancer
Conditions
Keywords
renal cancer, pancreatic cancer, epidemiology, renal cell carcinoma, nervous system cancer, lung cancer, breast cancer, case-control, GPRD, Gapabentin, cancer, anal cancer, bone and joint cancer, renal pelvis cancer, penis cancer, stomach cancer, bladder cancer
Brief summary
High doses of gabapentin are associated with pancreatic acinar cell tumors in rats, but there has been no post marketing pancreatic carcinogenicity signal with gabapentin as reported by spontaneous reports in AERS or in the published literature. In a published case-control screening study of the association of gabapentin with 55 cancers, the only cancer that met the screening criteria for possibly increased cancer risk with gabapentin exposure was renal (including renal pelvis) cancer. This association was judged to be likely due to or substantially accentuated by confounding by cigarette smoking, hypertension, and lifestyle (Cancer Causes Control 2009;20:1821-1835). The relationship between gabapentin exposure and pancreatic cancer and renal cancer is studied in NCT01138124, and supplemental analyses for these cancers are performed in the current study. The FDA recommended GSK also study the relationship between gabapentin and all-cancer sites, as well as cancer at the following specific sites: 1) stomach, 2) anus, anal canal, and anorectum, 3) lung and bronchus, 4) bones and joints, 5) breast, 6) penis, 7) urinary bladder, and 8) other nervous system. The primary objective of this study is to determine whether exposure to gabapentin is associated with an increased risk of developing all-cancer, and these specific cancers in the United Kingdom (UK) General Practice Research Database (GPRD). Each member of the UK population is registered with a General Practice, which centralizes the medical information not only from the general practitioners themselves but also from specialist referrals and hospital attendances. Over 487 General Practices contribute data to the GPRD. The study cohort from which cases and controls are drawn is all subjects in the GPRD 1993-2008. Gabapentin was approved in the UK in May 1993. Entry into the study cohort begins Jan 1, 1993 for all those who are registered in GPRD before that time, and at the time of registration if later than Jan 1, 1993. Subjects are excluded from the GPRD cohort if they have a cancer diagnosis or a history of cancer prior to the cohort entry date. Patients with a first diagnosis of the respective cancer 1995-2008 are risk set matched with up to 10 controls within the same General Practice for age at cohort entry (within two years), sex, and year of entry into the study cohort (within one year). For cases, the index date is the date of first diagnosis of the respective cancer. The index date for controls is set as the date at which the follow-up time from cohort entry is the same as the case. The index date is chosen so as to give the control equal follow-up time to that of the case for ascertainment of use of gabapentin. Cases and controls will be required to have at least 2 years of follow-up in the study cohort before their index date. Cases must have no history of any other cancer diagnosis prior to the index date. Controls are required to be free of cancer diagnosis in the database up to the control's index date. Data on gabapentin prescriptions are obtained for cases and controls from study cohort entry to the index date. Gabapentin exposure will be assessed as ever/never, number of prescriptions, cumulative dose, and cumulative duration, with a 2 year lag period incorporated to control for protopathic bias (gabapentin prescription for initial pain symptoms of undiagnosed cancer) and latency (time between cancer onset and specific GPRD cancer diagnosis). Crude and adjusted odds ratios and 95% confidence intervals (CI) will be produced from conditional logistic regression models, with additional analyses evaluating for dose-response. Covariates include indications for gabapentin use and risk factors for each cancer.
Detailed description
Actual number of patients may be less, as it is possible for a patient to be represented in more than one of the 22 arms (See Participant Flow: Overall Study Table) because of the risk set sampling.
Interventions
The exposure of interest is gabapentin use as defined by prescriptions recorded by the GPRD general practitioner (British National Formulry codes). Data on prescriptions for gabapentin will be extracted for each case and control from entry into the study cohort up to two years prior to the index date (the exposure window). A two year lagged exposure is incorporated to account for latency between cancer onset and GPRD diagnosis, and for protopathic bias (gabapentin prescription for initial pain symptoms of undiagnosed cancer). Gabapentin exposure will be parameterized as follows: (1) Ever versus never exposed; (2) Number of prescriptions; (3) Duration of exposure; and (4) Cumulative dose.
Sponsors
GlaxoSmithKline
Study design
Observational model
CASE_CONTROL
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
* The study cohort from which cases and controls are drawn is all subjects in the UK GPRD 1993-2008. Entry into the study cohort begins Jan 1, 1993 for all those who are registered in GPRD before that time, and at the time of registration if later than Jan 1, 1993. Follow-up ends Dec 31, 2008, or earlier if the subject leaves the GPRD for any reason including death.
Exclusion criteria
* Subjects are excluded from the GPRD cohort if they have a cancer diagnosis or a history of cancer prior to the cohort entry date. Cases and controls will be required to have at least 2 years of follow-up in the study cohort before their index date (For cases, the index date is the date of first diagnosis of the respective cancer. The index date for controls is set as the date at which the follow-up time from cohort entry is the same as the case.) Cases must have no history of any other cancer diagnosis prior to the index date. Controls are required to be free of cancer diagnosis in the database up to the control's index date.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of All-Cancer Cases and Matched Controls With the Indicated Exposure to Gabapentin | The case index date was the date of incident cancer diagnosis ascertained in the GPRD study cohort 1995-2008. The matched control index date was the date at which the follow-up time from his/her cohort entry was the same as that for the case. | Incidence of all cancers. Gabapentin Exposure Description: Without 2 year lag = Gabapentin prescription from cohort entry to index date. With 2 year lag = Gabapentin prescription from cohort entry to 2 years prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer). |
| Number of All-Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions | The case index date was the date of incident cancer diagnosis ascertained in the GPRD study cohort 1995-2008. The matched control index date was the date at which the follow-up time from his/her cohort entry was the same as that for the case. | Incidence of all cancers. Gabapentin Exposure Description: With 2 year lag = Gabapentin exposure from cohort entry to 2 years prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer). Without 2 year lag = Gabapentin exposure from cohort entry to index date. Tertile's with 2 year lag: Tertile 1 (1-2 prescriptions), Tertile 2 (3-7 prescriptions), Tertile 3 (8-298 prescriptions). Tertiles without 2 year lag: Tertile 1 (1-2 prescriptions), Tertile 2 (3-7 prescriptions), and Tertile 3 (8-388 prescriptions). |
| Number of All-Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin | The case index date was the date of incident cancer diagnosis ascertained in the GPRD study cohort 1995-2008. The matched control index date was the date at which the follow-up time from his/her cohort entry was the same as that for the case. | Incidence of all cancers. Gabapentin Exposure Description: With 2 year lag = Gabapentin exposure from cohort entry to 2 years prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer). Without 2 year lag = Gabapentin exposure from cohort entry to index date. Tertile's with 2 year lag: Tertile 1 (0.01 - 1.38 months), Tertile 2 (1.39 - 5.56 months), and Tertile 3 (5.57 - 105.82 months). Tertile's without 2 year lag: Tertile 1 (0.01 - 1.38 months), Tertile 2 (1.39 - 5.72 months), and Tertile 3 (5.73 - 123.70 months). |
| Number of All-Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin | The case index date was the date of incident cancer diagnosis ascertained in the GPRD study cohort 1995-2008. The matched control index date was the date at which the follow-up time from his/her cohort entry was the same as that for the case. | Incidence of all cancers. Gabapentin Exposure Description: With 2 year lag = Gabapentin exposure from cohort entry to 2 years prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer). Without 2 year lag = Gabapentin exposure from cohort entry to index date. |
| Number of All-Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin | The case index date was the date of incident cancer diagnosis ascertained in the GPRD study cohort 1995-2008. The matched control index date was the date at which the follow-up time from his/her cohort entry was the same as that for the case. | Incidence of all cancers. Gabapentin Exposure Description: With 2 year lag = Gabapentin exposure from cohort entry to 2 years prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer). Without 2 year lag = Gabapentin exposure from cohort entry to index date. Tertile's with 2 year lag: Tertile 1 (0.1 - 30.0 grams), Tertile 2 (30.1 - 189.0 grams), and Tertile 3 (189.1 - 9600.0 grams). Tertile's without 2 year lag: Tertile 1 (0.1 - 30.0 grams), Tertile 2 (30.1 - 189.0 grams), and Tertile 3 (189.1 - 11610.0 grams). |
| Number of Stomach Cancer Cases and Matched Controls With the Indicated Exposure to Gabapentin | The case index date was the date of incident stomach cancer diagnosis ascertained in the GPRD study cohort 1995-2008. The matched control index date was the date at which the follow-up time from his/her cohort entry was the same as that for the case | Incident stomach cancer. Gabapentin Exposure Description: With 2 year lag = Gabapentin prescription from cohort entry to 2 years prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer). Without 2 year lag = Gabapentin prescription from cohort entry to index date. |
| Number of Stomach Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions | The case index date was the date of incident stomach cancer diagnosis ascertained in the GPRD study cohort 1995-2008. The matched control index date was the date at which the follow-up time from his/her cohort entry was the same as that for the case | Incident stomach cancer. Gabapentin (Gaba.) Exposure Description: With 2 year (yr) lag=Gaba. exposure from cohort entry to 2 yr prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer). Without 2 yr lag=Gaba. exposure from cohort entry to index date. Tertiles (T) with 2 yr lag: T 1 (1-2 prescriptions \[prescrip\]), T 2 (3-7 prescrip), T 3 (8-298 prescrip). Tertiles without 2 yr lag: T 1 (1-2 prescrip), T 2 (3-7 prescrip), and T 3 (8-388 prescrip). Inestimable OR and 95% CI when no gaba.-exposed cancer cases or controls at the exposure level. |
| Number of Stomach Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin | The case index date was the date of incident stomach cancer diagnosis ascertained in the GPRD study cohort 1995-2008. The matched control index date was the date at which the follow-up time from his/her cohort entry was the same as that for the case | Incident stomach cancer. Gabapentin (Gaba.) Exposure Description: With 2 year (yr) lag=Gaba. exposure from cohort entry to 2 yr prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer). Without 2 yr lag=Gaba. exposure from cohort entry to index date. Tertiles (T) with 2 yr lag: T 1 (0.01-1.38 months \[mo.\]), T 2 (1.3-5.56 mo.), and T 3 (5.57-105.82 mo.). Tertiles without 2 yr lag: T 1 (0.01-1.38 m.), T 2 (1.39-5.72 mo.), and T 3 (5.73-123.70 mo.). Inestimable OR and 95% CI when no gaba.-exposed cancer cases or controls at the exposure level. |
| Number of Stomach Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin | The case index date was the date of incident stomach cancer diagnosis ascertained in the GPRD study cohort 1995-2008. The matched control index date was the date at which the follow-up time from his/her cohort entry was the same as that for the case | Incident stomach cancer. Gabapentin Exposure Description: With 2 year lag = Gabapentin exposure from cohort entry to 2 years prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer). Without 2 year lag = Gabapentin exposure from cohort entry to index date. |
| Number of Stomach Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin | The case index date was the date of incident stomach cancer diagnosis ascertained in the GPRD study cohort 1995-2008. The matched control index date was the date at which the follow-up time from his/her cohort entry was the same as that for the case | Incident stomach cancer. Gabapentin (Gaba.) Exposure Description: With 2 year (yr) lag=Gabapentin exposure from cohort entry to 2 years prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer). Without 2 yr lag=Gaba. exposure from cohort entry to index date. Tertiles (T) with 2 yr lag: T 1 (0.1-30.0 grams \[g\]), T 2 (30.1-189.0 g), and T 3 (189.1-9600.0 g). Tertiles without 2 yr lag: T 1 (0.1-30.0 g), T 2 (30.1-189.0 g), and T 3 (189.1-11610.0 g). Inestimable OR and 95% CI when no gaba.-exposed cancer cases or controls at the exposure level. |
| Number of Anal Cancer Cases and Matched Controls With the Indicated Exposure to Gabapentin | The case index date was the date of incident anal cancer diagnosis ascertained in the GPRD study cohort 1995-2008. The matched control index date was the date at which the follow-up time from his/her cohort entry was the same as that for the case. | Incident Anal cancer. Gabapentin Exposure Description: With 2 year lag = Gabapentin prescription from cohort entry to 2 years prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer). Without 2 year lag = Gabapentin prescription from cohort entry to index date. |
| Number of Anal Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions | The case index date was the date of incident anal cancer diagnosis ascertained in the GPRD study cohort 1995-2008. The matched control index date was the date at which the follow-up time from his/her cohort entry was the same as that for the case. | Incident anal cancer. Gabapentin (Gaba.) Exposure Description: With 2 year (yr) lag=Gaba. exposure from cohort entry to 2 yr prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer). Without 2 yr lag=Gaba. exposure from cohort entry to index date. Tertiles (T) with 2 yr lag: T 1 (1-2 prescriptions \[prescrip.\]), T 2 (3-7 prescrip.), T 3 (8-298 prescrip.). Tertiles without 2 yr lag: T 1 (1-2 prescrip.), T 2 (3-7 prescrip.), and T 3 (8-388 prescrip.). Inestimable OR and 95% CI when no gaba.-exposed cancer cases or controls at the exposure level. |
| Number of Anal Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin | The case index date was the date of incident anal cancer diagnosis ascertained in the GPRD study cohort 1995-2008. The matched control index date was the date at which the follow-up time from his/her cohort entry was the same as that for the case. | Incident anal cancer. Gabapentin (Gaba.) Exposure Description: With 2 year (yr) lag=Gaba. exposure from cohort entry to 2 yr prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer). Without 2 yr lag=Gaba. exposure from cohort entry to index date. Tertiles (T) with 2 yr lag: T 1 (0.01-1.38 months \[mo.\]), T 2 (1.39-5.56 mo.), and T 3 (5.57 -105.82 mo.). Tertiles without 2 yr lag: T 1 (0.01-1.38 mo.), T 2 (1.39-5.72 mo.), and T 3 (5.73-123.70 mo.). Inestimable OR and 95% CI when no gaba.-exposed cancer cases or controls at the exposure level. |
| Number of Anal Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin | The case index date was the date of incident anal cancer diagnosis ascertained in the GPRD study cohort 1995-2008. The matched control index date was the date at which the follow-up time from his/her cohort entry was the same as that for the case. | Incident anal cancer. Gabapentin Exposure Description: With 2 year lag = Gabapentin exposure from cohort entry to 2 years prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer). Without 2 year lag = Gabapentin exposure from cohort entry to index date. |
| Number of Anal Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin | The case index date was the date of incident anal cancer diagnosis ascertained in the GPRD study cohort 1995-2008. The matched control index date was the date at which the follow-up time from his/her cohort entry was the same as that for the case. | Incident anal cancer. Gabapentin (Gaba.) Exposure Description: With 2 yr lag=Gaba. exposure from cohort entry to 2 yr prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer). Without 2 yr lag=Gaba. exposure from cohort entry to index date. Tertiles (T) with 2 yr lag: T 1 (0.1-30.0 grams \[g\]), T 2 (30.1-189.0 g), and T 3 (189.1-9600.0 g). Tertiles without 2 yr lag: T 1 (0.1-30.0 g), T 2 (30.1-189.0 g), and T 3 (189.1-11610.0 g). Inestimable OR and 95% CI when no gaba.-exposed cancer cases or controls at the exposure level. |
| Number of Lung Cancer Cases and Matched Controls With the Indicated Exposure to Gabapentin | The case index date was the date of incident lung cancer diagnosis ascertained in the GPRD study cohort 1995-2008. The matched control index date was the date at which the follow-up time from his/her cohort entry was the same as that for the case. | Incident lung cancer. Gabapentin Exposure Description: With 2 year lag = Gabapentin prescription from cohort entry to 2 years prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer). Without 2 year lag = Gabapentin prescription from cohort entry to index date. |
| Number of Lung Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions | The case index date was the date of incident lung cancer diagnosis ascertained in the GPRD study cohort 1995-2008. The matched control index date was the date at which the follow-up time from his/her cohort entry was the same as that for the case. | Incident lung cancer. Gabapentin Exposure Description: With 2 year lag = Gabapentin exposure from cohort entry to 2 years prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer). Without 2 year lag = Gabapentin exposure from cohort entry to index date. Tertile's with 2 year lag: Tertile 1 (1-2 prescriptions), Tertile 2 (3-7 prescriptions), Tertile 3 (8-298 prescriptions). Tertiles without 2 year lag: Tertile 1 (1-2 prescriptions), Tertile 2 (3-7 prescriptions), and Tertile 3 (8-388 prescriptions). |
| Number of Lung Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin | The case index date was the date of incident lung cancer diagnosis ascertained in the GPRD study cohort 1995-2008. The matched control index date was the date at which the follow-up time from his/her cohort entry was the same as that for the case. | Incident lung cancer. Gabapentin Exposure Description: With 2 year lag = Gabapentin exposure from cohort entry to 2 years prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer). Without 2 year lag = Gabapentin exposure from cohort entry to index date. Tertile's with 2 year lag: Tertile 1 (0.01 - 1.38 months), Tertile 2 (1.39 - 5.56 months), and Tertile 3 (5.57 - 105.82 months). Tertile's without 2 year lag: Tertile 1 (0.01 - 1.38 months), Tertile 2 (1.39 - 5.72 months), and Tertile 3 (5.73 - 123.70 months). |
| Number of Lung Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin | The case index date was the date of incident lung cancer diagnosis ascertained in the GPRD study cohort 1995-2008. The matched control index date was the date at which the follow-up time from his/her cohort entry was the same as that for the case. | Incident lung cancer. Gabapentin Exposure Description: With 2 year lag = Gabapentin exposure from cohort entry to 2 years prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer). Without 2 year lag = Gabapentin exposure from cohort entry to index date. |
| Number of Lung Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin | The case index date was the date of incident lung cancer diagnosis ascertained in the GPRD study cohort 1995-2008. The matched control index date was the date at which the follow-up time from his/her cohort entry was the same as that for the case. | Incident lung cancer. Gabapentin Exposure Description: With 2 year lag = Gabapentin exposure from cohort entry to 2 years prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer). Without 2 year lag = Gabapentin exposure from cohort entry to index date. Tertile's with 2 year lag: Tertile 1 (0.1 - 30.0 grams), Tertile 2 (30.1 - 189.0 grams), and Tertile 3 (189.1 - 9600.0 grams). Tertile's without 2 year lag: Tertile 1 (0.1 - 30.0 grams), Tertile 2 (30.1 - 189.0 grams), and Tertile 3 (189.1 - 11610.0 grams). |
| Number of Bone/Joint Cancer Cases and Matched Controls With the Indicated Exposure to Gabapentin | The case index date was the date of incident bone/joint cancer diagnosis ascertained in the GPRD study cohort 1995-2008. The matched control index date was the date at which the follow-up time from his/her cohort entry was the same as for the case. | Incident bone/joint cancer. Gabapentin Exposure Description: With 2 year lag = Gabapentin prescription from cohort entry to 2 years prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer). Without 2 year lag = Gabapentin prescription from cohort entry to index date. Inestimable OR and 95% CI when no gabapentin-exposed cancer cases or no gabapentin-exposed controls at the exposure level. |
| Number of Bone/Joint Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions | The case index date was the date of incident bone/joint cancer diagnosis ascertained in the GPRD study cohort 1995-2008. The matched control index date was the date at which the follow-up time from his/her cohort entry was the same as for the case. | Incident bone/joint cancer. Gabapentin (Gaba.) Exposure Description: With 2 year (yr) lag=Gaba. exposure from cohort entry to 2 yr prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer). Without 2 yr lag=Gaba. exposure from cohort entry to index date. Tertiles (T) with 2 yr lag: T 1 (1-2 prescriptions \[prescrip.\]), T 2 (3-7 prescrip.), T 3 (8-298 prescrip.). Tertiles without 2 yr lag: T 1 (1-2 prescrip.), T 2 (3-7 prescrip.), and T 3 (8-388 prescrip.). Inestimable OR and 95% CI when no gaba.-exposed cases or controls at the exposure level. |
| Number of Bone/Joint Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin | The case index date was the date of incident bone/joint cancer diagnosis ascertained in the GPRD study cohort 1995-2008. The matched control index date was the date at which the follow-up time from his/her cohort entry was the same as for the case. | Incident bone/joint cancer. Gabapentin (Gaba.) Exposure Description: With 2 year (yr) lag=Gaba. exposure from cohort entry to 2 yr prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer). Without 2 yr lag=Gaba. exposure from cohort entry to index date. Tertiles (T) with 2 yr lag: T 1 (0.01-1.38 months \[mo.\]), T 2 (1.39-5.56 mo.), and T 3 (5.57-105.82 mo.). Tertiles without 2 yr lag: T 1 (0.01-1.38 mo.), T 2 (1.39-5.72 mo.), and T 3 (5.73-123.70 mo.). Inestimable OR and 95% CI when no gaba.-exposed cases or controls at the exposure level. |
| Number of Bone/Joint Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin | The case index date was the date of incident bone/joint cancer diagnosis ascertained in the GPRD study cohort 1995-2008. The matched control index date was the date at which the follow-up time from his/her cohort entry was the same as for the case. | Incident bone/joint cancer. Gabapentin Exposure Description: With 2 year lag = Gabapentin exposure from cohort entry to 2 years prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer). Without 2 year lag = Gabapentin exposure from cohort entry to index date. |
| Number of Bone/Joint Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin | The case index date was the date of incident bone/joint cancer diagnosis ascertained in the GPRD study cohort 1995-2008. The matched control index date was the date at which the follow-up time from his/her cohort entry was the same as for the case. | Incident bone/joint cancer. Gabapentin (Gaba.) Exposure Description: With 2 year (yr) lag=Gaba. exposure from cohort entry to 2 yr prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer). Without 2 yr lag=Gaba. exposure from cohort entry to index date. Tertiles (T) with 2 yr lag: T 1 (0.1-30.0 grams \[g\]), T 2 (30.1-189.0 g), and T 3 (189.1-9600.0 g). Tertiles without 2 yr lag: T 1 (0.1-30.0 g), T 2 (30.1-189.0 g), and T 3 (189.1-11610.0 g). Inestimable OR and 95% CI when no gaba.-exposed cancer cases or controls at the exposure level. |
| Number of Breast Cancer Cases and Matched Controls With the Indicated Exposure to Gabapentin | The case index date was the date of incident breast cancer diagnosis ascertained in the GPRD study cohort 1995-2008. The matched control index date was the date at which the follow-up time from his/her cohort entry was the same as that for the case. | Incident breast cancer. Gabapentin Exposure Description: With 2 year lag = Gabapentin prescription from cohort entry to 2 years prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer). Without 2 year lag = Gabapentin prescription from cohort entry to index date. |
| Number of Breast Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions | The case index date was the date of incident breast cancer diagnosis ascertained in the GPRD study cohort 1995-2008. The matched control index date was the date at which the follow-up time from his/her cohort entry was the same as that for the case. | Incident breast cancer. Gabapentin Exposure Description: With 2 year lag = Gabapentin exposure from cohort entry to 2 years prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer). Without 2 year lag = Gabapentin exposure from cohort entry to index date. Tertile's with 2 year lag: Tertile 1 (1-2 prescriptions), Tertile 2 (3-7 prescriptions), Tertile 3 (8-298 prescriptions). Tertiles without 2 year lag: Tertile 1 (1-2 prescriptions), Tertile 2 (3-7 prescriptions), and Tertile 3 (8-388 prescriptions). |
| Number of Breast Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin | The case index date was the date of incident breast cancer diagnosis ascertained in the GPRD study cohort 1995-2008. The matched control index date was the date at which the follow-up time from his/her cohort entry was the same as that for the case. | Incident breast cancer. Gabapentin Exposure Description: With 2 year lag = Gabapentin exposure from cohort entry to 2 years prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer). Without 2 year lag = Gabapentin exposure from cohort entry to index date. Tertile's with 2 year lag: Tertile 1 (0.01 - 1.38 months), Tertile 2 (1.39 - 5.56 months), and Tertile 3 (5.57 - 105.82 months). Tertile's without 2 year lag: Tertile 1 (0.01 - 1.38 months), Tertile 2 (1.39 - 5.72 months), and Tertile 3 (5.73 - 123.70 months). |
| Number of Breast Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin | The case index date was the date of incident breast cancer diagnosis ascertained in the GPRD study cohort 1995-2008. The matched control index date was the date at which the follow-up time from his/her cohort entry was the same as that for the case. | Incident breast cancer. Gabapentin Exposure Description: With 2 year lag = Gabapentin exposure from cohort entry to 2 years prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer). Without 2 year lag = Gabapentin exposure from cohort entry to index date. |
| Number of Breast Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin | The case index date was the date of incident breast cancer diagnosis ascertained in the GPRD study cohort 1995-2008. The matched control index date was the date at which the follow-up time from his/her cohort entry was the same as that for the case. | Incident breast cancer. Gabapentin Exposure Description: With 2 year lag = Gabapentin exposure from cohort entry to 2 years prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer). Without 2 year lag = Gabapentin exposure from cohort entry to index date. Tertile's with 2 year lag: Tertile 1 (0.1 - 30.0 grams), Tertile 2 (30.1 - 189.0 grams), and Tertile 3 (189.1 - 9600.0 grams). Tertile's without 2 year lag: Tertile 1 (0.1 - 30.0 grams), Tertile 2 (30.1 - 189.0 grams), and Tertile 3 (189.1 - 11610.0 grams). |
| Number of Penile Cancer Cases and Matched Controls With the Indicated Exposure to Gabapentin | The case index date was the date of incident penile cancer diagnosis ascertained in the GPRD study cohort 1995-2008. The matched control index date was the date at which the follow-up time from his/her cohort entry was the same as that for the case. | Incident penile cancer. Gabapentin Exposure Description: With 2 year lag = Gabapentin prescription from cohort entry to 2 years prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer). Without 2 year lag = Gabapentin prescription from cohort entry to index date. |
| Number of Penile Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions | The case index date was the date of incident penile cancer diagnosis ascertained in the GPRD study cohort 1995-2008. The matched control index date was the date at which the follow-up time from his/her cohort entry was the same as that for the case. | Incident penile cancer. Gabapentin (Gaba.) Exposure Description: With 2 year (yr) lag=Gaba. exposure from cohort entry to 2 yr prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer). Without 2 yr lag=Gaba. exposure from cohort entry to index date. Tertiles (T) with 2 yr lag: T 1 (1-2 prescriptions \[prescrip.\]), T 2 (3-7 prescrip.), T 3 (8-298 prescrip.). Tertiles without 2 yr lag: T 1 (1-2 prescrip.), T 2 (3-7 prescrip.), and T 3 (8-388 prescrip.). Inestimable OR/95% CI when no gaba.-exposed cancer cases or controls at the exposure level. |
| Number of Penile Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin | The case index date was the date of incident penile cancer diagnosis ascertained in the GPRD study cohort 1995-2008. The matched control index date was the date at which the follow-up time from his/her cohort entry was the same as that for the case. | Incident penile cancer. Gabapentin (Gaba.) Exposure Description: With 2 year (yr) lag=Gaba. exposure from cohort entry to 2 yr prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer). Without 2 yr lag=Gaba. exposure from cohort entry to index date. Tertiles (T) with 2 yr lag: T 1 (0.01-1.38 months \[mo.\]), T 2 (1.39-5.56 mo.), and T 3 (5.57-105.82 mo.). Tertiles without 2 yr lag: T 1 (0.01-1.38 mo.), T 2 (1.39-5.72 mo.), and T 3 (5.73-123.70 mo.). Inestimable OR and 95% CI when no gaba.-exposed cancer cases or controls at the exposure level. |
| Number of Penile Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin | The case index date was the date of incident penile cancer diagnosis ascertained in the GPRD study cohort 1995-2008. The matched control index date was the date at which the follow-up time from his/her cohort entry was the same as that for the case. | Incident penile cancer. Gabapentin Exposure Description: With 2 year lag = Gabapentin exposure from cohort entry to 2 years prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer). Without 2 year lag = Gabapentin exposure from cohort entry to index date. |
| Number of Penile Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin | The case index date was the date of incident penile cancer diagnosis ascertained in the GPRD study cohort 1995-2008. The matched control index date was the date at which the follow-up time from his/her cohort entry was the same as that for the case. | Incident penile cancer. Gabapentin (Gaba.) Exposure Description: With 2 year (yr) lag=Gaba. exposure from cohort entry to 2 yr prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer). Without 2 yr lag=Gaba. exposure from cohort entry to index date. Tertiles (T) with 2 yr lag: T 1 (0.1-30.0 grams \[g\]), T 2 (30.1-189.0 g), and T 3 (189.1-9600.0 g). Tertiles without 2 yr lag: T 1 (0.1-30.0 g), T 2 (30.1-189.0 g), and T 3 (189.1-11610.0 g). Inestimable OR and 95% CI when no gaba.-exposed cancer cases or controls at the exposure level. |
| Number of Bladder Cancer Cases and Matched Controls With the Indicated Exposure to Gabapentin | The case index date was the date of incident bladder cancer diagnosis ascertained in the GPRD study cohort 1995-2008. The matched control index date was the date at which the follow-up time from his/her cohort entry was the same as that for the case | Incident bladder cancer. Gabapentin Exposure Description: With 2 year lag = Gabapentin prescription from cohort entry to 2 years prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer). Without 2 year lag = Gabapentin prescription from cohort entry to index date. |
| Number of Bladder Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions | The case index date was the date of incident bladder cancer diagnosis ascertained in the GPRD study cohort 1995-2008. The matched control index date was the date at which the follow-up time from his/her cohort entry was the same as that for the case | Incident bladder cancer. Gabapentin Exposure Description: With 2 year lag = Gabapentin exposure from cohort entry to 2 years prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer). Without 2 year lag = Gabapentin exposure from cohort entry to index date. Tertile's with 2 year lag: Tertile 1 (1-2 prescriptions), Tertile 2 (3-7 prescriptions), Tertile 3 (8-298 prescriptions). Tertiles without 2 year lag: Tertile 1 (1-2 prescriptions), Tertile 2 (3-7 prescriptions), and Tertile 3 (8-388 prescriptions). |
| Number of Bladder Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin | The case index date was the date of incident bladder cancer diagnosis ascertained in the GPRD study cohort 1995-2008. The matched control index date was the date at which the follow-up time from his/her cohort entry was the same as that for the case | Incident bladder cancer. Gabapentin Exposure Description: With 2 year lag = Gabapentin exposure from cohort entry to 2 years prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer). Without 2 year lag = Gabapentin exposure from cohort entry to index date. Tertile's with 2 year lag: Tertile 1 (0.01 - 1.38 months), Tertile 2 (1.39 - 5.56 months), and Tertile 3 (5.57 - 105.82 months). Tertile's without 2 year lag: Tertile 1 (0.01 - 1.38 months), Tertile 2 (1.39 - 5.72 months), and Tertile 3 (5.73 - 123.70 months). |
| Number of Bladder Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin | The case index date was the date of incident bladder cancer diagnosis ascertained in the GPRD study cohort 1995-2008. The matched control index date was the date at which the follow-up time from his/her cohort entry was the same as that for the case | Incident bladder cancer. Gabapentin Exposure Description: With 2 year lag = Gabapentin exposure from cohort entry to 2 years prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer). Without 2 year lag = Gabapentin exposure from cohort entry to index date. |
| Number of Bladder Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin | The case index date was the date of incident bladder cancer diagnosis ascertained in the GPRD study cohort 1995-2008. The matched control index date was the date at which the follow-up time from his/her cohort entry was the same as that for the case | Incident bladder cancer. Gabapentin Exposure Description: With 2 year lag = Gabapentin exposure from cohort entry to 2 years prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer). Without 2 year lag = Gabapentin exposure from cohort entry to index date. Tertile's with 2 year lag: Tertile 1 (0.1 - 30.0 grams), Tertile 2 (30.1 - 189.0 grams), and Tertile 3 (189.1 - 9600.0 grams). Tertile's without 2 year lag: Tertile 1 (0.1 - 30.0 grams), Tertile 2 (30.1 - 189.0 grams), and Tertile 3 (189.1 - 11610.0 grams). |
| Number of Other Nervous System Cancer Cases and Matched Controls With the Indicated Exposure to Gabapentin | The case index date was the date of incident other nervous system cancer diagnosis ascertained in the GPRD study cohort 1995-2008. The matched control index date was the date at which the follow-up time from his cohort entry was the same as case. | Incident other nervous system cancer. Gabapentin Exposure Description: With 2 year lag = Gabapentin prescription from cohort entry to 2 years prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer). Without 2 year lag = Gabapentin prescription from cohort entry to index date. Inestimable OR and 95% CI when no gabapentin-exposed cancer cases or no gabapentin-exposed controls at the exposure level. |
| Number of Other Nervous System (ONS) Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions | The case index date was the date of incident other nervous system cancer diagnosis ascertained in the GPRD study cohort 1995-2008. The matched control index date was the date at which the follow-up time from his cohort entry was same as for case. | Incident ONS cancer. Gabapentin (Gaba.) Exposure Description: With 2 year (yr) lag=Gaba. exposure from cohort entry to 2 yr prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer). Without 2 yr lag=Gaba. exposure from cohort entry to index date. Tertiles (T) with 2 yr lag: T 1 (1-2 prescriptions \[prescrip.\]), T 2 (3-7 prescrip.), T 3 (8-298 prescrip.). Tertiles without 2 yr lag: T 1 (1-2 prescrip.), T 2 (3-7 prescrip.), and T 3 (8-388 prescrip.). Inestimable OR and 95% CI when no gaba.-exposed cancer cases or controls at the exposure level. |
| Number of Other Nervous System (ONS) Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin | The case index date was the date of incident other nervous system cancer diagnosis ascertained in the GPRD study cohort 1995-2008. The matched control index date was the date at which the follow-up time from his/her cohort entry was same as for case | Incident ONS cancer. Gabapentin (Gaba.) Exposure Description: With 2 yr lag=Gaba. exposure from cohort entry to 2 yr prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer). Without 2 yr lag=Gaba. exposure from cohort entry to index date. Tertiles (T) with 2 yr lag: T 1 (0.01-1.38 months \[mo.\]), T 2 (1.39-5.56 mo.), and T 3 (5.57-105.82 mo.). Tertiles without 2 yr lag: T 1 (0.01-1.38 mo.), T 2 (1.39-5.72 mo.), and T 3 (5.73-123.70 mo.). Inestimable OR and 95% CI when no gaba.-exposed cancer cases or controls at the exposure level. |
| Number of Other Nervous System Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin | The case index date was the date of incident other nervous system cancer diagnosis ascertained in the GPRD study cohort 1995-2008. The matched control index date was the date at which the follow-up time from his/her cohort entry was same as for case | Incident other nervous system cancer. Gabapentin Exposure Description: With 2 year lag = Gabapentin exposure from cohort entry to 2 years prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer). Without 2 year lag = Gabapentin exposure from cohort entry to index date. |
| Number of Other Nervous System (ONS) Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin | The case index date was the date of incident other nervous system cancer diagnosis ascertained in the GPRD study cohort 1995-2008. The matched control index date was the date at which the follow-up time from his/her cohort entry was same as for case | Incident ONS cancer. Gabapentin (Gaba.) Exposure Description: With 2 year (yr) lag=Gaba. exposure from cohort entry to 2 yr prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer). Without 2 yr lag=Gaba. exposure from cohort entry to index date. Tertiles (T) with 2 yr lag: T 1 (0.1-30.0 grams \[g\]), T 2 (30.1-189.0 g), and T 3 (189.1-9600.0 g). Tertiles without 2 yr lag: T 1 (0.1-30.0 g), T 2 (30.1-189.0 g), and T 3 (189.1-11610.0 g). Inestimable OR and 95% CI when no gaba.-exposed cancer cases or controls at the exposure level. |
| Number of Pancreatic Cancer Cases and Matched Controls With the Indicated Exposure to Gabapentin | The case index date was the date of incident pancreatic cancer diagnosis ascertained in the GPRD study cohort 1995-2008. The matched control index date was the date at which the follow-up time from his/her cohort entry was the same as for the case. | Incident pancreatic cancer. Gabapentin Exposure Description: With 2 year lag = Gabapentin prescription from cohort entry to 2 years prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer). Without 2 year lag = Gabapentin prescription from cohort entry to index date. |
| Number of Pancreatic Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions | The case index date was the date of incident pancreatic cancer diagnosis ascertained in the GPRD study cohort 1995-2008. The matched control index date was the date at which the follow-up time from his/her cohort entry was the same as for the case. | Incident pancreatic cancer. Gabapentin Exposure Description: With 2 year lag = Gabapentin exposure from cohort entry to 2 years prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer). Without 2 year lag = Gabapentin exposure from cohort entry to index date. Tertile's with 2 year lag: Tertile 1 (1-2 prescriptions), Tertile 2 (3-7 prescriptions), Tertile 3 (8-298 prescriptions). Tertiles without 2 year lag: Tertile 1 (1-2 prescriptions), Tertile 2 (3-7 prescriptions), and Tertile 3 (8-388 prescriptions). |
| Number of Pancreatic Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin | The case index date was the date of incident pancreatic cancer diagnosis ascertained in the GPRD study cohort 1995-2008. The matched control index date was the date at which the follow-up time from his/her cohort entry was the same as for the case. | Incident pancreatic cancer. Gabapentin Exposure Description: With 2 year lag = Gabapentin exposure from cohort entry to 2 years prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer). Without 2 year lag = Gabapentin exposure from cohort entry to index date. Tertile's with 2 year lag: Tertile 1 (0.01 - 1.38 months), Tertile 2 (1.39 - 5.56 months), and Tertile 3 (5.57 - 105.82 months). Tertile's without 2 year lag: Tertile 1 (0.01 - 1.38 months), Tertile 2 (1.39 - 5.72 months), and Tertile 3 (5.73 - 123.70 months). |
| Number of Pancreatic Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin | The case index date was the date of incident pancreatic cancer diagnosis ascertained in the GPRD study cohort 1995-2008. The matched control index date was the date at which the follow-up time from his/her cohort entry was the same as for the case | Incident pancreatic cancer. Gabapentin Exposure Description: With 2 year lag = Gabapentin exposure from cohort entry to 2 years prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer). Without 2 year lag = Gabapentin exposure from cohort entry to index date. |
| Number of Pancreatic Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin | The case index date was the date of incident pancreatic cancer diagnosis ascertained in the GPRD study cohort 1995-2008. The matched control index date was the date at which the follow-up time from his/her cohort entry was the same as for the case. | Incident pancreatic cancer. Gabapentin Exposure Description: With 2 year lag = Gabapentin exposure from cohort entry to 2 years prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer). Without 2 year lag = Gabapentin exposure from cohort entry to index date. Tertile's with 2 year lag: Tertile 1 (0.1 - 30.0 grams), Tertile 2 (30.1 - 189.0 grams), and Tertile 3 (189.1 - 9600.0 grams). Tertile's without 2 year lag: Tertile 1 (0.1 - 30.0 grams), Tertile 2 (30.1 - 189.0 grams), and Tertile 3 (189.1 - 11610.0 grams). |
| Number of Renal Cancer Cases and Matched Controls With the Indicated Exposure to Gabapentin | The case index date was the date of incident pancreatic cancer diagnosis ascertained in the GPRD study cohort 1995-2008. The matched control index date was the date at which the follow-up time from his/her cohort entry was the same as for the case. | Incident renal cancer. Gabapentin Exposure Description: With 2 year lag = Gabapentin prescription from cohort entry to 2 years prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer). Without 2 year lag = Gabapentin prescription from cohort entry to index date. |
| Number of Renal Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions | The case index date was the date of incident renal cancer diagnosis ascertained in the GPRD study cohort 1995-2008. The matched control index date was the date at which the follow-up time from his/her cohort entry was the same as that for the case. | Incident renal cancer. Gabapentin Exposure Description: With 2 year lag = Gabapentin exposure from cohort entry to 2 years prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer). Without 2 year lag = Gabapentin exposure from cohort entry to index date. Tertile's with 2 year lag: Tertile 1 (1-2 prescriptions), Tertile 2 (3-7 prescriptions), Tertile 3 (8-298 prescriptions). Tertiles without 2 year lag: Tertile 1 (1-2 prescriptions), Tertile 2 (3-7 prescriptions), and Tertile 3 (8-388 prescriptions). |
| Number of Renal Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin | The case index date was the date of incident renal cancer diagnosis ascertained in the GPRD study cohort 1995-2008. The matched control index date was the date at which the follow-up time from his/her cohort entry was the same as that for the case. | Incident renal cancer. Gabapentin Exposure Description: With 2 year lag = Gabapentin exposure from cohort entry to 2 years prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer). Without 2 year lag = Gabapentin exposure from cohort entry to index date. Tertile's with 2 year lag: Tertile 1 (0.01 - 1.38 months), Tertile 2 (1.39 - 5.56 months), and Tertile 3 (5.57 - 105.82 months). Tertile's without 2 year lag: Tertile 1 (0.01 - 1.38 months), Tertile 2 (1.39 - 5.72 months), and Tertile 3 (5.73 - 123.70 months). |
| Number of Renal Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin | The case index date was the date of incident renal cancer diagnosis ascertained in the GPRD study cohort 1995-2008. The matched control index date was the date at which the follow-up time from his/her cohort entry was the same as that for the case. | Incident renal cancer. Gabapentin Exposure Description: With 2 year lag = Gabapentin exposure from cohort entry to 2 years prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer). Without 2 year lag = Gabapentin exposure from cohort entry to index date. |
| Number of Renal Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin | The case index date was the date of incident renal cancer diagnosis ascertained in the GPRD study cohort 1995-2008. The matched control index date was the date at which the follow-up time from his/her cohort entry was the same as that for the case. | Incident renal cancer. Gabapentin Exposure Description: With 2 year lag = Gabapentin exposure from cohort entry to 2 years prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer). Without 2 year lag = Gabapentin exposure from cohort entry to index date. Tertile's with 2 year lag: Tertile 1 (0.1 - 30.0 grams), Tertile 2 (30.1 - 189.0 grams), and Tertile 3 (189.1 - 9600.0 grams). Tertile's without 2 year lag: Tertile 1 (0.1 - 30.0 grams), Tertile 2 (30.1 - 189.0 grams), and Tertile 3 (189.1 - 11610.0 grams). |
Participant flow
Recruitment details
Patients were not recruited for nor enrolled in this study. This study is a retrospective observational study. Data from medical records or insurance claims databases are anonymized and used to develop a patient cohort. All diagnoses and treatments are recorded in the course of routine medical practice.
Pre-assignment details
Actual number of patients may be less, as it is possible for a patient to be represented in more than 1 of the 22 arms (See Participant Flow: Overall Study Table) because of the risk set sampling.
Participants by arm
| Arm | Count |
|---|---|
| All-Cancer: Cases Incidence of all cancers defined as first time incident cancer diagnosis (READ/Oxford Medical Information System \[OXMIS\] codes) in the General Practice Research Database (GPRD) study cohort. Entry into the study cohort began January 1, 1993, or at the time of GPRD registration if after January 1, 1993. Follow-up ended December 31, 2008, or earlier if the respective cancer was diagnosed or if the participant left the GPRD for any reason including death. Participants with a prior history of cancer were excluded. | 179,138 |
| All-Cancer: Controls Cancer cases were risk set matched with up to 10 controls for sex, age at GPRD study cohort entry (within two years), calendar year of cohort entry (within one year), and General Practice site. The index date for controls was set as the date at which the follow-up time from cohort entry was the same as the case. The index date was chosen so as to give the control equal follow-up time to that of the case for ascertainment of use of gabapentin. Participants with a history of cancer prior to the index date were excluded as controls. | 1,710,950 |
| Stomach Cancer: Cases Incidence of stomach cancer defined as first time incident cancer diagnosis (READ/Oxford Medical Information System \[OXMIS\] codes) in the General Practice Research Database (GPRD) study cohort. Entry into the study cohort began January 1, 1993, or at the time of GPRD registration if after January 1, 1993. Follow-up ended December 31, 2008, or earlier if the respective cancer was diagnosed or if the participant left the GPRD for any reason including death. Participants with a prior history of cancer were excluded. | 1,877 |
| Stomach Cancer: Controls Cancer cases were risk set matched with up to 10 controls for sex, age at GPRD study cohort entry (within two years), calendar year of cohort entry (within one year), and General Practice site. The index date for controls was set as the date at which the follow-up time from cohort entry was the same as the case. The index date was chosen so as to give the control equal follow-up time to that of the case for ascertainment of use of gabapentin. Participants with a history of cancer prior to the index date were excluded as controls. | 17,853 |
| Anal Cancer: Cases Incidence of anal cancer defined as first time incident cancer diagnosis (READ/Oxford Medical Information System \[OXMIS\] codes) in the General Practice Research Database (GPRD) study cohort. Entry into the study cohort began January 1, 1993, or at the time of GPRD registration if after January 1, 1993. Follow-up ended December 31, 2008, or earlier if the respective cancer was diagnosed or if the participant left the GPRD for any reason including death. Participants with a prior history of cancer were excluded. | 212 |
| Anal Cancer: Controls Cancer cases were risk set matched with up to 10 controls for sex, age at GPRD study cohort entry (within two years), calendar year of cohort entry (within one year), and General Practice site. The index date for controls was set as the date at which the follow-up time from cohort entry was the same as the case. The index date was chosen so as to give the control equal follow-up time to that of the case for ascertainment of use of gabapentin. Participants with a history of cancer prior to the index date were excluded as controls. | 2,067 |
| Lung Cancer: Cases Incidence of lung cancer defined as first time incident cancer diagnosis (READ/Oxford Medical Information System \[OXMIS\] codes) in the General Practice Research Database (GPRD) study cohort. Entry into the study cohort began January 1, 1993, or at the time of GPRD registration if after January 1, 1993. Follow-up ended December 31, 2008, or earlier if the respective cancer was diagnosed or if the participant left the GPRD for any reason including death. Participants with a prior history of cancer were excluded. | 10,855 |
| Lung Cancer: Controls Cancer cases were risk set matched with up to 10 controls for sex, age at GPRD study cohort entry (within two years), calendar year of cohort entry (within one year), and General Practice site. The index date for controls was set as the date at which the follow-up time from cohort entry was the same as the case. The index date was chosen so as to give the control equal follow-up time to that of the case for ascertainment of use of gabapentin. Participants with a history of cancer prior to the index date were excluded as controls. | 102,836 |
| Bone/Joint Cancer: Cases Incidence of bone/joint cancer defined as first time incident cancer diagnosis (READ/Oxford Medical Information System \[OXMIS\] codes) in the General Practice Research Database (GPRD) study cohort. Entry into the study cohort began January 1, 1993, or at the time of GPRD registration if after January 1, 1993. Follow-up ended December 31, 2008, or earlier if the respective cancer was diagnosed or if the participant left the GPRD for any reason including death. Participants with a prior history of cancer were excluded. | 300 |
| Bone/Joint Cancer: Controls Cancer cases were risk set matched with up to 10 controls for sex, age at GPRD study cohort entry (within two years), calendar year of cohort entry (within one year), and General Practice site. The index date for controls was set as the date at which the follow-up time from cohort entry was the same as the case. The index date was chosen so as to give the control equal follow-up time to that of the case for ascertainment of use of gabapentin. Participants with a history of cancer prior to the index date were excluded as controls. | 2,935 |
| Breast Cancer: Cases Incidence of breast cancer defined as first time incident cancer diagnosis (READ/Oxford Medical Information System \[OXMIS\] codes) in the General Practice Research Database (GPRD) study cohort. Entry into the study cohort began January 1, 1993, or at the time of GPRD registration if after January 1, 1993. Follow-up ended December 31, 2008, or earlier if the respective cancer was diagnosed or if the participant left the GPRD for any reason including death. Participants with a prior history of cancer were excluded. | 19,564 |
| Breast Cancer: Controls Cancer cases were risk set matched with up to 10 controls for sex, age at GPRD study cohort entry (within two years), calendar year of cohort entry (within one year), and General Practice site. The index date for controls was set as the date at which the follow-up time from cohort entry was the same as the case. The index date was chosen so as to give the control equal follow-up time to that of the case for ascertainment of use of gabapentin. Participants with a history of cancer prior to the index date were excluded as controls. | 188,924 |
| Penile Cancer: Cases Incidence of penile cancer defined as first time incident cancer diagnosis (READ/Oxford Medical Information System \[OXMIS\] codes) in the General Practice Research Database (GPRD) study cohort. Entry into the study cohort began January 1, 1993, or at the time of GPRD registration if after January 1, 1993. Follow-up ended December 31, 2008, or earlier if the respective cancer was diagnosed or if the participant left the GPRD for any reason including death. Participants with a prior history of cancer were excluded. | 148 |
| Penile Cancer: Controls Cancer cases were risk set matched with up to 10 controls for sex, age at GPRD study cohort entry (within two years), calendar year of cohort entry (within one year), and General Practice site. The index date for controls was set as the date at which the follow-up time from cohort entry was the same as the case. The index date was chosen so as to give the control equal follow-up time to that of the case for ascertainment of use of gabapentin. Participants with a history of cancer prior to the index date were excluded as controls. | 1,396 |
| Bladder Cancer: Cases Incidence of bladder cancer defined as first time incident cancer diagnosis (READ/Oxford Medical Information System \[OXMIS\] codes) in the General Practice Research Database (GPRD) study cohort. Entry into the study cohort began January 1, 1993, or at the time of GPRD registration if after January 1, 1993. Follow-up ended December 31, 2008, or earlier if the respective cancer was diagnosed or if the participant left the GPRD for any reason including death. Participants with a prior history of cancer were excluded. | 4,600 |
| Bladder Cancer: Controls Cancer cases were risk set matched with up to 10 controls for sex, age at GPRD study cohort entry (within two years), calendar year of cohort entry (within one year), and General Practice site. The index date for controls was set as the date at which the follow-up time from cohort entry was the same as the case. The index date was chosen so as to give the control equal follow-up time to that of the case for ascertainment of use of gabapentin. Participants with a history of cancer prior to the index date were excluded as controls. | 43,559 |
| Other Nervous System Cancer: Cases Incidence of other nervous system cancer defined as first time incident cancer diagnosis (READ/Oxford Medical Information System \[OXMIS\] codes) in the General Practice Research Database (GPRD) study cohort. Entry into the study cohort began January 1, 1993, or at the time of GPRD registration if after January 1, 1993. Follow-up ended December 31, 2008, or earlier if the respective cancer was diagnosed or if the participant left the GPRD for any reason including death. Participants with a prior history of cancer were excluded. | 38 |
| Other Nervous System Cancer: Controls Cancer cases were risk set matched with up to 10 controls for sex, age at GPRD study cohort entry (within two years), calendar year of cohort entry (within one year), and General Practice site. The index date for controls was set as the date at which the follow-up time from cohort entry was the same as the case. The index date was chosen so as to give the control equal follow-up time to that of the case for ascertainment of use of gabapentin. Participants with a history of cancer prior to the index date were excluded as controls. | 380 |
| Pancreatic Cancer: Cases Incidence of pancreatic cancer defined as first time incident cancer diagnosis (READ/Oxford Medical Information System \[OXMIS\] codes) in the General Practice Research Database (GPRD) study cohort. Entry into the study cohort began January 1, 1993, or at the time of GPRD registration if after January 1, 1993. Follow-up ended December 31, 2008, or earlier if the respective cancer was diagnosed or if the participant left the GPRD for any reason including death. Participants with a prior history of cancer were excluded. | 2,155 |
| Pancreatic Cancer: Controls Cancer cases were risk set matched with up to 10 controls for sex, age at GPRD study cohort entry (within two years), calendar year of cohort entry (within one year), and General Practice site. The index date for controls was set as the date at which the follow-up time from cohort entry was the same as the case. The index date was chosen so as to give the control equal follow-up time to that of the case for ascertainment of use of gabapentin. Participants with a history of cancer prior to the index date were excluded as controls. | 20,382 |
| Renal Cancer: Cases Incidence of renal cancer defined as first time incident cancer diagnosis (READ/Oxford Medical Information System \[OXMIS\] codes) in the General Practice Research Database (GPRD) study cohort. Entry into the study cohort began January 1, 1993, or at the time of GPRD registration if after January 1, 1993. Follow-up ended December 31, 2008, or earlier if the respective cancer was diagnosed or if the participant left the GPRD for any reason including death. Participants with a prior history of cancer were excluded. | 1,272 |
| Renal Cancer: Controls Cancer cases were risk set matched with up to 10 controls for sex, age at GPRD study cohort entry (within two years), calendar year of cohort entry (within one year), and General Practice site. The index date for controls was set as the date at which the follow-up time from cohort entry was the same as the case. The index date was chosen so as to give the control equal follow-up time to that of the case for ascertainment of use of gabapentin. Participants with a history of cancer prior to the index date were excluded as controls. | 12,167 |
| Total | 2,323,608 |
Baseline characteristics
| Characteristic | Total | All-Cancer: Cases | All-Cancer: Controls | Stomach Cancer: Cases | Stomach Cancer: Controls | Anal Cancer: Cases | Anal Cancer: Controls | Lung Cancer: Cases | Lung Cancer: Controls | Bone/Joint Cancer: Cases | Bone/Joint Cancer: Controls | Breast Cancer: Cases | Breast Cancer: Controls | Penile Cancer: Cases | Penile Cancer: Controls | Bladder Cancer: Cases | Bladder Cancer: Controls | Other Nervous System Cancer: Cases | Other Nervous System Cancer: Controls | Pancreatic Cancer: Cases | Pancreatic Cancer: Controls | Renal Cancer: Cases | Renal Cancer: Controls |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, Customized 40-49 years | 185111 participants | 13112 participants | 132244 participants | 48 participants | 469 participants | 18 participants | 200 participants | 294 participants | 2973 participants | 21 participants | 254 participants | 2827 participants | 29167 participants | 16 participants | 154 participants | 120 participants | 1285 participants | 8 participants | 78 participants | 65 participants | 669 participants | 99 participants | 990 participants |
| Age, Customized < 40 years | 125731 participants | 10246 participants | 101968 participants | 16 participants | 155 participants | 12 participants | 118 participants | 36 participants | 369 participants | 120 participants | 1173 participants | 915 participants | 9346 participants | 9 participants | 90 participants | 56 participants | 552 participants | 5 participants | 54 participants | 11 participants | 132 participants | 31 participants | 317 participants |
| Age, Customized 50-59 years | 392635 participants | 28392 participants | 279797 participants | 135 participants | 1388 participants | 47 participants | 467 participants | 1256 participants | 12388 participants | 46 participants | 422 participants | 5319 participants | 51266 participants | 30 participants | 300 participants | 547 participants | 5296 participants | 5 participants | 54 participants | 261 participants | 2564 participants | 249 participants | 2406 participants |
| Age, Customized 60-69 years | 566705 participants | 43077 participants | 415567 participants | 395 participants | 3850 participants | 45 participants | 464 participants | 2944 participants | 28526 participants | 38 participants | 360 participants | 4665 participants | 44769 participants | 32 participants | 320 participants | 1127 participants | 11021 participants | 9 participants | 78 participants | 515 participants | 5043 participants | 362 participants | 3498 participants |
| Age, Customized 70-79 years | 641161 participants | 50072 participants | 475887 participants | 679 participants | 6559 participants | 50 participants | 440 participants | 4092 participants | 38557 participants | 51 participants | 501 participants | 3334 participants | 32051 participants | 44 participants | 388 participants | 1644 participants | 15471 participants | 4 participants | 48 participants | 716 participants | 6813 participants | 361 participants | 3399 participants |
| Age, Customized 80+ years | 412265 participants | 34239 participants | 305487 participants | 604 participants | 5432 participants | 40 participants | 378 participants | 2233 participants | 20023 participants | 24 participants | 225 participants | 2504 participants | 22325 participants | 17 participants | 144 participants | 1106 participants | 9934 participants | 7 participants | 68 participants | 587 participants | 5161 participants | 170 participants | 1557 participants |
| Number of participants using indicated class of medications or having the indicated comorbidities Acid suppressing drugs (>6 mo. before index date) | 5998 participants | 0 participants | 0 participants | 796 participants | 5202 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants |
| Number of participants using indicated class of medications or having the indicated comorbidities Back pain | 1055224 participants | 87337 participants | 765861 participants | 924 participants | 7779 participants | 92 participants | 924 participants | 5626 participants | 46417 participants | 130 participants | 1008 participants | 9603 participants | 91302 participants | 59 participants | 569 participants | 2149 participants | 18811 participants | 23 participants | 192 participants | 1081 participants | 9186 participants | 678 participants | 5473 participants |
| Number of participants using indicated class of medications or having the indicated comorbidities Benign breast disease | 6402 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 894 participants | 5508 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants |
| Number of participants using indicated class of medications or having the indicated comorbidities Chronic obstructive pulmonary disease (COPD) | 9171 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 2532 participants | 6639 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants |
| Number of participants using indicated class of medications or having the indicated comorbidities Chronic pancreatitis | 21 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 13 participants | 8 participants | 0 participants | 0 participants |
| Number of participants using indicated class of medications or having the indicated comorbidities Current estrogen (within 6 months of index date) | 25492 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 2916 participants | 22576 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants |
| Number of participants using indicated class of medications or having the indicated comorbidities Diabetes | 176793 participants | 15280 participants | 130210 participants | 208 participants | 1592 participants | 17 participants | 139 participants | 1086 participants | 9448 participants | 15 participants | 155 participants | 1162 participants | 9899 participants | 18 participants | 104 participants | 559 participants | 4087 participants | 3 participants | 32 participants | 241 participants | 1415 participants | 155 participants | 968 participants |
| Number of participants using indicated class of medications or having the indicated comorbidities Diuretic use (at any time up to the index date) | 4369 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 554 participants | 3815 participants |
| Number of participants using indicated class of medications or having the indicated comorbidities Epilepsy | 33460 participants | 3015 participants | 24226 participants | 32 participants | 271 participants | 8 participants | 23 participants | 214 participants | 1577 participants | 3 participants | 33 participants | 285 participants | 2486 participants | 0 participants | 28 participants | 78 participants | 654 participants | 3 participants | 4 participants | 35 participants | 289 participants | 20 participants | 176 participants |
| Number of participants using indicated class of medications or having the indicated comorbidities Human immunodeficiency virus (HIV) | 3 participants | 0 participants | 0 participants | 0 participants | 0 participants | 3 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants |
| Number of participants using indicated class of medications or having the indicated comorbidities Human papillomavirus (HPV) (genital) | 43 participants | 0 participants | 0 participants | 0 participants | 0 participants | 15 participants | 7 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 9 participants | 12 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants |
| Number of participants using indicated class of medications or having the indicated comorbidities Hypertension | 6329 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 749 participants | 5580 participants |
| Number of participants using indicated class of medications or having the indicated comorbidities Hysterectomy | 37853 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 3563 participants | 34290 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants |
| Number of participants using indicated class of medications or having the indicated comorbidities Neuropathic pain | 466531 participants | 38561 participants | 338723 participants | 382 participants | 3485 participants | 47 participants | 406 participants | 2485 participants | 21202 participants | 49 participants | 387 participants | 4055 participants | 39494 participants | 25 participants | 229 participants | 998 participants | 8539 participants | 15 participants | 71 participants | 474 participants | 4195 participants | 275 participants | 2434 participants |
| Number of participants using indicated class of medications or having the indicated comorbidities Phimosis | 85 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 54 participants | 31 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants |
| Number of participants using indicated class of medications or having the indicated comorbidities Prior estrogen | 67643 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 6803 participants | 60840 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants |
| Number of participants using indicated class of medications or having the indicated comorbidities Upper gastro-intestinal disorder | 3302 participants | 0 participants | 0 participants | 442 participants | 2860 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants |
| Number of participants with the indicated alcohol consumption (per day) 0 units/day | 454063 participants | 36134 participants | 340399 participants | 422 participants | 3817 participants | 0 participants | 0 participants | 2412 participants | 21471 participants | 0 participants | 0 participants | 4585 participants | 44823 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants |
| Number of participants with the indicated alcohol consumption (per day) 1-2 units/day | 1051644 participants | 86422 participants | 801383 participants | 839 participants | 7659 participants | 0 participants | 0 participants | 4661 participants | 46769 participants | 0 participants | 0 participants | 9947 participants | 93964 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants |
| Number of participants with the indicated alcohol consumption (per day) 3-6 units/day | 128153 participants | 11929 participants | 102201 participants | 115 participants | 1118 participants | 0 participants | 0 participants | 868 participants | 6843 participants | 0 participants | 0 participants | 535 participants | 4544 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants |
| Number of participants with the indicated alcohol consumption (per day) 7+ units/day | 18964 participants | 1992 participants | 15014 participants | 18 participants | 157 participants | 0 participants | 0 participants | 202 participants | 1132 participants | 0 participants | 0 participants | 50 participants | 399 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants |
| Number of participants with the indicated alcohol consumption (per day) Missing | 579173 participants | 42661 participants | 451953 participants | 483 participants | 5102 participants | 0 participants | 0 participants | 2712 participants | 26621 participants | 0 participants | 0 participants | 4447 participants | 45194 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants |
| Number of participants with the indicated Body Mass Index (BMI) BMI: < 18.5 kg/m^2 | 28057 participants | 2393 participants | 19861 participants | 30 participants | 190 participants | 5 participants | 30 participants | 255 participants | 1081 participants | 7 participants | 38 participants | 267 participants | 3059 participants | 1 participants | 7 participants | 52 participants | 380 participants | 0 participants | 4 participants | 30 participants | 232 participants | 7 participants | 128 participants |
| Number of participants with the indicated Body Mass Index (BMI) BMI: 18.5 to 24.99 kg/m^2 | 784515 participants | 61913 participants | 569726 participants | 580 participants | 5429 participants | 82 participants | 674 participants | 3912 participants | 31787 participants | 72 participants | 741 participants | 7813 participants | 75516 participants | 42 participants | 420 participants | 1408 participants | 13224 participants | 11 participants | 106 participants | 662 participants | 6313 participants | 331 participants | 3753 participants |
| Number of participants with the indicated Body Mass Index (BMI) BMI: 25 to 29.99 kg/m^2 | 687070 participants | 54471 participants | 508109 participants | 579 participants | 5483 participants | 55 participants | 581 participants | 3070 participants | 33035 participants | 70 participants | 580 participants | 5054 participants | 47989 participants | 50 participants | 461 participants | 1591 participants | 14390 participants | 11 participants | 111 participants | 662 participants | 6313 participants | 447 participants | 3958 participants |
| Number of participants with the indicated Body Mass Index (BMI) BMI: 30 kg/m^2 or greater | 284287 participants | 22152 participants | 206232 participants | 245 participants | 2001 participants | 21 participants | 254 participants | 1097 participants | 12814 participants | 25 participants | 285 participants | 2773 participants | 25819 participants | 22 participants | 142 participants | 587 participants | 5117 participants | 7 participants | 37 participants | 294 participants | 2492 participants | 245 participants | 1626 participants |
| Number of participants with the indicated Body Mass Index (BMI) BMI: Missing | 539674 participants | 38209 participants | 407022 participants | 443 participants | 4750 participants | 49 participants | 528 participants | 2521 participants | 24119 participants | 126 participants | 1291 participants | 3657 participants | 36541 participants | 33 participants | 366 participants | 962 participants | 10448 participants | 9 participants | 122 participants | 507 participants | 5027 participants | 242 participants | 2702 participants |
| Number of participants with the indicated duration of follow-up from cohort entry to index date 0-1 years | 3216 participants | 0 participants | 0 participants | 0 participants | 3216 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants |
| Number of participants with the indicated duration of follow-up from cohort entry to index date 2-3 years | 311699 participants | 24693 participants | 226195 participants | 351 participants | 3216 participants | 32 participants | 319 participants | 1627 participants | 14736 participants | 48 participants | 458 participants | 2784 participants | 26004 participants | 24 participants | 212 participants | 592 participants | 5351 participants | 2 participants | 20 participants | 310 participants | 2835 participants | 186 participants | 1704 participants |
| Number of participants with the indicated duration of follow-up from cohort entry to index date 4-5 years | 305162 participants | 24123 participants | 223084 participants | 281 participants | 2628 participants | 32 participants | 288 participants | 1489 participants | 13563 participants | 48 participants | 451 participants | 2718 participants | 25616 participants | 28 participants | 264 participants | 609 participants | 5502 participants | 2 participants | 20 participants | 283 participants | 2596 participants | 149 participants | 1388 participants |
| Number of participants with the indicated duration of follow-up from cohort entry to index date 6-7 years | 328429 participants | 25608 participants | 241586 participants | 231 participants | 2108 participants | 26 participants | 257 participants | 1577 participants | 14855 participants | 49 participants | 490 participants | 2830 participants | 27109 participants | 17 participants | 159 participants | 618 participants | 5824 participants | 6 participants | 60 participants | 318 participants | 2972 participants | 165 participants | 1564 participants |
| Number of participants with the indicated duration of follow-up from cohort entry to index date 8+ years | 1378318 participants | 104714 participants | 1020085 participants | 1014 participants | 9901 participants | 122 participants | 1203 participants | 6162 participants | 59682 participants | 155 participants | 1536 participants | 11232 participants | 110195 participants | 79 participants | 761 participants | 2781 participants | 26882 participants | 28 participants | 280 participants | 1244 participants | 11979 participants | 772 participants | 7511 participants |
| Number of participants with the indicated duration of follow-up from registration to index date 0-1 years | 11846 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 11846 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants | 0 participants |
| Number of participants with the indicated duration of follow-up from registration to index date 2-3 years | 136486 participants | 12001 participants | 99830 participants | 115 participants | 866 participants | 14 participants | 135 participants | 644 participants | 5014 participants | 35 participants | 331 participants | 1361 participants | 11846 participants | 9 participants | 73 participants | 251 participants | 2007 participants | 2 participants | 13 participants | 118 participants | 968 participants | 91 participants | 762 participants |
| Number of participants with the indicated duration of follow-up from registration to index date 4-5 years | 147965 participants | 12675 participants | 108112 participants | 123 participants | 1048 participants | 20 participants | 164 participants | 708 participants | 5868 participants | 35 participants | 308 participants | 1426 participants | 12724 participants | 15 participants | 136 participants | 283 participants | 2403 participants | 0 participants | 0 participants | 122 participants | 1028 participants | 72 participants | 695 participants |
| Number of participants with the indicated duration of follow-up from registration to index date 6-7 years | 164009 participants | 13403 participants | 119691 participants | 157 participants | 1321 participants | 13 participants | 121 participants | 802 participants | 6978 participants | 29 participants | 264 participants | 1508 participants | 14037 participants | 12 participants | 104 participants | 304 participants | 2694 participants | 5 participants | 41 participants | 173 participants | 1418 participants | 95 participants | 839 participants |
| Number of participants with the indicated duration of follow-up from registration to index date 8+ years | 1875128 participants | 141059 participants | 1383317 participants | 1482 participants | 14618 participants | 165 participants | 1647 participants | 8681 participants | 84976 participants | 201 participants | 2032 participants | 15269 participants | 150317 participants | 112 participants | 1083 participants | 3762 participants | 36455 participants | 31 participants | 326 participants | 1742 participants | 16968 participants | 1014 participants | 9871 participants |
| Number of participants with the indicated smoking status Current Smoker | 426275 participants | 38033 participants | 306184 participants | 375 participants | 2902 participants | 63 participants | 379 participants | 4806 participants | 18856 participants | 51 participants | 476 participants | 3572 participants | 34818 participants | 51 participants | 297 participants | 1310 participants | 7502 participants | 10 participants | 71 participants | 518 participants | 3368 participants | 309 participants | 2324 participants |
| Number of participants with the indicated smoking status Ex-Smoker | 481341 participants | 41270 participants | 354651 participants | 531 participants | 4134 participants | 41 participants | 380 participants | 3594 participants | 24290 participants | 43 participants | 385 participants | 3156 participants | 28210 participants | 29 participants | 334 participants | 1307 participants | 11070 participants | 6 participants | 77 participants | 499 participants | 4247 participants | 319 participants | 2768 participants |
| Number of participants with the indicated smoking status Never Smoked | 1162688 participants | 85483 participants | 854263 participants | 810 participants | 8540 participants | 83 participants | 1048 participants | 1766 participants | 48127 participants | 133 participants | 1255 participants | 11396 participants | 109463 participants | 58 participants | 587 participants | 1636 participants | 20018 participants | 17 participants | 176 participants | 929 participants | 10455 participants | 570 participants | 5875 participants |
| Number of participants with the indicated smoking status Unknown | 253304 participants | 14352 participants | 195852 participants | 161 participants | 2277 participants | 25 participants | 260 participants | 689 participants | 11563 participants | 73 participants | 819 participants | 1440 participants | 16433 participants | 10 participants | 178 participants | 347 participants | 4969 participants | 5 participants | 56 participants | 209 participants | 2312 participants | 74 participants | 1200 participants |
| Sex: Female, Male Female | 1269049 Participants | 92099 Participants | 883331 Participants | 716 Participants | 6789 Participants | 133 Participants | 1294 Participants | 4259 Participants | 40345 Participants | 156 Participants | 1538 Participants | 19564 Participants | 188924 Participants | 0 Participants | 0 Participants | 1229 Participants | 11552 Participants | 14 Participants | 140 Participants | 1109 Participants | 10530 Participants | 507 Participants | 4820 Participants |
| Sex: Female, Male Male | 1054559 Participants | 87039 Participants | 827619 Participants | 1161 Participants | 11064 Participants | 79 Participants | 773 Participants | 6596 Participants | 62491 Participants | 144 Participants | 1397 Participants | 0 Participants | 0 Participants | 148 Participants | 1396 Participants | 3371 Participants | 32007 Participants | 24 Participants | 240 Participants | 1046 Participants | 9852 Participants | 765 Participants | 7347 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk | EG004 affected / at risk | EG005 affected / at risk | EG006 affected / at risk | EG007 affected / at risk | EG008 affected / at risk | EG009 affected / at risk | EG010 affected / at risk | EG011 affected / at risk | EG012 affected / at risk | EG013 affected / at risk | EG014 affected / at risk | EG015 affected / at risk | EG016 affected / at risk | EG017 affected / at risk | EG018 affected / at risk | EG019 affected / at risk | EG020 affected / at risk | EG021 affected / at risk |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — | — / — | — / — | — / — | — / — | — / — | — / — | — / — | — / — | — / — | — / — | — / — | — / — | — / — | — / — | — / — | — / — | — / — | — / — | — / — | — / — |
| other Total, other adverse events | 0 / 0 | 0 / 0 | 0 / 0 | 0 / 0 | 0 / 0 | 0 / 0 | 0 / 0 | 0 / 0 | 0 / 0 | 0 / 0 | 0 / 0 | 0 / 0 | 0 / 0 | 0 / 0 | 0 / 0 | 0 / 0 | 0 / 0 | 0 / 0 | 0 / 0 | 0 / 0 | 0 / 0 | 0 / 0 |
| serious Total, serious adverse events | 0 / 0 | 0 / 0 | 0 / 0 | 0 / 0 | 0 / 0 | 0 / 0 | 0 / 0 | 0 / 0 | 0 / 0 | 0 / 0 | 0 / 0 | 0 / 0 | 0 / 0 | 0 / 0 | 0 / 0 | 0 / 0 | 0 / 0 | 0 / 0 | 0 / 0 | 0 / 0 | 0 / 0 | 0 / 0 |
Outcome results
Primary
Number of All-Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin
Incidence of all cancers. Gabapentin Exposure Description: With 2 year lag = Gabapentin exposure from cohort entry to 2 years prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer). Without 2 year lag = Gabapentin exposure from cohort entry to index date. Tertile's with 2 year lag: Tertile 1 (0.1 - 30.0 grams), Tertile 2 (30.1 - 189.0 grams), and Tertile 3 (189.1 - 9600.0 grams). Tertile's without 2 year lag: Tertile 1 (0.1 - 30.0 grams), Tertile 2 (30.1 - 189.0 grams), and Tertile 3 (189.1 - 11610.0 grams).
Time frame: The case index date was the date of incident cancer diagnosis ascertained in the GPRD study cohort 1995-2008. The matched control index date was the date at which the follow-up time from his/her cohort entry was the same as that for the case.
Population: Cases \& controls drawn from the GPRD study cohort. Entry into study cohort began January 1, 1993, or at time of GPRD registration if after Jan. 1, 1993. Follow-up ended December 31, 2008, or earlier if respective cancer was diagnosed or if participant left the GPRD for any reason including death. Participants with prior history of cancer excluded.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Incident All-cancer Patients | Number of All-Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin | Never (with 2 year lag) | 178334 participants |
| Incident All-cancer Patients | Number of All-Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin | Tertile 1 (with 2 year lag) | 269 participants |
| Incident All-cancer Patients | Number of All-Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin | Tertile 2 (with 2 year lag) | 268 participants |
| Incident All-cancer Patients | Number of All-Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin | Tertile 3 (with 2 year lag) | 267 participants |
| Incident All-cancer Patients | Number of All-Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin | Never (without 2 year lag) | 177409 participants |
| Incident All-cancer Patients | Number of All-Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin | Tertile 1 (without 2 year lag) | 640 participants |
| Incident All-cancer Patients | Number of All-Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin | Tertile 2 (without 2 year lag) | 585 participants |
| Incident All-cancer Patients | Number of All-Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin | Tertile 3 (without 2 year lag) | 504 participants |
| Matched Controls for Incident All-cancer Patients | Number of All-Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin | Tertile 3 (without 2 year lag) | 4150 participants |
| Matched Controls for Incident All-cancer Patients | Number of All-Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin | Never (with 2 year lag) | 1704443 participants |
| Matched Controls for Incident All-cancer Patients | Number of All-Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin | Never (without 2 year lag) | 1698480 participants |
| Matched Controls for Incident All-cancer Patients | Number of All-Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin | Tertile 1 (with 2 year lag) | 2222 participants |
| Matched Controls for Incident All-cancer Patients | Number of All-Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin | Tertile 2 (without 2 year lag) | 3882 participants |
| Matched Controls for Incident All-cancer Patients | Number of All-Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin | Tertile 2 (with 2 year lag) | 2118 participants |
| Matched Controls for Incident All-cancer Patients | Number of All-Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin | Tertile 1 (without 2 year lag) | 4438 participants |
| Matched Controls for Incident All-cancer Patients | Number of All-Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin | Tertile 3 (with 2 year lag) | 2167 participants |
p-value: 0.070995% CI: [0.99, 1.28]Conditional Logistic Regression
p-value: 0.499695% CI: [0.92, 1.19]Conditional Logistic Regression
p-value: <0.000195% CI: [1.23, 1.45]Conditional Logistic Regression
p-value: <0.000195% CI: [1.14, 1.35]Conditional Logistic Regression
p-value: 0.006295% CI: [1.05, 1.36]Conditional Logistic Regression
p-value: 0.114495% CI: [0.98, 1.26]Conditional Logistic Regression
p-value: <0.000195% CI: [1.3, 1.55]Conditional Logistic Regression
p-value: <0.000195% CI: [1.2, 1.43]Conditional Logistic Regression
p-value: 0.046995% CI: [1, 1.29]Conditional Logistic Regression
p-value: 0.516995% CI: [0.92, 1.19]Conditional Logistic Regression
p-value: 0.010395% CI: [1.03, 1.24]Conditional Logistic Regression
p-value: 0.418295% CI: [0.95, 1.14]Conditional Logistic Regression
Primary
Number of All-Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin
Incidence of all cancers. Gabapentin Exposure Description: With 2 year lag = Gabapentin exposure from cohort entry to 2 years prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer). Without 2 year lag = Gabapentin exposure from cohort entry to index date. Tertile's with 2 year lag: Tertile 1 (0.01 - 1.38 months), Tertile 2 (1.39 - 5.56 months), and Tertile 3 (5.57 - 105.82 months). Tertile's without 2 year lag: Tertile 1 (0.01 - 1.38 months), Tertile 2 (1.39 - 5.72 months), and Tertile 3 (5.73 - 123.70 months).
Time frame: The case index date was the date of incident cancer diagnosis ascertained in the GPRD study cohort 1995-2008. The matched control index date was the date at which the follow-up time from his/her cohort entry was the same as that for the case.
Population: Cases \& controls drawn from the GPRD study cohort. Entry into study cohort began January 1, 1993, or at time of GPRD registration if after Jan. 1, 1993. Follow-up ended December 31, 2008, or earlier if respective cancer was diagnosed or if participant left the GPRD for any reason including death. Participants with prior history of cancer excluded.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Incident All-cancer Patients | Number of All-Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin | Tertile 3 (with 2 year lag) | 277 participants |
| Incident All-cancer Patients | Number of All-Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin | Never (with 2 year lag) | 178334 participants |
| Incident All-cancer Patients | Number of All-Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin | Tertile 1 (with 2 year lag) | 258 participants |
| Incident All-cancer Patients | Number of All-Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin | Tertile 2 (with 2 year lag) | 269 participants |
| Incident All-cancer Patients | Number of All-Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin | Never (without 2 year lag) | 177409 participants |
| Incident All-cancer Patients | Number of All-Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin | Tertile 1 (without 2 year lag) | 620 participants |
| Incident All-cancer Patients | Number of All-Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin | Tertile 2 (without 2 year lag) | 587 participants |
| Incident All-cancer Patients | Number of All-Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin | Tertile 3 (without 2 year lag) | 522 participants |
| Matched Controls for Incident All-cancer Patients | Number of All-Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin | Tertile 3 (without 2 year lag) | 4153 participants |
| Matched Controls for Incident All-cancer Patients | Number of All-Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin | Never (without 2 year lag) | 1698480 participants |
| Matched Controls for Incident All-cancer Patients | Number of All-Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin | Never (with 2 year lag) | 1704443 participants |
| Matched Controls for Incident All-cancer Patients | Number of All-Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin | Tertile 2 (without 2 year lag) | 4104 participants |
| Matched Controls for Incident All-cancer Patients | Number of All-Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin | Tertile 1 (with 2 year lag) | 2175 participants |
| Matched Controls for Incident All-cancer Patients | Number of All-Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin | Tertile 1 (without 2 year lag) | 4213 participants |
| Matched Controls for Incident All-cancer Patients | Number of All-Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin | Tertile 2 (with 2 year lag) | 2163 participants |
| Matched Controls for Incident All-cancer Patients | Number of All-Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin | Tertile 3 (with 2 year lag) | 2169 participants |
p-value: <0.000195% CI: [1.14, 1.36]Conditional Logistic Regression
p-value: 0.013195% CI: [1.03, 1.33]Conditional Logistic Regression
p-value: 0.273195% CI: [0.95, 1.22]Conditional Logistic Regression
p-value: 0.119495% CI: [0.97, 1.26]Conditional Logistic Regression
p-value: 0.700495% CI: [0.9, 1.17]Conditional Logistic Regression
p-value: <0.000195% CI: [1.26, 1.49]Conditional Logistic Regression
p-value: <0.000195% CI: [1.16, 1.38]Conditional Logistic Regression
p-value: 0.013495% CI: [1.03, 1.34]Conditional Logistic Regression
p-value: 0.159295% CI: [0.96, 1.25]Conditional Logistic Regression
p-value: <0.000195% CI: [1.24, 1.47]Conditional Logistic Regression
p-value: 0.001295% CI: [1.06, 1.28]Conditional Logistic Regression
p-value: 0.147795% CI: [0.98, 1.17]Conditional Logistic Regression
Primary
Number of All-Cancer Cases and Matched Controls With the Indicated Exposure to Gabapentin
Incidence of all cancers. Gabapentin Exposure Description: Without 2 year lag = Gabapentin prescription from cohort entry to index date. With 2 year lag = Gabapentin prescription from cohort entry to 2 years prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer).
Time frame: The case index date was the date of incident cancer diagnosis ascertained in the GPRD study cohort 1995-2008. The matched control index date was the date at which the follow-up time from his/her cohort entry was the same as that for the case.
Population: Cases \& controls drawn from the GPRD study cohort. Entry into study cohort began January 1, 1993, or at time of GPRD registration if after Jan. 1, 1993. Follow-up ended December 31, 2008, or earlier if respective cancer was diagnosed or if participant left the GPRD for any reason including death. Participants with prior history of cancer excluded.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Incident All-cancer Patients | Number of All-Cancer Cases and Matched Controls With the Indicated Exposure to Gabapentin | Ever (without 2 year lag) | 1729 participants |
| Incident All-cancer Patients | Number of All-Cancer Cases and Matched Controls With the Indicated Exposure to Gabapentin | Ever (with 2 year lag) | 804 participants |
| Incident All-cancer Patients | Number of All-Cancer Cases and Matched Controls With the Indicated Exposure to Gabapentin | Never (without 2 year lag) | 177409 participants |
| Incident All-cancer Patients | Number of All-Cancer Cases and Matched Controls With the Indicated Exposure to Gabapentin | Never (with 2 year lag) | 178334 participants |
| Matched Controls for Incident All-cancer Patients | Number of All-Cancer Cases and Matched Controls With the Indicated Exposure to Gabapentin | Never (without 2 year lag) | 1698480 participants |
| Matched Controls for Incident All-cancer Patients | Number of All-Cancer Cases and Matched Controls With the Indicated Exposure to Gabapentin | Ever (with 2 year lag) | 6507 participants |
| Matched Controls for Incident All-cancer Patients | Number of All-Cancer Cases and Matched Controls With the Indicated Exposure to Gabapentin | Ever (without 2 year lag) | 12470 participants |
| Matched Controls for Incident All-cancer Patients | Number of All-Cancer Cases and Matched Controls With the Indicated Exposure to Gabapentin | Never (with 2 year lag) | 1704443 participants |
p-value: 0.000295% CI: [1.07, 1.24]Conditional Logistic Regression
p-value: 0.097695% CI: [0.99, 1.15]Conditional Logistic Regression
p-value: <0.000195% CI: [1.23, 1.36]Conditional Logistic Regression
p-value: <0.000195% CI: [1.13, 1.26]Conditional Logistic Regression
Primary
Number of All-Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin
Incidence of all cancers. Gabapentin Exposure Description: With 2 year lag = Gabapentin exposure from cohort entry to 2 years prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer). Without 2 year lag = Gabapentin exposure from cohort entry to index date.
Time frame: The case index date was the date of incident cancer diagnosis ascertained in the GPRD study cohort 1995-2008. The matched control index date was the date at which the follow-up time from his/her cohort entry was the same as that for the case.
Population: Cases \& controls drawn from the GPRD study cohort. Entry into study cohort began January 1, 1993, or at time of GPRD registration if after Jan. 1, 1993. Follow-up ended December 31, 2008, or earlier if respective cancer was diagnosed or if participant left the GPRD for any reason including death. Participants with prior history of cancer excluded.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Incident All-cancer Patients | Number of All-Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin | > 3 year (with 2 year lag) | 25 participants |
| Incident All-cancer Patients | Number of All-Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin | > 1 year (with 2 year lag) | 157 participants |
| Incident All-cancer Patients | Number of All-Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin | Never (without 2 year lag) | 177409 participants |
| Incident All-cancer Patients | Number of All-Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin | Never (with 2 year lag) | 178334 participants |
| Incident All-cancer Patients | Number of All-Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin | > 1 year (without 2 year lag) | 301 participants |
| Incident All-cancer Patients | Number of All-Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin | > 2 year (with 2 year lag) | 64 participants |
| Incident All-cancer Patients | Number of All-Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin | > 3 year (without 2 year lag) | 76 participants |
| Incident All-cancer Patients | Number of All-Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin | > 2 year (without 2 year lag) | 159 participants |
| Matched Controls for Incident All-cancer Patients | Number of All-Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin | > 3 year (without 2 year lag) | 549 participants |
| Matched Controls for Incident All-cancer Patients | Number of All-Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin | Never (with 2 year lag) | 1704443 participants |
| Matched Controls for Incident All-cancer Patients | Number of All-Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin | > 1 year (with 2 year lag) | 1217 participants |
| Matched Controls for Incident All-cancer Patients | Number of All-Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin | > 2 year (with 2 year lag) | 463 participants |
| Matched Controls for Incident All-cancer Patients | Number of All-Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin | > 3 year (with 2 year lag) | 197 participants |
| Matched Controls for Incident All-cancer Patients | Number of All-Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin | Never (without 2 year lag) | 1698480 participants |
| Matched Controls for Incident All-cancer Patients | Number of All-Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin | > 2 year (without 2 year lag) | 1207 participants |
| Matched Controls for Incident All-cancer Patients | Number of All-Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin | > 1 year (without 2 year lag) | 2499 participants |
p-value: 0.036995% CI: [1.01, 1.41]Conditional Logistic Regression
p-value: 0.313295% CI: [0.92, 1.29]Conditional Logistic Regression
p-value: 0.076295% CI: [0.99, 1.26]Conditional Logistic Regression
p-value: 0.724395% CI: [0.91, 1.15]Conditional Logistic Regression
p-value: 0.077595% CI: [0.97, 1.65]Conditional Logistic Regression
p-value: 0.264995% CI: [0.89, 1.52]Conditional Logistic Regression
p-value: 0.025795% CI: [1.02, 1.43]Conditional Logistic Regression
p-value: 0.25495% CI: [0.93, 1.3]Conditional Logistic Regression
p-value: 0.514195% CI: [0.76, 1.75]Conditional Logistic Regression
p-value: 0.820895% CI: [0.69, 1.6]Conditional Logistic Regression
p-value: 0.056295% CI: [0.99, 1.62]Conditional Logistic Regression
p-value: 0.259695% CI: [0.9, 1.47]Conditional Logistic Regression
Primary
Number of All-Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions
Incidence of all cancers. Gabapentin Exposure Description: With 2 year lag = Gabapentin exposure from cohort entry to 2 years prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer). Without 2 year lag = Gabapentin exposure from cohort entry to index date. Tertile's with 2 year lag: Tertile 1 (1-2 prescriptions), Tertile 2 (3-7 prescriptions), Tertile 3 (8-298 prescriptions). Tertiles without 2 year lag: Tertile 1 (1-2 prescriptions), Tertile 2 (3-7 prescriptions), and Tertile 3 (8-388 prescriptions).
Time frame: The case index date was the date of incident cancer diagnosis ascertained in the GPRD study cohort 1995-2008. The matched control index date was the date at which the follow-up time from his/her cohort entry was the same as that for the case.
Population: Cases \& controls drawn from the GPRD study cohort. Entry into study cohort began January 1, 1993, or at time of GPRD registration if after Jan. 1, 1993. Follow-up ended December 31, 2008, or earlier if respective cancer was diagnosed or if participant left the GPRD for any reason including death. Participants with prior history of cancer excluded.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Incident All-cancer Patients | Number of All-Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions | Never (with 2 year lag) | 178334 participants |
| Incident All-cancer Patients | Number of All-Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions | Tertile 1 (with 2 year lag) | 319 participants |
| Incident All-cancer Patients | Number of All-Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions | Tertile 2 (with 2 year lag) | 216 participants |
| Incident All-cancer Patients | Number of All-Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions | Tertile 3 (with 2 year lag) | 269 participants |
| Incident All-cancer Patients | Number of All-Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions | Never (without 2 year lag) | 177409 participants |
| Incident All-cancer Patients | Number of All-Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions | Tertile 1 (without 2 year lag) | 781 participants |
| Incident All-cancer Patients | Number of All-Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions | Tertile 2 (without 2 year lag) | 413 participants |
| Incident All-cancer Patients | Number of All-Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions | Tertile 3 (without 2 year lag) | 535 participants |
| Matched Controls for Incident All-cancer Patients | Number of All-Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions | Tertile 3 (without 2 year lag) | 4152 participants |
| Matched Controls for Incident All-cancer Patients | Number of All-Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions | Never (with 2 year lag) | 1704443 participants |
| Matched Controls for Incident All-cancer Patients | Number of All-Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions | Never (without 2 year lag) | 1698480 participants |
| Matched Controls for Incident All-cancer Patients | Number of All-Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions | Tertile 1 (with 2 year lag) | 2739 participants |
| Matched Controls for Incident All-cancer Patients | Number of All-Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions | Tertile 2 (without 2 year lag) | 3033 participants |
| Matched Controls for Incident All-cancer Patients | Number of All-Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions | Tertile 2 (with 2 year lag) | 1645 participants |
| Matched Controls for Incident All-cancer Patients | Number of All-Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions | Tertile 1 (without 2 year lag) | 5285 participants |
| Matched Controls for Incident All-cancer Patients | Number of All-Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions | Tertile 3 (with 2 year lag) | 2123 participants |
p-value: 0.146895% CI: [0.97, 1.23]Conditional Logistic Regression
p-value: 0.854595% CI: [0.9, 1.14]Conditional Logistic Regression
p-value: <0.000195% CI: [1.27, 1.48]Conditional Logistic Regression
p-value: <0.000195% CI: [1.18, 1.37]Conditional Logistic Regression
p-value: 0.003395% CI: [1.07, 1.43]Conditional Logistic Regression
p-value: 0.047495% CI: [1, 1.33]Conditional Logistic Regression
p-value: <0.000195% CI: [1.16, 1.43]Conditional Logistic Regression
p-value: 0.000895% CI: [1.08, 1.32]Conditional Logistic Regression
p-value: 0.01995% CI: [1.03, 1.33]Conditional Logistic Regression
p-value: 0.336695% CI: [0.94, 1.21]Conditional Logistic Regression
p-value: 0.000195% CI: [1.09, 1.31]Conditional Logistic Regression
p-value: 0.046495% CI: [1, 1.2]Conditional Logistic Regression
Primary
Number of Anal Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin
Incident anal cancer. Gabapentin (Gaba.) Exposure Description: With 2 yr lag=Gaba. exposure from cohort entry to 2 yr prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer). Without 2 yr lag=Gaba. exposure from cohort entry to index date. Tertiles (T) with 2 yr lag: T 1 (0.1-30.0 grams \[g\]), T 2 (30.1-189.0 g), and T 3 (189.1-9600.0 g). Tertiles without 2 yr lag: T 1 (0.1-30.0 g), T 2 (30.1-189.0 g), and T 3 (189.1-11610.0 g). Inestimable OR and 95% CI when no gaba.-exposed cancer cases or controls at the exposure level.
Time frame: The case index date was the date of incident anal cancer diagnosis ascertained in the GPRD study cohort 1995-2008. The matched control index date was the date at which the follow-up time from his/her cohort entry was the same as that for the case.
Population: Cases \& controls drawn from the GPRD study cohort. Entry into study cohort began January 1, 1993, or at time of GPRD registration if after Jan. 1, 1993. Follow-up ended December 31, 2008, or earlier if respective cancer was diagnosed or if participant left the GPRD for any reason including death. Participants with prior history of cancer excluded.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Incident All-cancer Patients | Number of Anal Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin | Never (with 2 year lag) | 208 participants |
| Incident All-cancer Patients | Number of Anal Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin | Tertile 1 (with 2 year lag) | 2 participants |
| Incident All-cancer Patients | Number of Anal Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin | Tertile 2 (with 2 year lag) | 1 participants |
| Incident All-cancer Patients | Number of Anal Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin | Tertile 3 (with 2 year lag) | 1 participants |
| Incident All-cancer Patients | Number of Anal Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin | Never (without 2 year lag) | 207 participants |
| Incident All-cancer Patients | Number of Anal Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin | Tertile 1 (without 2 year lag) | 3 participants |
| Incident All-cancer Patients | Number of Anal Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin | Tertile 2 (without 2 year lag) | 0 participants |
| Incident All-cancer Patients | Number of Anal Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin | Tertile 3 (without 2 year lag) | 2 participants |
| Matched Controls for Incident All-cancer Patients | Number of Anal Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin | Tertile 3 (without 2 year lag) | 5 participants |
| Matched Controls for Incident All-cancer Patients | Number of Anal Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin | Never (with 2 year lag) | 2061 participants |
| Matched Controls for Incident All-cancer Patients | Number of Anal Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin | Never (without 2 year lag) | 2052 participants |
| Matched Controls for Incident All-cancer Patients | Number of Anal Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin | Tertile 1 (with 2 year lag) | 1 participants |
| Matched Controls for Incident All-cancer Patients | Number of Anal Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin | Tertile 2 (without 2 year lag) | 3 participants |
| Matched Controls for Incident All-cancer Patients | Number of Anal Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin | Tertile 2 (with 2 year lag) | 3 participants |
| Matched Controls for Incident All-cancer Patients | Number of Anal Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin | Tertile 1 (without 2 year lag) | 7 participants |
| Matched Controls for Incident All-cancer Patients | Number of Anal Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin | Tertile 3 (with 2 year lag) | 2 participants |
p-value: 0.014495% CI: [1.81, 220.5]Conditional Logistic Regression
p-value: 0.015795% CI: [1.78, 260.2]Conditional Logistic Regression
p-value: 0.052495% CI: [0.99, 15.14]Conditional Logistic Regression
p-value: 0.033395% CI: [1.13, 20.31]Conditional Logistic Regression
p-value: 0.296695% CI: [0.35, 32.06]Conditional Logistic Regression
p-value: 0.75195% CI: [0.03, 12.31]Conditional Logistic Regression
p-value: 0.186895% CI: [0.4, 113.4]Conditional Logistic Regression
p-value: 0.755895% CI: [0.07, 40.61]Conditional Logistic Regression
p-value: 0.094495% CI: [0.78, 24.07]Conditional Logistic Regression
p-value: 0.924495% CI: [0.1, 7.81]Conditional Logistic Regression
Primary
Number of Anal Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin
Incident anal cancer. Gabapentin (Gaba.) Exposure Description: With 2 year (yr) lag=Gaba. exposure from cohort entry to 2 yr prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer). Without 2 yr lag=Gaba. exposure from cohort entry to index date. Tertiles (T) with 2 yr lag: T 1 (0.01-1.38 months \[mo.\]), T 2 (1.39-5.56 mo.), and T 3 (5.57 -105.82 mo.). Tertiles without 2 yr lag: T 1 (0.01-1.38 mo.), T 2 (1.39-5.72 mo.), and T 3 (5.73-123.70 mo.). Inestimable OR and 95% CI when no gaba.-exposed cancer cases or controls at the exposure level.
Time frame: The case index date was the date of incident anal cancer diagnosis ascertained in the GPRD study cohort 1995-2008. The matched control index date was the date at which the follow-up time from his/her cohort entry was the same as that for the case.
Population: Cases \& controls drawn from the GPRD study cohort. Entry into study cohort began January 1, 1993, or at time of GPRD registration if after Jan. 1, 1993. Follow-up ended December 31, 2008, or earlier if respective cancer was diagnosed or if participant left the GPRD for any reason including death. Participants with prior history of cancer excluded.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Incident All-cancer Patients | Number of Anal Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin | Never (with 2 year lag) | 208 participants |
| Incident All-cancer Patients | Number of Anal Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin | Tertile 1 (with 2 year lag) | 2 participants |
| Incident All-cancer Patients | Number of Anal Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin | Tertile 2 (with 2 year lag) | 1 participants |
| Incident All-cancer Patients | Number of Anal Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin | Tertile 3 (with 2 year lag) | 1 participants |
| Incident All-cancer Patients | Number of Anal Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin | Never (without 2 year lag) | 207 participants |
| Incident All-cancer Patients | Number of Anal Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin | Tertile 1 (without 2 year lag) | 3 participants |
| Incident All-cancer Patients | Number of Anal Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin | Tertile 2 (without 2 year lag) | 0 participants |
| Incident All-cancer Patients | Number of Anal Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin | Tertile 3 (without 2 year lag) | 2 participants |
| Matched Controls for Incident All-cancer Patients | Number of Anal Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin | Tertile 3 (without 2 year lag) | 5 participants |
| Matched Controls for Incident All-cancer Patients | Number of Anal Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin | Never (with 2 year lag) | 2061 participants |
| Matched Controls for Incident All-cancer Patients | Number of Anal Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin | Never (without 2 year lag) | 2052 participants |
| Matched Controls for Incident All-cancer Patients | Number of Anal Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin | Tertile 1 (with 2 year lag) | 1 participants |
| Matched Controls for Incident All-cancer Patients | Number of Anal Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin | Tertile 2 (without 2 year lag) | 5 participants |
| Matched Controls for Incident All-cancer Patients | Number of Anal Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin | Tertile 2 (with 2 year lag) | 2 participants |
| Matched Controls for Incident All-cancer Patients | Number of Anal Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin | Tertile 1 (without 2 year lag) | 5 participants |
| Matched Controls for Incident All-cancer Patients | Number of Anal Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin | Tertile 3 (with 2 year lag) | 3 participants |
p-value: 0.014495% CI: [1.81, 220.5]Conditional Logistic Regression
p-value: 0.015895% CI: [1.78, 258.8]Conditional Logistic Regression
p-value: 0.014195% CI: [1.43, 25.11]Conditional Logistic Regression
p-value: 0.006395% CI: [1.83, 40.02]Conditional Logistic Regression
p-value: 0.188895% CI: [0.45, 55.14]Conditional Logistic Regression
p-value: 0.99995% CI: [0.03, 32.21]Conditional Logistic Regression
p-value: 0.288595% CI: [0.33, 43.08]Conditional Logistic Regression
p-value: 0.960895% CI: [0.06, 13.87]Conditional Logistic Regression
p-value: 0.094495% CI: [0.78, 24.07]Conditional Logistic Regression
p-value: 0.938195% CI: [0.11, 7.97]Conditional Logistic Regression
Primary
Number of Anal Cancer Cases and Matched Controls With the Indicated Exposure to Gabapentin
Incident Anal cancer. Gabapentin Exposure Description: With 2 year lag = Gabapentin prescription from cohort entry to 2 years prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer). Without 2 year lag = Gabapentin prescription from cohort entry to index date.
Time frame: The case index date was the date of incident anal cancer diagnosis ascertained in the GPRD study cohort 1995-2008. The matched control index date was the date at which the follow-up time from his/her cohort entry was the same as that for the case.
Population: Cases \& controls drawn from the GPRD study cohort. Entry into study cohort began January 1, 1993, or at time of GPRD registration if after Jan. 1, 1993. Follow-up ended December 31, 2008, or earlier if respective cancer was diagnosed or if participant left the GPRD for any reason including death. Participants with prior history of cancer excluded.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Incident All-cancer Patients | Number of Anal Cancer Cases and Matched Controls With the Indicated Exposure to Gabapentin | Ever (with 2 year lag) | 4 participants |
| Incident All-cancer Patients | Number of Anal Cancer Cases and Matched Controls With the Indicated Exposure to Gabapentin | Never (with 2 year lag) | 208 participants |
| Incident All-cancer Patients | Number of Anal Cancer Cases and Matched Controls With the Indicated Exposure to Gabapentin | Ever (without 2 year lag) | 5 participants |
| Incident All-cancer Patients | Number of Anal Cancer Cases and Matched Controls With the Indicated Exposure to Gabapentin | Never (without 2 year lag) | 207 participants |
| Matched Controls for Incident All-cancer Patients | Number of Anal Cancer Cases and Matched Controls With the Indicated Exposure to Gabapentin | Never (without 2 year lag) | 2052 participants |
| Matched Controls for Incident All-cancer Patients | Number of Anal Cancer Cases and Matched Controls With the Indicated Exposure to Gabapentin | Ever (with 2 year lag) | 6 participants |
| Matched Controls for Incident All-cancer Patients | Number of Anal Cancer Cases and Matched Controls With the Indicated Exposure to Gabapentin | Ever (without 2 year lag) | 15 participants |
| Matched Controls for Incident All-cancer Patients | Number of Anal Cancer Cases and Matched Controls With the Indicated Exposure to Gabapentin | Never (with 2 year lag) | 2061 participants |
p-value: 0.003295% CI: [1.95, 27.56]Conditional Logistic Regression
p-value: 0.125195% CI: [0.71, 16.17]Conditional Logistic Regression
p-value: 0.026195% CI: [1.15, 9.01]Conditional Logistic Regression
p-value: 0.20995% CI: [0.65, 7.17]Conditional Logistic Regression
Primary
Number of Anal Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin
Incident anal cancer. Gabapentin Exposure Description: With 2 year lag = Gabapentin exposure from cohort entry to 2 years prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer). Without 2 year lag = Gabapentin exposure from cohort entry to index date.
Time frame: The case index date was the date of incident anal cancer diagnosis ascertained in the GPRD study cohort 1995-2008. The matched control index date was the date at which the follow-up time from his/her cohort entry was the same as that for the case.
Population: Cases \& controls drawn from the GPRD study cohort. Entry into study cohort began January 1, 1993, or at time of GPRD registration if after Jan. 1, 1993. Follow-up ended December 31, 2008, or earlier if respective cancer was diagnosed or if participant left the GPRD for any reason including death. Participants with prior history of cancer excluded.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Incident All-cancer Patients | Number of Anal Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin | Never (with 2 year lag) | 208 participants |
| Incident All-cancer Patients | Number of Anal Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin | > 1 year (with 2 year lag) | 0 participants |
| Incident All-cancer Patients | Number of Anal Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin | > 2 year (with 2 year lag) | 0 participants |
| Incident All-cancer Patients | Number of Anal Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin | > 3 year (with 2 year lag) | 0 participants |
| Incident All-cancer Patients | Number of Anal Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin | Never (without 2 year lag) | 207 participants |
| Incident All-cancer Patients | Number of Anal Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin | > 1 year (without 2 year lag) | 2 participants |
| Incident All-cancer Patients | Number of Anal Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin | > 2 year (without 2 year lag) | 0 participants |
| Incident All-cancer Patients | Number of Anal Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin | > 3 year (without 2 year lag) | 0 participants |
| Matched Controls for Incident All-cancer Patients | Number of Anal Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin | > 3 year (without 2 year lag) | 1 participants |
| Matched Controls for Incident All-cancer Patients | Number of Anal Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin | Never (with 2 year lag) | 2061 participants |
| Matched Controls for Incident All-cancer Patients | Number of Anal Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin | Never (without 2 year lag) | 2052 participants |
| Matched Controls for Incident All-cancer Patients | Number of Anal Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin | > 1 year (with 2 year lag) | 1 participants |
| Matched Controls for Incident All-cancer Patients | Number of Anal Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin | > 2 year (without 2 year lag) | 1 participants |
| Matched Controls for Incident All-cancer Patients | Number of Anal Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin | > 2 year (with 2 year lag) | 1 participants |
| Matched Controls for Incident All-cancer Patients | Number of Anal Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin | > 1 year (without 2 year lag) | 3 participants |
| Matched Controls for Incident All-cancer Patients | Number of Anal Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin | > 3 year (with 2 year lag) | 1 participants |
Primary
Number of Anal Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions
Incident anal cancer. Gabapentin (Gaba.) Exposure Description: With 2 year (yr) lag=Gaba. exposure from cohort entry to 2 yr prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer). Without 2 yr lag=Gaba. exposure from cohort entry to index date. Tertiles (T) with 2 yr lag: T 1 (1-2 prescriptions \[prescrip.\]), T 2 (3-7 prescrip.), T 3 (8-298 prescrip.). Tertiles without 2 yr lag: T 1 (1-2 prescrip.), T 2 (3-7 prescrip.), and T 3 (8-388 prescrip.). Inestimable OR and 95% CI when no gaba.-exposed cancer cases or controls at the exposure level.
Time frame: The case index date was the date of incident anal cancer diagnosis ascertained in the GPRD study cohort 1995-2008. The matched control index date was the date at which the follow-up time from his/her cohort entry was the same as that for the case.
Population: Cases \& controls drawn from the GPRD study cohort. Entry into study cohort began January 1, 1993, or at time of GPRD registration if after Jan. 1, 1993. Follow-up ended December 31, 2008, or earlier if respective cancer was diagnosed or if participant left the GPRD for any reason including death. Participants with prior history of cancer excluded.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Incident All-cancer Patients | Number of Anal Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions | Never (with 2 year lag) | 208 participants |
| Incident All-cancer Patients | Number of Anal Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions | Tertile 1 (with 2 year lag) | 2 participants |
| Incident All-cancer Patients | Number of Anal Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions | Tertile 2 (with 2 year lag) | 1 participants |
| Incident All-cancer Patients | Number of Anal Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions | Tertile 3 (with 2 year lag) | 1 participants |
| Incident All-cancer Patients | Number of Anal Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions | Never (without 2 year lag) | 207 participants |
| Incident All-cancer Patients | Number of Anal Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions | Tertile 1 (without 2 year lag) | 3 participants |
| Incident All-cancer Patients | Number of Anal Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions | Tertile 2 (without 2 year lag) | 0 participants |
| Incident All-cancer Patients | Number of Anal Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions | Tertile 3 (without 2 year lag) | 2 participants |
| Matched Controls for Incident All-cancer Patients | Number of Anal Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions | Tertile 3 (without 2 year lag) | 5 participants |
| Matched Controls for Incident All-cancer Patients | Number of Anal Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions | Never (with 2 year lag) | 2061 participants |
| Matched Controls for Incident All-cancer Patients | Number of Anal Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions | Never (without 2 year lag) | 2052 participants |
| Matched Controls for Incident All-cancer Patients | Number of Anal Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions | Tertile 1 (with 2 year lag) | 1 participants |
| Matched Controls for Incident All-cancer Patients | Number of Anal Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions | Tertile 2 (without 2 year lag) | 3 participants |
| Matched Controls for Incident All-cancer Patients | Number of Anal Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions | Tertile 2 (with 2 year lag) | 2 participants |
| Matched Controls for Incident All-cancer Patients | Number of Anal Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions | Tertile 1 (without 2 year lag) | 7 participants |
| Matched Controls for Incident All-cancer Patients | Number of Anal Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions | Tertile 3 (with 2 year lag) | 3 participants |
p-value: 0.014495% CI: [1.81, 220.5]Conditional Logistic Regression
p-value: 0.015895% CI: [1.78, 258.8]Conditional Logistic Regression
p-value: 0.052495% CI: [0.99, 15.14]Conditional Logistic Regression
p-value: 0.026995% CI: [1.21, 22.51]Conditional Logistic Regression
p-value: 0.188895% CI: [0.45, 55.14]Conditional Logistic Regression
p-value: 0.99995% CI: [0.03, 32.21]Conditional Logistic Regression
p-value: 0.288595% CI: [0.33, 43.08]Conditional Logistic Regression
p-value: 0.960895% CI: [0.06, 13.87]Conditional Logistic Regression
p-value: 0.094495% CI: [0.78, 24.07]Conditional Logistic Regression
p-value: 0.925395% CI: [0.1, 7.82]Conditional Logistic Regression
Primary
Number of Bladder Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin
Incident bladder cancer. Gabapentin Exposure Description: With 2 year lag = Gabapentin exposure from cohort entry to 2 years prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer). Without 2 year lag = Gabapentin exposure from cohort entry to index date. Tertile's with 2 year lag: Tertile 1 (0.1 - 30.0 grams), Tertile 2 (30.1 - 189.0 grams), and Tertile 3 (189.1 - 9600.0 grams). Tertile's without 2 year lag: Tertile 1 (0.1 - 30.0 grams), Tertile 2 (30.1 - 189.0 grams), and Tertile 3 (189.1 - 11610.0 grams).
Time frame: The case index date was the date of incident bladder cancer diagnosis ascertained in the GPRD study cohort 1995-2008. The matched control index date was the date at which the follow-up time from his/her cohort entry was the same as that for the case
Population: Cases \& controls drawn from the GPRD study cohort. Entry into study cohort began January 1, 1993, or at time of GPRD registration if after Jan. 1, 1993. Follow-up ended December 31, 2008, or earlier if respective cancer was diagnosed or if participant left the GPRD for any reason including death. Participants with prior history of cancer excluded.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Incident All-cancer Patients | Number of Bladder Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin | Never (with 2 year lag) | 4585 participants |
| Incident All-cancer Patients | Number of Bladder Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin | Tertile 1 (with 2 year lag) | 6 participants |
| Incident All-cancer Patients | Number of Bladder Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin | Tertile 2 (with 2 year lag) | 4 participants |
| Incident All-cancer Patients | Number of Bladder Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin | Tertile 3 (with 2 year lag) | 5 participants |
| Incident All-cancer Patients | Number of Bladder Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin | Never (without 2 year lag) | 4567 participants |
| Incident All-cancer Patients | Number of Bladder Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin | Tertile 1 (without 2 year lag) | 14 participants |
| Incident All-cancer Patients | Number of Bladder Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin | Tertile 2 (without 2 year lag) | 10 participants |
| Incident All-cancer Patients | Number of Bladder Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin | Tertile 3 (without 2 year lag) | 9 participants |
| Matched Controls for Incident All-cancer Patients | Number of Bladder Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin | Tertile 3 (without 2 year lag) | 84 participants |
| Matched Controls for Incident All-cancer Patients | Number of Bladder Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin | Never (with 2 year lag) | 43415 participants |
| Matched Controls for Incident All-cancer Patients | Number of Bladder Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin | Never (without 2 year lag) | 43260 participants |
| Matched Controls for Incident All-cancer Patients | Number of Bladder Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin | Tertile 1 (with 2 year lag) | 52 participants |
| Matched Controls for Incident All-cancer Patients | Number of Bladder Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin | Tertile 2 (without 2 year lag) | 103 participants |
| Matched Controls for Incident All-cancer Patients | Number of Bladder Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin | Tertile 2 (with 2 year lag) | 51 participants |
| Matched Controls for Incident All-cancer Patients | Number of Bladder Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin | Tertile 1 (without 2 year lag) | 112 participants |
| Matched Controls for Incident All-cancer Patients | Number of Bladder Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin | Tertile 3 (with 2 year lag) | 41 participants |
p-value: 0.811195% CI: [0.48, 2.59]Conditional Logistic Regression
p-value: 0.910495% CI: [0.45, 2.46]Conditional Logistic Regression
p-value: 0.559295% CI: [0.68, 2.07]Conditional Logistic Regression
p-value: 0.852195% CI: [0.6, 1.85]Conditional Logistic Regression
p-value: 0.552995% CI: [0.26, 2.04]Conditional Logistic Regression
p-value: 0.327595% CI: [0.21, 1.68]Conditional Logistic Regression
p-value: 0.7395% CI: [0.46, 1.72]Conditional Logistic Regression
p-value: 0.483195% CI: [0.41, 1.53]Conditional Logistic Regression
p-value: 0.769395% CI: [0.45, 2.92]Conditional Logistic Regression
p-value: 0.818995% CI: [0.35, 2.3]Conditional Logistic Regression
p-value: 0.9895% CI: [0.5, 1.98]Conditional Logistic Regression
p-value: 0.494495% CI: [0.39, 1.58]Conditional Logistic Regression
Primary
Number of Bladder Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin
Incident bladder cancer. Gabapentin Exposure Description: With 2 year lag = Gabapentin exposure from cohort entry to 2 years prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer). Without 2 year lag = Gabapentin exposure from cohort entry to index date. Tertile's with 2 year lag: Tertile 1 (0.01 - 1.38 months), Tertile 2 (1.39 - 5.56 months), and Tertile 3 (5.57 - 105.82 months). Tertile's without 2 year lag: Tertile 1 (0.01 - 1.38 months), Tertile 2 (1.39 - 5.72 months), and Tertile 3 (5.73 - 123.70 months).
Time frame: The case index date was the date of incident bladder cancer diagnosis ascertained in the GPRD study cohort 1995-2008. The matched control index date was the date at which the follow-up time from his/her cohort entry was the same as that for the case
Population: Cases \& controls drawn from the GPRD study cohort. Entry into study cohort began January 1, 1993, or at time of GPRD registration if after Jan. 1, 1993. Follow-up ended December 31, 2008, or earlier if respective cancer was diagnosed or if participant left the GPRD for any reason including death. Participants with prior history of cancer excluded.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Incident All-cancer Patients | Number of Bladder Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin | Never (with 2 year lag) | 4585 participants |
| Incident All-cancer Patients | Number of Bladder Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin | Tertile 1 (with 2 year lag) | 5 participants |
| Incident All-cancer Patients | Number of Bladder Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin | Tertile 2 (with 2 year lag) | 4 participants |
| Incident All-cancer Patients | Number of Bladder Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin | Tertile 3 (with 2 year lag) | 6 participants |
| Incident All-cancer Patients | Number of Bladder Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin | Never (without 2 year lag) | 4567 participants |
| Incident All-cancer Patients | Number of Bladder Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin | Tertile 1 (without 2 year lag) | 12 participants |
| Incident All-cancer Patients | Number of Bladder Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin | Tertile 2 (without 2 year lag) | 11 participants |
| Incident All-cancer Patients | Number of Bladder Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin | Tertile 3 (without 2 year lag) | 10 participants |
| Matched Controls for Incident All-cancer Patients | Number of Bladder Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin | Tertile 3 (without 2 year lag) | 87 participants |
| Matched Controls for Incident All-cancer Patients | Number of Bladder Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin | Never (with 2 year lag) | 43415 participants |
| Matched Controls for Incident All-cancer Patients | Number of Bladder Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin | Never (without 2 year lag) | 43260 participants |
| Matched Controls for Incident All-cancer Patients | Number of Bladder Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin | Tertile 1 (with 2 year lag) | 51 participants |
| Matched Controls for Incident All-cancer Patients | Number of Bladder Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin | Tertile 2 (without 2 year lag) | 100 participants |
| Matched Controls for Incident All-cancer Patients | Number of Bladder Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin | Tertile 2 (with 2 year lag) | 52 participants |
| Matched Controls for Incident All-cancer Patients | Number of Bladder Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin | Tertile 1 (without 2 year lag) | 112 participants |
| Matched Controls for Incident All-cancer Patients | Number of Bladder Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin | Tertile 3 (with 2 year lag) | 41 participants |
p-value: 0.865595% CI: [0.37, 2.33]Conditional Logistic Regression
p-value: 0.648295% CI: [0.32, 2.05]Conditional Logistic Regression
p-value: 0.900395% CI: [0.53, 1.76]Conditional Logistic Regression
p-value: 0.695% CI: [0.46, 1.56]Conditional Logistic Regression
p-value: 0.56795% CI: [0.27, 2.06]Conditional Logistic Regression
p-value: 0.435395% CI: [0.24, 1.85]Conditional Logistic Regression
p-value: 0.892295% CI: [0.56, 1.95]Conditional Logistic Regression
p-value: 0.859195% CI: [0.5, 1.77]Conditional Logistic Regression
p-value: 0.477995% CI: [0.58, 3.23]Conditional Logistic Regression
p-value: 0.899495% CI: [0.44, 2.52]Conditional Logistic Regression
p-value: 0.7895% CI: [0.57, 2.12]Conditional Logistic Regression
p-value: 0.657795% CI: [0.44, 1.67]Conditional Logistic Regression
Primary
Number of Bladder Cancer Cases and Matched Controls With the Indicated Exposure to Gabapentin
Incident bladder cancer. Gabapentin Exposure Description: With 2 year lag = Gabapentin prescription from cohort entry to 2 years prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer). Without 2 year lag = Gabapentin prescription from cohort entry to index date.
Time frame: The case index date was the date of incident bladder cancer diagnosis ascertained in the GPRD study cohort 1995-2008. The matched control index date was the date at which the follow-up time from his/her cohort entry was the same as that for the case
Population: Cases \& controls drawn from the GPRD study cohort. Entry into study cohort began January 1, 1993, or at time of GPRD registration if after Jan. 1, 1993. Follow-up ended December 31, 2008, or earlier if respective cancer was diagnosed or if participant left the GPRD for any reason including death. Participants with prior history of cancer excluded.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Incident All-cancer Patients | Number of Bladder Cancer Cases and Matched Controls With the Indicated Exposure to Gabapentin | Ever (with 2 year lag) | 15 participants |
| Incident All-cancer Patients | Number of Bladder Cancer Cases and Matched Controls With the Indicated Exposure to Gabapentin | Ever (without 2 year lag) | 33 participants |
| Incident All-cancer Patients | Number of Bladder Cancer Cases and Matched Controls With the Indicated Exposure to Gabapentin | Never (without 2 year lag) | 4567 participants |
| Incident All-cancer Patients | Number of Bladder Cancer Cases and Matched Controls With the Indicated Exposure to Gabapentin | Never (with 2 year lag) | 4585 participants |
| Matched Controls for Incident All-cancer Patients | Number of Bladder Cancer Cases and Matched Controls With the Indicated Exposure to Gabapentin | Never (without 2 year lag) | 43260 participants |
| Matched Controls for Incident All-cancer Patients | Number of Bladder Cancer Cases and Matched Controls With the Indicated Exposure to Gabapentin | Ever (with 2 year lag) | 144 participants |
| Matched Controls for Incident All-cancer Patients | Number of Bladder Cancer Cases and Matched Controls With the Indicated Exposure to Gabapentin | Never (with 2 year lag) | 43415 participants |
| Matched Controls for Incident All-cancer Patients | Number of Bladder Cancer Cases and Matched Controls With the Indicated Exposure to Gabapentin | Ever (without 2 year lag) | 299 participants |
p-value: 0.507895% CI: [0.61, 1.28]Conditional Logistic Regression
p-value: 0.961495% CI: [0.58, 1.69]Conditional Logistic Regression
p-value: 0.517995% CI: [0.49, 1.44]Conditional Logistic Regression
p-value: 0.885695% CI: [0.71, 1.48]Conditional Logistic Regression
Primary
Number of Bladder Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin
Incident bladder cancer. Gabapentin Exposure Description: With 2 year lag = Gabapentin exposure from cohort entry to 2 years prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer). Without 2 year lag = Gabapentin exposure from cohort entry to index date.
Time frame: The case index date was the date of incident bladder cancer diagnosis ascertained in the GPRD study cohort 1995-2008. The matched control index date was the date at which the follow-up time from his/her cohort entry was the same as that for the case
Population: Cases \& controls drawn from the GPRD study cohort. Entry into study cohort began January 1, 1993, or at time of GPRD registration if after Jan. 1, 1993. Follow-up ended December 31, 2008, or earlier if respective cancer was diagnosed or if participant left the GPRD for any reason including death. Participants with prior history of cancer excluded.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Incident All-cancer Patients | Number of Bladder Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin | Never (with 2 year lag) | 4585 participants |
| Incident All-cancer Patients | Number of Bladder Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin | > 1 year (with 2 year lag) | 2 participants |
| Incident All-cancer Patients | Number of Bladder Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin | > 2 year (with 2 year lag) | 0 participants |
| Incident All-cancer Patients | Number of Bladder Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin | > 3 year (with 2 year lag) | 0 participants |
| Incident All-cancer Patients | Number of Bladder Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin | Never (without 2 year lag) | 4567 participants |
| Incident All-cancer Patients | Number of Bladder Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin | > 1 year (without 2 year lag) | 6 participants |
| Incident All-cancer Patients | Number of Bladder Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin | > 2 year (without 2 year lag) | 2 participants |
| Incident All-cancer Patients | Number of Bladder Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin | > 3 year (without 2 year lag) | 1 participants |
| Matched Controls for Incident All-cancer Patients | Number of Bladder Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin | > 3 year (without 2 year lag) | 10 participants |
| Matched Controls for Incident All-cancer Patients | Number of Bladder Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin | Never (with 2 year lag) | 43415 participants |
| Matched Controls for Incident All-cancer Patients | Number of Bladder Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin | Never (without 2 year lag) | 43260 participants |
| Matched Controls for Incident All-cancer Patients | Number of Bladder Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin | > 1 year (with 2 year lag) | 21 participants |
| Matched Controls for Incident All-cancer Patients | Number of Bladder Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin | > 2 year (without 2 year lag) | 24 participants |
| Matched Controls for Incident All-cancer Patients | Number of Bladder Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin | > 2 year (with 2 year lag) | 7 participants |
| Matched Controls for Incident All-cancer Patients | Number of Bladder Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin | > 1 year (without 2 year lag) | 52 participants |
| Matched Controls for Incident All-cancer Patients | Number of Bladder Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin | > 3 year (with 2 year lag) | 3 participants |
Primary
Number of Bladder Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions
Incident bladder cancer. Gabapentin Exposure Description: With 2 year lag = Gabapentin exposure from cohort entry to 2 years prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer). Without 2 year lag = Gabapentin exposure from cohort entry to index date. Tertile's with 2 year lag: Tertile 1 (1-2 prescriptions), Tertile 2 (3-7 prescriptions), Tertile 3 (8-298 prescriptions). Tertiles without 2 year lag: Tertile 1 (1-2 prescriptions), Tertile 2 (3-7 prescriptions), and Tertile 3 (8-388 prescriptions).
Time frame: The case index date was the date of incident bladder cancer diagnosis ascertained in the GPRD study cohort 1995-2008. The matched control index date was the date at which the follow-up time from his/her cohort entry was the same as that for the case
Population: Cases \& controls drawn from the GPRD study cohort. Entry into study cohort began January 1, 1993, or at time of GPRD registration if after Jan. 1, 1993. Follow-up ended December 31, 2008, or earlier if respective cancer was diagnosed or if participant left the GPRD for any reason including death. Participants with prior history of cancer excluded.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Incident All-cancer Patients | Number of Bladder Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions | Never (with 2 year lag) | 4585 participants |
| Incident All-cancer Patients | Number of Bladder Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions | Tertile 1 (with 2 year lag) | 6 participants |
| Incident All-cancer Patients | Number of Bladder Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions | Tertile 2 (with 2 year lag) | 3 participants |
| Incident All-cancer Patients | Number of Bladder Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions | Tertile 3 (with 2 year lag) | 6 participants |
| Incident All-cancer Patients | Number of Bladder Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions | Never (without 2 year lag) | 4567 participants |
| Incident All-cancer Patients | Number of Bladder Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions | Tertile 1 (without 2 year lag) | 13 participants |
| Incident All-cancer Patients | Number of Bladder Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions | Tertile 2 (without 2 year lag) | 10 participants |
| Incident All-cancer Patients | Number of Bladder Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions | Tertile 3 (without 2 year lag) | 10 participants |
| Matched Controls for Incident All-cancer Patients | Number of Bladder Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions | Tertile 3 (without 2 year lag) | 90 participants |
| Matched Controls for Incident All-cancer Patients | Number of Bladder Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions | Never (with 2 year lag) | 43415 participants |
| Matched Controls for Incident All-cancer Patients | Number of Bladder Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions | Never (without 2 year lag) | 43260 participants |
| Matched Controls for Incident All-cancer Patients | Number of Bladder Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions | Tertile 1 (with 2 year lag) | 68 participants |
| Matched Controls for Incident All-cancer Patients | Number of Bladder Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions | Tertile 2 (without 2 year lag) | 71 participants |
| Matched Controls for Incident All-cancer Patients | Number of Bladder Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions | Tertile 2 (with 2 year lag) | 35 participants |
| Matched Controls for Incident All-cancer Patients | Number of Bladder Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions | Tertile 1 (without 2 year lag) | 138 participants |
| Matched Controls for Incident All-cancer Patients | Number of Bladder Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions | Tertile 3 (with 2 year lag) | 41 participants |
p-value: 0.688895% CI: [0.36, 1.95]Conditional Logistic Regression
p-value: 0.502495% CI: [0.32, 1.75]Conditional Logistic Regression
p-value: 0.616495% CI: [0.49, 1.53]Conditional Logistic Regression
p-value: 0.400295% CI: [0.44, 1.39]Conditional Logistic Regression
p-value: 0.732995% CI: [0.25, 2.66]Conditional Logistic Regression
p-value: 0.573195% CI: [0.22, 2.33]Conditional Logistic Regression
p-value: 0.376295% CI: [0.69, 2.63]Conditional Logistic Regression
p-value: 0.58295% CI: [0.62, 2.36]Conditional Logistic Regression
p-value: 0.478295% CI: [0.58, 3.23]Conditional Logistic Regression
p-value: 0.899895% CI: [0.44, 2.52]Conditional Logistic Regression
p-value: 0.930895% CI: [0.53, 1.99]Conditional Logistic Regression
p-value: 0.512595% CI: [0.41, 1.56]Conditional Logistic Regression
Primary
Number of Bone/Joint Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin
Incident bone/joint cancer. Gabapentin (Gaba.) Exposure Description: With 2 year (yr) lag=Gaba. exposure from cohort entry to 2 yr prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer). Without 2 yr lag=Gaba. exposure from cohort entry to index date. Tertiles (T) with 2 yr lag: T 1 (0.1-30.0 grams \[g\]), T 2 (30.1-189.0 g), and T 3 (189.1-9600.0 g). Tertiles without 2 yr lag: T 1 (0.1-30.0 g), T 2 (30.1-189.0 g), and T 3 (189.1-11610.0 g). Inestimable OR and 95% CI when no gaba.-exposed cancer cases or controls at the exposure level.
Time frame: The case index date was the date of incident bone/joint cancer diagnosis ascertained in the GPRD study cohort 1995-2008. The matched control index date was the date at which the follow-up time from his/her cohort entry was the same as for the case.
Population: Cases \& controls drawn from the GPRD study cohort. Entry into study cohort began January 1, 1993, or at time of GPRD registration if after Jan. 1, 1993. Follow-up ended December 31, 2008, or earlier if respective cancer was diagnosed or if participant left the GPRD for any reason including death. Participants with prior history of cancer excluded.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Incident All-cancer Patients | Number of Bone/Joint Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin | Never (with 2 year lag) | 300 participants |
| Incident All-cancer Patients | Number of Bone/Joint Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin | Tertile 1 (with 2 year lag) | 0 participants |
| Incident All-cancer Patients | Number of Bone/Joint Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin | Tertile 2 (with 2 year lag) | 0 participants |
| Incident All-cancer Patients | Number of Bone/Joint Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin | Tertile 3 (with 2 year lag) | 0 participants |
| Incident All-cancer Patients | Number of Bone/Joint Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin | Never (without 2 year lag) | 299 participants |
| Incident All-cancer Patients | Number of Bone/Joint Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin | Tertile 1 (without 2 year lag) | 1 participants |
| Incident All-cancer Patients | Number of Bone/Joint Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin | Tertile 2 (without 2 year lag) | 0 participants |
| Incident All-cancer Patients | Number of Bone/Joint Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin | Tertile 3 (without 2 year lag) | 0 participants |
| Matched Controls for Incident All-cancer Patients | Number of Bone/Joint Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin | Tertile 3 (without 2 year lag) | 8 participants |
| Matched Controls for Incident All-cancer Patients | Number of Bone/Joint Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin | Never (with 2 year lag) | 2925 participants |
| Matched Controls for Incident All-cancer Patients | Number of Bone/Joint Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin | Never (without 2 year lag) | 2916 participants |
| Matched Controls for Incident All-cancer Patients | Number of Bone/Joint Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin | Tertile 1 (with 2 year lag) | 4 participants |
| Matched Controls for Incident All-cancer Patients | Number of Bone/Joint Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin | Tertile 2 (without 2 year lag) | 3 participants |
| Matched Controls for Incident All-cancer Patients | Number of Bone/Joint Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin | Tertile 2 (with 2 year lag) | 6 participants |
| Matched Controls for Incident All-cancer Patients | Number of Bone/Joint Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin | Tertile 1 (without 2 year lag) | 8 participants |
| Matched Controls for Incident All-cancer Patients | Number of Bone/Joint Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin | Tertile 3 (with 2 year lag) | 0 participants |
p-value: 0.914195% CI: [0.14, 9.03]Conditional Logistic Regression
p-value: 0.961395% CI: [0.12, 7.78]Conditional Logistic Regression
Primary
Number of Bone/Joint Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin
Incident bone/joint cancer. Gabapentin (Gaba.) Exposure Description: With 2 year (yr) lag=Gaba. exposure from cohort entry to 2 yr prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer). Without 2 yr lag=Gaba. exposure from cohort entry to index date. Tertiles (T) with 2 yr lag: T 1 (0.01-1.38 months \[mo.\]), T 2 (1.39-5.56 mo.), and T 3 (5.57-105.82 mo.). Tertiles without 2 yr lag: T 1 (0.01-1.38 mo.), T 2 (1.39-5.72 mo.), and T 3 (5.73-123.70 mo.). Inestimable OR and 95% CI when no gaba.-exposed cases or controls at the exposure level.
Time frame: The case index date was the date of incident bone/joint cancer diagnosis ascertained in the GPRD study cohort 1995-2008. The matched control index date was the date at which the follow-up time from his/her cohort entry was the same as for the case.
Population: Cases \& controls drawn from the GPRD study cohort. Entry into study cohort began January 1, 1993, or at time of GPRD registration if after Jan. 1, 1993. Follow-up ended December 31, 2008, or earlier if respective cancer was diagnosed or if participant left the GPRD for any reason including death. Participants with prior history of cancer excluded.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Incident All-cancer Patients | Number of Bone/Joint Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin | Never (with 2 year lag) | 300 participants |
| Incident All-cancer Patients | Number of Bone/Joint Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin | Tertile 1 (with 2 year lag) | 0 participants |
| Incident All-cancer Patients | Number of Bone/Joint Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin | Tertile 2 (with 2 year lag) | 0 participants |
| Incident All-cancer Patients | Number of Bone/Joint Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin | Tertile 3 (with 2 year lag) | 0 participants |
| Incident All-cancer Patients | Number of Bone/Joint Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin | Never (without 2 year lag) | 299 participants |
| Incident All-cancer Patients | Number of Bone/Joint Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin | Tertile 1 (without 2 year lag) | 1 participants |
| Incident All-cancer Patients | Number of Bone/Joint Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin | Tertile 2 (without 2 year lag) | 0 participants |
| Incident All-cancer Patients | Number of Bone/Joint Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin | Tertile 3 (without 2 year lag) | 0 participants |
| Matched Controls for Incident All-cancer Patients | Number of Bone/Joint Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin | Tertile 3 (without 2 year lag) | 9 participants |
| Matched Controls for Incident All-cancer Patients | Number of Bone/Joint Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin | Never (with 2 year lag) | 2925 participants |
| Matched Controls for Incident All-cancer Patients | Number of Bone/Joint Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin | Never (without 2 year lag) | 2916 participants |
| Matched Controls for Incident All-cancer Patients | Number of Bone/Joint Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin | Tertile 1 (with 2 year lag) | 4 participants |
| Matched Controls for Incident All-cancer Patients | Number of Bone/Joint Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin | Tertile 2 (without 2 year lag) | 5 participants |
| Matched Controls for Incident All-cancer Patients | Number of Bone/Joint Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin | Tertile 2 (with 2 year lag) | 1 participants |
| Matched Controls for Incident All-cancer Patients | Number of Bone/Joint Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin | Tertile 1 (without 2 year lag) | 5 participants |
| Matched Controls for Incident All-cancer Patients | Number of Bone/Joint Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin | Tertile 3 (with 2 year lag) | 5 participants |
p-value: 0.625295% CI: [0.2, 14.84]Conditional Logistic Regression
p-value: 0.720895% CI: [0.17, 13.28]Conditional Logistic Regression
Primary
Number of Bone/Joint Cancer Cases and Matched Controls With the Indicated Exposure to Gabapentin
Incident bone/joint cancer. Gabapentin Exposure Description: With 2 year lag = Gabapentin prescription from cohort entry to 2 years prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer). Without 2 year lag = Gabapentin prescription from cohort entry to index date. Inestimable OR and 95% CI when no gabapentin-exposed cancer cases or no gabapentin-exposed controls at the exposure level.
Time frame: The case index date was the date of incident bone/joint cancer diagnosis ascertained in the GPRD study cohort 1995-2008. The matched control index date was the date at which the follow-up time from his/her cohort entry was the same as for the case.
Population: Cases \& controls drawn from the GPRD study cohort. Entry into study cohort began January 1, 1993, or at time of GPRD registration if after Jan. 1, 1993. Follow-up ended December 31, 2008, or earlier if respective cancer was diagnosed or if participant left the GPRD for any reason including death. Participants with prior history of cancer excluded.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Incident All-cancer Patients | Number of Bone/Joint Cancer Cases and Matched Controls With the Indicated Exposure to Gabapentin | Never (with 2 year lag) | 300 participants |
| Incident All-cancer Patients | Number of Bone/Joint Cancer Cases and Matched Controls With the Indicated Exposure to Gabapentin | Ever (with 2 year lag) | 0 participants |
| Incident All-cancer Patients | Number of Bone/Joint Cancer Cases and Matched Controls With the Indicated Exposure to Gabapentin | Ever (without 2 year lag) | 1 participants |
| Incident All-cancer Patients | Number of Bone/Joint Cancer Cases and Matched Controls With the Indicated Exposure to Gabapentin | Never (without 2 year lag) | 299 participants |
| Matched Controls for Incident All-cancer Patients | Number of Bone/Joint Cancer Cases and Matched Controls With the Indicated Exposure to Gabapentin | Never (without 2 year lag) | 2916 participants |
| Matched Controls for Incident All-cancer Patients | Number of Bone/Joint Cancer Cases and Matched Controls With the Indicated Exposure to Gabapentin | Ever (without 2 year lag) | 19 participants |
| Matched Controls for Incident All-cancer Patients | Number of Bone/Joint Cancer Cases and Matched Controls With the Indicated Exposure to Gabapentin | Ever (with 2 year lag) | 10 participants |
| Matched Controls for Incident All-cancer Patients | Number of Bone/Joint Cancer Cases and Matched Controls With the Indicated Exposure to Gabapentin | Never (with 2 year lag) | 2925 participants |
p-value: 0.493395% CI: [0.07, 3.72]Conditional Logistic Regression
p-value: 0.414795% CI: [0.06, 3.27]Conditional Logistic Regression
Primary
Number of Bone/Joint Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin
Incident bone/joint cancer. Gabapentin Exposure Description: With 2 year lag = Gabapentin exposure from cohort entry to 2 years prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer). Without 2 year lag = Gabapentin exposure from cohort entry to index date.
Time frame: The case index date was the date of incident bone/joint cancer diagnosis ascertained in the GPRD study cohort 1995-2008. The matched control index date was the date at which the follow-up time from his/her cohort entry was the same as for the case.
Population: Cases \& controls drawn from the GPRD study cohort. Entry into study cohort began January 1, 1993, or at time of GPRD registration if after Jan. 1, 1993. Follow-up ended December 31, 2008, or earlier if respective cancer was diagnosed or if participant left the GPRD for any reason including death. Participants with prior history of cancer excluded.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Incident All-cancer Patients | Number of Bone/Joint Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin | Never (with 2 year lag) | 300 participants |
| Incident All-cancer Patients | Number of Bone/Joint Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin | > 1 year (with 2 year lag) | 0 participants |
| Incident All-cancer Patients | Number of Bone/Joint Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin | > 2 year (with 2 year lag) | 0 participants |
| Incident All-cancer Patients | Number of Bone/Joint Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin | > 3 year (with 2 year lag) | 0 participants |
| Incident All-cancer Patients | Number of Bone/Joint Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin | Never (without 2 year lag) | 299 participants |
| Incident All-cancer Patients | Number of Bone/Joint Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin | > 1 year (without 2 year lag) | 0 participants |
| Incident All-cancer Patients | Number of Bone/Joint Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin | > 2 year (without 2 year lag) | 0 participants |
| Incident All-cancer Patients | Number of Bone/Joint Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin | > 3 year (without 2 year lag) | 0 participants |
| Matched Controls for Incident All-cancer Patients | Number of Bone/Joint Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin | > 3 year (without 2 year lag) | 0 participants |
| Matched Controls for Incident All-cancer Patients | Number of Bone/Joint Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin | Never (with 2 year lag) | 2925 participants |
| Matched Controls for Incident All-cancer Patients | Number of Bone/Joint Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin | Never (without 2 year lag) | 2916 participants |
| Matched Controls for Incident All-cancer Patients | Number of Bone/Joint Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin | > 1 year (with 2 year lag) | 3 participants |
| Matched Controls for Incident All-cancer Patients | Number of Bone/Joint Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin | > 2 year (without 2 year lag) | 1 participants |
| Matched Controls for Incident All-cancer Patients | Number of Bone/Joint Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin | > 2 year (with 2 year lag) | 0 participants |
| Matched Controls for Incident All-cancer Patients | Number of Bone/Joint Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin | > 1 year (without 2 year lag) | 5 participants |
| Matched Controls for Incident All-cancer Patients | Number of Bone/Joint Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin | > 3 year (with 2 year lag) | 0 participants |
Primary
Number of Bone/Joint Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions
Incident bone/joint cancer. Gabapentin (Gaba.) Exposure Description: With 2 year (yr) lag=Gaba. exposure from cohort entry to 2 yr prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer). Without 2 yr lag=Gaba. exposure from cohort entry to index date. Tertiles (T) with 2 yr lag: T 1 (1-2 prescriptions \[prescrip.\]), T 2 (3-7 prescrip.), T 3 (8-298 prescrip.). Tertiles without 2 yr lag: T 1 (1-2 prescrip.), T 2 (3-7 prescrip.), and T 3 (8-388 prescrip.). Inestimable OR and 95% CI when no gaba.-exposed cases or controls at the exposure level.
Time frame: The case index date was the date of incident bone/joint cancer diagnosis ascertained in the GPRD study cohort 1995-2008. The matched control index date was the date at which the follow-up time from his/her cohort entry was the same as for the case.
Population: Cases \& controls drawn from the GPRD study cohort. Entry into study cohort began January 1, 1993, or at time of GPRD registration if after Jan. 1, 1993. Follow-up ended December 31, 2008, or earlier if respective cancer was diagnosed or if participant left the GPRD for any reason including death. Participants with prior history of cancer excluded.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Incident All-cancer Patients | Number of Bone/Joint Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions | Never (with 2 year lag) | 300 participants |
| Incident All-cancer Patients | Number of Bone/Joint Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions | Tertile 1 (with 2 year lag) | 0 participants |
| Incident All-cancer Patients | Number of Bone/Joint Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions | Tertile 2 (with 2 year lag) | 0 participants |
| Incident All-cancer Patients | Number of Bone/Joint Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions | Tertile 3 (with 2 year lag) | 0 participants |
| Incident All-cancer Patients | Number of Bone/Joint Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions | Never (without 2 year lag) | 299 participants |
| Incident All-cancer Patients | Number of Bone/Joint Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions | Tertile 1 (without 2 year lag) | 1 participants |
| Incident All-cancer Patients | Number of Bone/Joint Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions | Tertile 2 (without 2 year lag) | 0 participants |
| Incident All-cancer Patients | Number of Bone/Joint Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions | Tertile 3 (without 2 year lag) | 0 participants |
| Matched Controls for Incident All-cancer Patients | Number of Bone/Joint Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions | Tertile 3 (without 2 year lag) | 8 participants |
| Matched Controls for Incident All-cancer Patients | Number of Bone/Joint Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions | Never (with 2 year lag) | 2925 participants |
| Matched Controls for Incident All-cancer Patients | Number of Bone/Joint Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions | Never (without 2 year lag) | 2916 participants |
| Matched Controls for Incident All-cancer Patients | Number of Bone/Joint Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions | Tertile 1 (with 2 year lag) | 4 participants |
| Matched Controls for Incident All-cancer Patients | Number of Bone/Joint Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions | Tertile 2 (without 2 year lag) | 4 participants |
| Matched Controls for Incident All-cancer Patients | Number of Bone/Joint Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions | Tertile 2 (with 2 year lag) | 2 participants |
| Matched Controls for Incident All-cancer Patients | Number of Bone/Joint Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions | Tertile 1 (without 2 year lag) | 7 participants |
| Matched Controls for Incident All-cancer Patients | Number of Bone/Joint Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions | Tertile 3 (with 2 year lag) | 4 participants |
p-value: 0.825795% CI: [0.15, 10.38]Conditional Logistic Regression
p-value: 0.946795% CI: [0.13, 9.02]Conditional Logistic Regression
p-value: 0.985995% CI: [0, 0]Conditional Logistic Regression
p-value: 0.985795% CI: [0, 0]Conditional Logistic Regression
p-value: 0.98695% CI: [0, 0]Conditional Logistic Regression
p-value: 0.985895% CI: [0, 0]Conditional Logistic Regression
p-value: 0.979895% CI: [0, 0]Conditional Logistic Regression
p-value: 0.979695% CI: [0, 0]Conditional Logistic Regression
Primary
Number of Breast Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin
Incident breast cancer. Gabapentin Exposure Description: With 2 year lag = Gabapentin exposure from cohort entry to 2 years prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer). Without 2 year lag = Gabapentin exposure from cohort entry to index date. Tertile's with 2 year lag: Tertile 1 (0.1 - 30.0 grams), Tertile 2 (30.1 - 189.0 grams), and Tertile 3 (189.1 - 9600.0 grams). Tertile's without 2 year lag: Tertile 1 (0.1 - 30.0 grams), Tertile 2 (30.1 - 189.0 grams), and Tertile 3 (189.1 - 11610.0 grams).
Time frame: The case index date was the date of incident breast cancer diagnosis ascertained in the GPRD study cohort 1995-2008. The matched control index date was the date at which the follow-up time from his/her cohort entry was the same as that for the case.
Population: Cases \& controls drawn from the GPRD study cohort. Entry into study cohort began January 1, 1993, or at time of GPRD registration if after Jan. 1, 1993. Follow-up ended December 31, 2008, or earlier if respective cancer was diagnosed or if participant left the GPRD for any reason including death. Participants with prior history of cancer excluded.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Incident All-cancer Patients | Number of Breast Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin | Never (with 2 year lag) | 19468 participants |
| Incident All-cancer Patients | Number of Breast Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin | Tertile 1 (with 2 year lag) | 31 participants |
| Incident All-cancer Patients | Number of Breast Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin | Tertile 2 (with 2 year lag) | 30 participants |
| Incident All-cancer Patients | Number of Breast Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin | Tertile 3 (with 2 year lag) | 35 participants |
| Incident All-cancer Patients | Number of Breast Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin | Never (without 2 year lag) | 19390 participants |
| Incident All-cancer Patients | Number of Breast Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin | Tertile 1 (without 2 year lag) | 66 participants |
| Incident All-cancer Patients | Number of Breast Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin | Tertile 2 (without 2 year lag) | 44 participants |
| Incident All-cancer Patients | Number of Breast Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin | Tertile 3 (without 2 year lag) | 64 participants |
| Matched Controls for Incident All-cancer Patients | Number of Breast Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin | Tertile 3 (without 2 year lag) | 476 participants |
| Matched Controls for Incident All-cancer Patients | Number of Breast Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin | Never (with 2 year lag) | 188199 participants |
| Matched Controls for Incident All-cancer Patients | Number of Breast Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin | Never (without 2 year lag) | 187532 participants |
| Matched Controls for Incident All-cancer Patients | Number of Breast Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin | Tertile 1 (with 2 year lag) | 254 participants |
| Matched Controls for Incident All-cancer Patients | Number of Breast Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin | Tertile 2 (without 2 year lag) | 423 participants |
| Matched Controls for Incident All-cancer Patients | Number of Breast Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin | Tertile 2 (with 2 year lag) | 225 participants |
| Matched Controls for Incident All-cancer Patients | Number of Breast Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin | Tertile 1 (without 2 year lag) | 493 participants |
| Matched Controls for Incident All-cancer Patients | Number of Breast Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin | Tertile 3 (with 2 year lag) | 246 participants |
p-value: 0.423395% CI: [0.8, 1.7]Conditional Logistic Regression
p-value: 0.590895% CI: [0.76, 1.62]Conditional Logistic Regression
p-value: 0.05495% CI: [1, 1.67]Conditional Logistic Regression
p-value: 0.093995% CI: [0.96, 1.62]Conditional Logistic Regression
p-value: 0.21495% CI: [0.87, 1.87]Conditional Logistic Regression
p-value: 0.29495% CI: [0.84, 1.8]Conditional Logistic Regression
p-value: 0.835295% CI: [0.71, 1.32]Conditional Logistic Regression
p-value: 0.780995% CI: [0.7, 1.31]Conditional Logistic Regression
p-value: 0.092195% CI: [0.95, 1.94]Conditional Logistic Regression
p-value: 0.109195% CI: [0.94, 1.92]Conditional Logistic Regression
p-value: 0.056495% CI: [0.99, 1.68]Conditional Logistic Regression
p-value: 0.093995% CI: [0.96, 1.63]Conditional Logistic Regression
Primary
Number of Breast Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin
Incident breast cancer. Gabapentin Exposure Description: With 2 year lag = Gabapentin exposure from cohort entry to 2 years prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer). Without 2 year lag = Gabapentin exposure from cohort entry to index date. Tertile's with 2 year lag: Tertile 1 (0.01 - 1.38 months), Tertile 2 (1.39 - 5.56 months), and Tertile 3 (5.57 - 105.82 months). Tertile's without 2 year lag: Tertile 1 (0.01 - 1.38 months), Tertile 2 (1.39 - 5.72 months), and Tertile 3 (5.73 - 123.70 months).
Time frame: The case index date was the date of incident breast cancer diagnosis ascertained in the GPRD study cohort 1995-2008. The matched control index date was the date at which the follow-up time from his/her cohort entry was the same as that for the case.
Population: Cases \& controls drawn from the GPRD study cohort. Entry into study cohort began January 1, 1993, or at time of GPRD registration if after Jan. 1, 1993. Follow-up ended December 31, 2008, or earlier if respective cancer was diagnosed or if participant left the GPRD for any reason including death. Participants with prior history of cancer excluded.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Incident All-cancer Patients | Number of Breast Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin | Never (with 2 year lag) | 19468 participants |
| Incident All-cancer Patients | Number of Breast Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin | Tertile 1 (with 2 year lag) | 29 participants |
| Incident All-cancer Patients | Number of Breast Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin | Tertile 2 (with 2 year lag) | 32 participants |
| Incident All-cancer Patients | Number of Breast Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin | Tertile 3 (with 2 year lag) | 35 participants |
| Incident All-cancer Patients | Number of Breast Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin | Never (without 2 year lag) | 19390 participants |
| Incident All-cancer Patients | Number of Breast Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin | Tertile 1 (without 2 year lag) | 58 participants |
| Incident All-cancer Patients | Number of Breast Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin | Tertile 2 (without 2 year lag) | 52 participants |
| Incident All-cancer Patients | Number of Breast Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin | Tertile 3 (without 2 year lag) | 64 participants |
| Matched Controls for Incident All-cancer Patients | Number of Breast Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin | Tertile 3 (without 2 year lag) | 454 participants |
| Matched Controls for Incident All-cancer Patients | Number of Breast Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin | Never (with 2 year lag) | 188199 participants |
| Matched Controls for Incident All-cancer Patients | Number of Breast Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin | Never (without 2 year lag) | 187532 participants |
| Matched Controls for Incident All-cancer Patients | Number of Breast Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin | Tertile 1 (with 2 year lag) | 245 participants |
| Matched Controls for Incident All-cancer Patients | Number of Breast Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin | Tertile 2 (without 2 year lag) | 473 participants |
| Matched Controls for Incident All-cancer Patients | Number of Breast Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin | Tertile 2 (with 2 year lag) | 247 participants |
| Matched Controls for Incident All-cancer Patients | Number of Breast Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin | Tertile 1 (without 2 year lag) | 465 participants |
| Matched Controls for Incident All-cancer Patients | Number of Breast Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin | Tertile 3 (with 2 year lag) | 233 participants |
p-value: 0.504395% CI: [0.77, 1.68]Conditional Logistic Regression
p-value: 0.712995% CI: [0.73, 1.59]Conditional Logistic Regression
p-value: 0.205595% CI: [0.91, 1.57]Conditional Logistic Regression
p-value: 0.300595% CI: [0.88, 1.52]Conditional Logistic Regression
p-value: 0.284995% CI: [0.84, 1.77]Conditional Logistic Regression
p-value: 0.36595% CI: [0.82, 1.72]Conditional Logistic Regression
p-value: 0.755995% CI: [0.78, 1.4]Conditional Logistic Regression
p-value: 0.85295% CI: [0.77, 1.37]Conditional Logistic Regression
p-value: 0.045995% CI: [1.01, 2.06]Conditional Logistic Regression
p-value: 0.054295% CI: [0.99, 2.04]Conditional Logistic Regression
p-value: 0.031295% CI: [1.03, 1.74]Conditional Logistic Regression
p-value: 0.050895% CI: [1, 1.7]Conditional Logistic Regression
Primary
Number of Breast Cancer Cases and Matched Controls With the Indicated Exposure to Gabapentin
Incident breast cancer. Gabapentin Exposure Description: With 2 year lag = Gabapentin prescription from cohort entry to 2 years prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer). Without 2 year lag = Gabapentin prescription from cohort entry to index date.
Time frame: The case index date was the date of incident breast cancer diagnosis ascertained in the GPRD study cohort 1995-2008. The matched control index date was the date at which the follow-up time from his/her cohort entry was the same as that for the case.
Population: Cases \& controls drawn from the GPRD study cohort. Entry into study cohort began January 1, 1993, or at time of GPRD registration if after Jan. 1, 1993. Follow-up ended December 31, 2008, or earlier if respective cancer was diagnosed or if participant left the GPRD for any reason including death. Participants with prior history of cancer excluded.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Incident All-cancer Patients | Number of Breast Cancer Cases and Matched Controls With the Indicated Exposure to Gabapentin | Ever (with 2 year lag) | 96 participants |
| Incident All-cancer Patients | Number of Breast Cancer Cases and Matched Controls With the Indicated Exposure to Gabapentin | Never (with 2 year lag) | 19468 participants |
| Incident All-cancer Patients | Number of Breast Cancer Cases and Matched Controls With the Indicated Exposure to Gabapentin | Ever (without 2 year lag) | 174 participants |
| Incident All-cancer Patients | Number of Breast Cancer Cases and Matched Controls With the Indicated Exposure to Gabapentin | Never (without 2 year lag) | 19390 participants |
| Matched Controls for Incident All-cancer Patients | Number of Breast Cancer Cases and Matched Controls With the Indicated Exposure to Gabapentin | Never (without 2 year lag) | 187532 participants |
| Matched Controls for Incident All-cancer Patients | Number of Breast Cancer Cases and Matched Controls With the Indicated Exposure to Gabapentin | Ever (with 2 year lag) | 725 participants |
| Matched Controls for Incident All-cancer Patients | Number of Breast Cancer Cases and Matched Controls With the Indicated Exposure to Gabapentin | Ever (without 2 year lag) | 1392 participants |
| Matched Controls for Incident All-cancer Patients | Number of Breast Cancer Cases and Matched Controls With the Indicated Exposure to Gabapentin | Never (with 2 year lag) | 188199 participants |
p-value: 0.032395% CI: [1.02, 1.57]Conditional Logistic Regression
p-value: 0.068295% CI: [0.99, 1.52]Conditional Logistic Regression
p-value: 0.032695% CI: [1.01, 1.4]Conditional Logistic Regression
p-value: 0.069995% CI: [0.99, 1.36]Conditional Logistic Regression
Primary
Number of Breast Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin
Incident breast cancer. Gabapentin Exposure Description: With 2 year lag = Gabapentin exposure from cohort entry to 2 years prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer). Without 2 year lag = Gabapentin exposure from cohort entry to index date.
Time frame: The case index date was the date of incident breast cancer diagnosis ascertained in the GPRD study cohort 1995-2008. The matched control index date was the date at which the follow-up time from his/her cohort entry was the same as that for the case.
Population: Cases \& controls drawn from the GPRD study cohort. Entry into study cohort began January 1, 1993, or at time of GPRD registration if after Jan. 1, 1993. Follow-up ended December 31, 2008, or earlier if respective cancer was diagnosed or if participant left the GPRD for any reason including death. Participants with prior history of cancer excluded.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Incident All-cancer Patients | Number of Breast Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin | Never (with 2 year lag) | 19468 participants |
| Incident All-cancer Patients | Number of Breast Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin | Never (without 2 year lag) | 19390 participants |
| Incident All-cancer Patients | Number of Breast Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin | > 2 year (with 2 year lag) | 9 participants |
| Incident All-cancer Patients | Number of Breast Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin | > 1 year (without 2 year lag) | 46 participants |
| Incident All-cancer Patients | Number of Breast Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin | > 1 year (with 2 year lag) | 20 participants |
| Incident All-cancer Patients | Number of Breast Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin | > 3 year (with 2 year lag) | 2 participants |
| Incident All-cancer Patients | Number of Breast Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin | > 3 year (without 2 year lag) | 10 participants |
| Incident All-cancer Patients | Number of Breast Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin | > 2 year (without 2 year lag) | 24 participants |
| Matched Controls for Incident All-cancer Patients | Number of Breast Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin | > 3 year (without 2 year lag) | 54 participants |
| Matched Controls for Incident All-cancer Patients | Number of Breast Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin | Never (with 2 year lag) | 188199 participants |
| Matched Controls for Incident All-cancer Patients | Number of Breast Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin | > 1 year (with 2 year lag) | 131 participants |
| Matched Controls for Incident All-cancer Patients | Number of Breast Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin | > 2 year (with 2 year lag) | 54 participants |
| Matched Controls for Incident All-cancer Patients | Number of Breast Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin | > 3 year (with 2 year lag) | 27 participants |
| Matched Controls for Incident All-cancer Patients | Number of Breast Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin | Never (without 2 year lag) | 187532 participants |
| Matched Controls for Incident All-cancer Patients | Number of Breast Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin | > 1 year (without 2 year lag) | 291 participants |
| Matched Controls for Incident All-cancer Patients | Number of Breast Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin | > 2 year (without 2 year lag) | 133 participants |
p-value: 0.089295% CI: [0.94, 2.42]Conditional Logistic Regression
p-value: 0.104395% CI: [0.92, 2.39]Conditional Logistic Regression
p-value: 0.010195% CI: [1.1, 2.06]Conditional Logistic Regression
p-value: 0.018695% CI: [1.07, 2]Conditional Logistic Regression
p-value: 0.145895% CI: [0.83, 3.43]Conditional Logistic Regression
p-value: 0.185995% CI: [0.79, 3.29]Conditional Logistic Regression
p-value: 0.012295% CI: [1.13, 2.72]Conditional Logistic Regression
p-value: 0.016295% CI: [1.1, 2.67]Conditional Logistic Regression
p-value: 0.757395% CI: [0.19, 3.36]Conditional Logistic Regression
p-value: 0.708895% CI: [0.18, 3.21]Conditional Logistic Regression
p-value: 0.078795% CI: [0.93, 3.64]Conditional Logistic Regression
p-value: 0.087395% CI: [0.92, 3.58]Conditional Logistic Regression
Primary
Number of Breast Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions
Incident breast cancer. Gabapentin Exposure Description: With 2 year lag = Gabapentin exposure from cohort entry to 2 years prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer). Without 2 year lag = Gabapentin exposure from cohort entry to index date. Tertile's with 2 year lag: Tertile 1 (1-2 prescriptions), Tertile 2 (3-7 prescriptions), Tertile 3 (8-298 prescriptions). Tertiles without 2 year lag: Tertile 1 (1-2 prescriptions), Tertile 2 (3-7 prescriptions), and Tertile 3 (8-388 prescriptions).
Time frame: The case index date was the date of incident breast cancer diagnosis ascertained in the GPRD study cohort 1995-2008. The matched control index date was the date at which the follow-up time from his/her cohort entry was the same as that for the case.
Population: Cases \& controls drawn from the GPRD study cohort. Entry into study cohort began January 1, 1993, or at time of GPRD registration if after Jan. 1, 1993. Follow-up ended December 31, 2008, or earlier if respective cancer was diagnosed or if participant left the GPRD for any reason including death. Participants with prior history of cancer excluded.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Incident All-cancer Patients | Number of Breast Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions | Never (with 2 year lag) | 19468 participants |
| Incident All-cancer Patients | Number of Breast Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions | Tertile 1 (with 2 year lag) | 38 participants |
| Incident All-cancer Patients | Number of Breast Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions | Tertile 2 (with 2 year lag) | 24 participants |
| Incident All-cancer Patients | Number of Breast Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions | Tertile 3 (with 2 year lag) | 34 participants |
| Incident All-cancer Patients | Number of Breast Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions | Never (without 2 year lag) | 19390 participants |
| Incident All-cancer Patients | Number of Breast Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions | Tertile 1 (without 2 year lag) | 75 participants |
| Incident All-cancer Patients | Number of Breast Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions | Tertile 2 (without 2 year lag) | 32 participants |
| Incident All-cancer Patients | Number of Breast Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions | Tertile 3 (without 2 year lag) | 67 participants |
| Matched Controls for Incident All-cancer Patients | Number of Breast Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions | Tertile 3 (without 2 year lag) | 460 participants |
| Matched Controls for Incident All-cancer Patients | Number of Breast Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions | Never (with 2 year lag) | 188199 participants |
| Matched Controls for Incident All-cancer Patients | Number of Breast Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions | Never (without 2 year lag) | 187532 participants |
| Matched Controls for Incident All-cancer Patients | Number of Breast Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions | Tertile 1 (with 2 year lag) | 306 participants |
| Matched Controls for Incident All-cancer Patients | Number of Breast Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions | Tertile 2 (without 2 year lag) | 355 participants |
| Matched Controls for Incident All-cancer Patients | Number of Breast Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions | Tertile 2 (with 2 year lag) | 182 participants |
| Matched Controls for Incident All-cancer Patients | Number of Breast Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions | Tertile 1 (without 2 year lag) | 577 participants |
| Matched Controls for Incident All-cancer Patients | Number of Breast Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions | Tertile 3 (with 2 year lag) | 237 participants |
p-value: 0.289395% CI: [0.86, 1.69]Conditional Logistic Regression
p-value: 0.430195% CI: [0.82, 1.61]Conditional Logistic Regression
p-value: 0.080695% CI: [0.97, 1.58]Conditional Logistic Regression
p-value: 0.122695% CI: [0.95, 1.55]Conditional Logistic Regression
p-value: 0.350295% CI: [0.8, 1.89]Conditional Logistic Regression
p-value: 0.465495% CI: [0.76, 1.81]Conditional Logistic Regression
p-value: 0.398795% CI: [0.59, 1.23]Conditional Logistic Regression
p-value: 0.334995% CI: [0.58, 1.2]Conditional Logistic Regression
p-value: 0.082795% CI: [0.96, 1.98]Conditional Logistic Regression
p-value: 0.093295% CI: [0.95, 1.96]Conditional Logistic Regression
p-value: 0.01395% CI: [1.07, 1.8]Conditional Logistic Regression
p-value: 0.024195% CI: [1.04, 1.75]Conditional Logistic Regression
Primary
Number of Lung Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin
Incident lung cancer. Gabapentin Exposure Description: With 2 year lag = Gabapentin exposure from cohort entry to 2 years prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer). Without 2 year lag = Gabapentin exposure from cohort entry to index date. Tertile's with 2 year lag: Tertile 1 (0.1 - 30.0 grams), Tertile 2 (30.1 - 189.0 grams), and Tertile 3 (189.1 - 9600.0 grams). Tertile's without 2 year lag: Tertile 1 (0.1 - 30.0 grams), Tertile 2 (30.1 - 189.0 grams), and Tertile 3 (189.1 - 11610.0 grams).
Time frame: The case index date was the date of incident lung cancer diagnosis ascertained in the GPRD study cohort 1995-2008. The matched control index date was the date at which the follow-up time from his/her cohort entry was the same as that for the case.
Population: Cases \& controls drawn from the GPRD study cohort. Entry into study cohort began January 1, 1993, or at time of GPRD registration if after Jan. 1, 1993. Follow-up ended December 31, 2008, or earlier if respective cancer was diagnosed or if participant left the GPRD for any reason including death. Participants with prior history of cancer excluded.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Incident All-cancer Patients | Number of Lung Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin | Never (with 2 year lag) | 10800 participants |
| Incident All-cancer Patients | Number of Lung Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin | Tertile 1 (with 2 year lag) | 21 participants |
| Incident All-cancer Patients | Number of Lung Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin | Tertile 2 (with 2 year lag) | 16 participants |
| Incident All-cancer Patients | Number of Lung Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin | Tertile 3 (with 2 year lag) | 18 participants |
| Incident All-cancer Patients | Number of Lung Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin | Never (without 2 year lag) | 10700 participants |
| Incident All-cancer Patients | Number of Lung Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin | Tertile 1 (without 2 year lag) | 62 participants |
| Incident All-cancer Patients | Number of Lung Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin | Tertile 2 (without 2 year lag) | 56 participants |
| Incident All-cancer Patients | Number of Lung Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin | Tertile 3 (without 2 year lag) | 37 participants |
| Matched Controls for Incident All-cancer Patients | Number of Lung Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin | Tertile 3 (without 2 year lag) | 271 participants |
| Matched Controls for Incident All-cancer Patients | Number of Lung Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin | Never (with 2 year lag) | 102434 participants |
| Matched Controls for Incident All-cancer Patients | Number of Lung Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin | Never (without 2 year lag) | 102053 participants |
| Matched Controls for Incident All-cancer Patients | Number of Lung Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin | Tertile 1 (with 2 year lag) | 139 participants |
| Matched Controls for Incident All-cancer Patients | Number of Lung Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin | Tertile 2 (without 2 year lag) | 224 participants |
| Matched Controls for Incident All-cancer Patients | Number of Lung Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin | Tertile 2 (with 2 year lag) | 120 participants |
| Matched Controls for Incident All-cancer Patients | Number of Lung Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin | Tertile 1 (without 2 year lag) | 288 participants |
| Matched Controls for Incident All-cancer Patients | Number of Lung Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin | Tertile 3 (with 2 year lag) | 143 participants |
p-value: 0.152895% CI: [0.88, 2.24]Conditional Logistic Regression
p-value: 0.962595% CI: [0.62, 1.65]Conditional Logistic Regression
p-value: <0.000195% CI: [1.48, 2.59]Conditional Logistic Regression
p-value: 0.000695% CI: [1.25, 2.29]Conditional Logistic Regression
p-value: 0.351595% CI: [0.76, 2.16]Conditional Logistic Regression
p-value: 0.906995% CI: [0.59, 1.82]Conditional Logistic Regression
p-value: <0.000195% CI: [1.78, 3.21]Conditional Logistic Regression
p-value: <0.000195% CI: [1.48, 2.81]Conditional Logistic Regression
p-value: 0.594895% CI: [0.7, 1.88]Conditional Logistic Regression
p-value: 0.398495% CI: [0.47, 1.35]Conditional Logistic Regression
p-value: 0.187295% CI: [0.89, 1.79]Conditional Logistic Regression
p-value: 0.677295% CI: [0.64, 1.34]Conditional Logistic Regression
Primary
Number of Lung Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin
Incident lung cancer. Gabapentin Exposure Description: With 2 year lag = Gabapentin exposure from cohort entry to 2 years prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer). Without 2 year lag = Gabapentin exposure from cohort entry to index date. Tertile's with 2 year lag: Tertile 1 (0.01 - 1.38 months), Tertile 2 (1.39 - 5.56 months), and Tertile 3 (5.57 - 105.82 months). Tertile's without 2 year lag: Tertile 1 (0.01 - 1.38 months), Tertile 2 (1.39 - 5.72 months), and Tertile 3 (5.73 - 123.70 months).
Time frame: The case index date was the date of incident lung cancer diagnosis ascertained in the GPRD study cohort 1995-2008. The matched control index date was the date at which the follow-up time from his/her cohort entry was the same as that for the case.
Population: Cases \& controls drawn from the GPRD study cohort. Entry into study cohort began January 1, 1993, or at time of GPRD registration if after Jan. 1, 1993. Follow-up ended December 31, 2008, or earlier if respective cancer was diagnosed or if participant left the GPRD for any reason including death. Participants with prior history of cancer excluded.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Incident All-cancer Patients | Number of Lung Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin | Never (with 2 year lag) | 10800 participants |
| Incident All-cancer Patients | Number of Lung Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin | Tertile 1 (with 2 year lag) | 21 participants |
| Incident All-cancer Patients | Number of Lung Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin | Tertile 2 (with 2 year lag) | 15 participants |
| Incident All-cancer Patients | Number of Lung Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin | Tertile 3 (with 2 year lag) | 19 participants |
| Incident All-cancer Patients | Number of Lung Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin | Never (without 2 year lag) | 10700 participants |
| Incident All-cancer Patients | Number of Lung Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin | Tertile 1 (without 2 year lag) | 67 participants |
| Incident All-cancer Patients | Number of Lung Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin | Tertile 2 (without 2 year lag) | 48 participants |
| Incident All-cancer Patients | Number of Lung Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin | Tertile 3 (without 2 year lag) | 40 participants |
| Matched Controls for Incident All-cancer Patients | Number of Lung Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin | Tertile 3 (without 2 year lag) | 269 participants |
| Matched Controls for Incident All-cancer Patients | Number of Lung Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin | Never (with 2 year lag) | 102434 participants |
| Matched Controls for Incident All-cancer Patients | Number of Lung Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin | Never (without 2 year lag) | 102053 participants |
| Matched Controls for Incident All-cancer Patients | Number of Lung Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin | Tertile 1 (with 2 year lag) | 131 participants |
| Matched Controls for Incident All-cancer Patients | Number of Lung Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin | Tertile 2 (without 2 year lag) | 247 participants |
| Matched Controls for Incident All-cancer Patients | Number of Lung Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin | Tertile 2 (with 2 year lag) | 130 participants |
| Matched Controls for Incident All-cancer Patients | Number of Lung Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin | Tertile 1 (without 2 year lag) | 267 participants |
| Matched Controls for Incident All-cancer Patients | Number of Lung Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin | Tertile 3 (with 2 year lag) | 141 participants |
p-value: 0.079895% CI: [0.95, 2.41]Conditional Logistic Regression
p-value: 0.835795% CI: [0.64, 1.73]Conditional Logistic Regression
p-value: <0.000195% CI: [1.75, 3.01]Conditional Logistic Regression
p-value: <0.000195% CI: [1.53, 2.76]Conditional Logistic Regression
p-value: 0.779495% CI: [0.63, 1.85]Conditional Logistic Regression
p-value: 0.807595% CI: [0.52, 1.66]Conditional Logistic Regression
p-value: 0.000195% CI: [1.35, 2.52]Conditional Logistic Regression
p-value: 0.016195% CI: [1.08, 2.12]Conditional Logistic Regression
p-value: 0.397295% CI: [0.76, 2]Conditional Logistic Regression
p-value: 0.49595% CI: [0.5, 1.39]Conditional Logistic Regression
p-value: 0.060195% CI: [0.99, 1.94]Conditional Logistic Regression
p-value: 0.928695% CI: [0.71, 1.45]Conditional Logistic Regression
Primary
Number of Lung Cancer Cases and Matched Controls With the Indicated Exposure to Gabapentin
Incident lung cancer. Gabapentin Exposure Description: With 2 year lag = Gabapentin prescription from cohort entry to 2 years prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer). Without 2 year lag = Gabapentin prescription from cohort entry to index date.
Time frame: The case index date was the date of incident lung cancer diagnosis ascertained in the GPRD study cohort 1995-2008. The matched control index date was the date at which the follow-up time from his/her cohort entry was the same as that for the case.
Population: Cases \& controls drawn from the GPRD study cohort. Entry into study cohort began January 1, 1993, or at time of GPRD registration if after Jan. 1, 1993. Follow-up ended December 31, 2008, or earlier if respective cancer was diagnosed or if participant left the GPRD for any reason including death. Participants with prior history of cancer excluded.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Incident All-cancer Patients | Number of Lung Cancer Cases and Matched Controls With the Indicated Exposure to Gabapentin | Ever (with 2 year lag) | 55 participants |
| Incident All-cancer Patients | Number of Lung Cancer Cases and Matched Controls With the Indicated Exposure to Gabapentin | Ever (without 2 year lag) | 155 participants |
| Incident All-cancer Patients | Number of Lung Cancer Cases and Matched Controls With the Indicated Exposure to Gabapentin | Never (with 2 year lag) | 10800 participants |
| Incident All-cancer Patients | Number of Lung Cancer Cases and Matched Controls With the Indicated Exposure to Gabapentin | Never (without 2 year lag) | 10700 participants |
| Matched Controls for Incident All-cancer Patients | Number of Lung Cancer Cases and Matched Controls With the Indicated Exposure to Gabapentin | Never (with 2 year lag) | 102434 participants |
| Matched Controls for Incident All-cancer Patients | Number of Lung Cancer Cases and Matched Controls With the Indicated Exposure to Gabapentin | Ever (with 2 year lag) | 402 participants |
| Matched Controls for Incident All-cancer Patients | Number of Lung Cancer Cases and Matched Controls With the Indicated Exposure to Gabapentin | Never (without 2 year lag) | 102053 participants |
| Matched Controls for Incident All-cancer Patients | Number of Lung Cancer Cases and Matched Controls With the Indicated Exposure to Gabapentin | Ever (without 2 year lag) | 783 participants |
p-value: 0.096395% CI: [0.96, 1.7]Conditional Logistic Regression
p-value: 0.67195% CI: [0.69, 1.27]Conditional Logistic Regression
p-value: <0.000195% CI: [1.54, 2.2]Conditional Logistic Regression
p-value: <0.000195% CI: [1.24, 1.81]Conditional Logistic Regression
Primary
Number of Lung Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin
Incident lung cancer. Gabapentin Exposure Description: With 2 year lag = Gabapentin exposure from cohort entry to 2 years prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer). Without 2 year lag = Gabapentin exposure from cohort entry to index date.
Time frame: The case index date was the date of incident lung cancer diagnosis ascertained in the GPRD study cohort 1995-2008. The matched control index date was the date at which the follow-up time from his/her cohort entry was the same as that for the case.
Population: Cases \& controls drawn from the GPRD study cohort. Entry into study cohort began January 1, 1993, or at time of GPRD registration if after Jan. 1, 1993. Follow-up ended December 31, 2008, or earlier if respective cancer was diagnosed or if participant left the GPRD for any reason including death. Participants with prior history of cancer excluded.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Incident All-cancer Patients | Number of Lung Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin | Never (with 2 year lag) | 10800 participants |
| Incident All-cancer Patients | Number of Lung Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin | > 1 year (with 2 year lag) | 10 participants |
| Incident All-cancer Patients | Number of Lung Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin | > 2 year (with 2 year lag) | 4 participants |
| Incident All-cancer Patients | Number of Lung Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin | > 3 year (with 2 year lag) | 1 participants |
| Incident All-cancer Patients | Number of Lung Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin | Never (without 2 year lag) | 10700 participants |
| Incident All-cancer Patients | Number of Lung Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin | > 1 year (without 2 year lag) | 21 participants |
| Incident All-cancer Patients | Number of Lung Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin | > 2 year (without 2 year lag) | 11 participants |
| Incident All-cancer Patients | Number of Lung Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin | > 3 year (without 2 year lag) | 4 participants |
| Matched Controls for Incident All-cancer Patients | Number of Lung Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin | > 3 year (without 2 year lag) | 33 participants |
| Matched Controls for Incident All-cancer Patients | Number of Lung Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin | Never (with 2 year lag) | 102434 participants |
| Matched Controls for Incident All-cancer Patients | Number of Lung Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin | Never (without 2 year lag) | 102053 participants |
| Matched Controls for Incident All-cancer Patients | Number of Lung Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin | > 1 year (with 2 year lag) | 75 participants |
| Matched Controls for Incident All-cancer Patients | Number of Lung Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin | > 2 year (without 2 year lag) | 77 participants |
| Matched Controls for Incident All-cancer Patients | Number of Lung Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin | > 2 year (with 2 year lag) | 24 participants |
| Matched Controls for Incident All-cancer Patients | Number of Lung Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin | > 1 year (without 2 year lag) | 167 participants |
| Matched Controls for Incident All-cancer Patients | Number of Lung Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin | > 3 year (with 2 year lag) | 6 participants |
p-value: 0.539495% CI: [0.63, 2.39]Conditional Logistic Regression
p-value: 0.50795% CI: [0.39, 1.58]Conditional Logistic Regression
p-value: 0.542695% CI: [0.73, 1.83]Conditional Logistic Regression
p-value: 0.51595% CI: [0.52, 1.38]Conditional Logistic Regression
p-value: 0.43595% CI: [0.53, 4.42]Conditional Logistic Regression
p-value: 0.827695% CI: [0.37, 3.43]Conditional Logistic Regression
p-value: 0.402295% CI: [0.69, 2.5]Conditional Logistic Regression
p-value: 0.868195% CI: [0.48, 1.86]Conditional Logistic Regression
p-value: 0.632695% CI: [0.2, 13.86]Conditional Logistic Regression
p-value: 0.57795% CI: [0.21, 16.86]Conditional Logistic Regression
p-value: 0.808795% CI: [0.4, 3.21]Conditional Logistic Regression
p-value: 0.849795% CI: [0.31, 2.64]Conditional Logistic Regression
Primary
Number of Lung Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions
Incident lung cancer. Gabapentin Exposure Description: With 2 year lag = Gabapentin exposure from cohort entry to 2 years prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer). Without 2 year lag = Gabapentin exposure from cohort entry to index date. Tertile's with 2 year lag: Tertile 1 (1-2 prescriptions), Tertile 2 (3-7 prescriptions), Tertile 3 (8-298 prescriptions). Tertiles without 2 year lag: Tertile 1 (1-2 prescriptions), Tertile 2 (3-7 prescriptions), and Tertile 3 (8-388 prescriptions).
Time frame: The case index date was the date of incident lung cancer diagnosis ascertained in the GPRD study cohort 1995-2008. The matched control index date was the date at which the follow-up time from his/her cohort entry was the same as that for the case.
Population: Cases \& controls drawn from the GPRD study cohort. Entry into study cohort began January 1, 1993, or at time of GPRD registration if after Jan. 1, 1993. Follow-up ended December 31, 2008, or earlier if respective cancer was diagnosed or if participant left the GPRD for any reason including death. Participants with prior history of cancer excluded.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Incident All-cancer Patients | Number of Lung Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions | Never (with 2 year lag) | 10800 participants |
| Incident All-cancer Patients | Number of Lung Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions | Tertile 1 (with 2 year lag) | 24 participants |
| Incident All-cancer Patients | Number of Lung Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions | Tertile 2 (with 2 year lag) | 13 participants |
| Incident All-cancer Patients | Number of Lung Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions | Tertile 3 (with 2 year lag) | 18 participants |
| Incident All-cancer Patients | Number of Lung Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions | Never (without 2 year lag) | 10700 participants |
| Incident All-cancer Patients | Number of Lung Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions | Tertile 1 (without 2 year lag) | 81 participants |
| Incident All-cancer Patients | Number of Lung Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions | Tertile 2 (without 2 year lag) | 32 participants |
| Incident All-cancer Patients | Number of Lung Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions | Tertile 3 (without 2 year lag) | 42 participants |
| Matched Controls for Incident All-cancer Patients | Number of Lung Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions | Tertile 3 (without 2 year lag) | 270 participants |
| Matched Controls for Incident All-cancer Patients | Number of Lung Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions | Never (with 2 year lag) | 102434 participants |
| Matched Controls for Incident All-cancer Patients | Number of Lung Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions | Never (without 2 year lag) | 102053 participants |
| Matched Controls for Incident All-cancer Patients | Number of Lung Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions | Tertile 1 (with 2 year lag) | 160 participants |
| Matched Controls for Incident All-cancer Patients | Number of Lung Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions | Tertile 2 (without 2 year lag) | 186 participants |
| Matched Controls for Incident All-cancer Patients | Number of Lung Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions | Tertile 2 (with 2 year lag) | 105 participants |
| Matched Controls for Incident All-cancer Patients | Number of Lung Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions | Tertile 1 (without 2 year lag) | 327 participants |
| Matched Controls for Incident All-cancer Patients | Number of Lung Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions | Tertile 3 (with 2 year lag) | 137 participants |
p-value: 0.118495% CI: [0.92, 2.18]Conditional Logistic Regression
p-value: 0.801695% CI: [0.59, 1.5]Conditional Logistic Regression
p-value: <0.000195% CI: [1.77, 2.91]Conditional Logistic Regression
p-value: <0.000195% CI: [1.51, 2.58]Conditional Logistic Regression
p-value: 0.610595% CI: [0.65, 2.08]Conditional Logistic Regression
p-value: 0.679795% CI: [0.62, 2.09]Conditional Logistic Regression
p-value: 0.010395% CI: [1.12, 2.39]Conditional Logistic Regression
p-value: 0.162995% CI: [0.89, 2]Conditional Logistic Regression
p-value: 0.471395% CI: [0.73, 1.97]Conditional Logistic Regression
p-value: 0.450595% CI: [0.49, 1.38]Conditional Logistic Regression
p-value: 0.028495% CI: [1.04, 2.01]Conditional Logistic Regression
p-value: 0.626295% CI: [0.77, 1.54]Conditional Logistic Regression
Primary
Number of Other Nervous System Cancer Cases and Matched Controls With the Indicated Exposure to Gabapentin
Incident other nervous system cancer. Gabapentin Exposure Description: With 2 year lag = Gabapentin prescription from cohort entry to 2 years prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer). Without 2 year lag = Gabapentin prescription from cohort entry to index date. Inestimable OR and 95% CI when no gabapentin-exposed cancer cases or no gabapentin-exposed controls at the exposure level.
Time frame: The case index date was the date of incident other nervous system cancer diagnosis ascertained in the GPRD study cohort 1995-2008. The matched control index date was the date at which the follow-up time from his cohort entry was the same as case.
Population: Cases \& controls drawn from the GPRD study cohort. Entry into study cohort began January 1, 1993, or at time of GPRD registration if after Jan. 1, 1993. Follow-up ended December 31, 2008, or earlier if respective cancer was diagnosed or if participant left the GPRD for any reason including death. Participants with prior history of cancer excluded.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Incident All-cancer Patients | Number of Other Nervous System Cancer Cases and Matched Controls With the Indicated Exposure to Gabapentin | Ever (with 2 year lag) | 0 participants |
| Incident All-cancer Patients | Number of Other Nervous System Cancer Cases and Matched Controls With the Indicated Exposure to Gabapentin | Never (with 2 year lag) | 38 participants |
| Incident All-cancer Patients | Number of Other Nervous System Cancer Cases and Matched Controls With the Indicated Exposure to Gabapentin | Ever (without 2 year lag) | 2 participants |
| Incident All-cancer Patients | Number of Other Nervous System Cancer Cases and Matched Controls With the Indicated Exposure to Gabapentin | Never (without 2 year lag) | 36 participants |
| Matched Controls for Incident All-cancer Patients | Number of Other Nervous System Cancer Cases and Matched Controls With the Indicated Exposure to Gabapentin | Never (without 2 year lag) | 379 participants |
| Matched Controls for Incident All-cancer Patients | Number of Other Nervous System Cancer Cases and Matched Controls With the Indicated Exposure to Gabapentin | Ever (with 2 year lag) | 0 participants |
| Matched Controls for Incident All-cancer Patients | Number of Other Nervous System Cancer Cases and Matched Controls With the Indicated Exposure to Gabapentin | Ever (without 2 year lag) | 1 participants |
| Matched Controls for Incident All-cancer Patients | Number of Other Nervous System Cancer Cases and Matched Controls With the Indicated Exposure to Gabapentin | Never (with 2 year lag) | 380 participants |
p-value: 0.014495% CI: [1.81, 220.5]Conditional Logistic Regression
p-value: 0.074395% CI: [0.79, 147]Conditional Logistic Regression
Primary
Number of Other Nervous System Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin
Incident other nervous system cancer. Gabapentin Exposure Description: With 2 year lag = Gabapentin exposure from cohort entry to 2 years prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer). Without 2 year lag = Gabapentin exposure from cohort entry to index date.
Time frame: The case index date was the date of incident other nervous system cancer diagnosis ascertained in the GPRD study cohort 1995-2008. The matched control index date was the date at which the follow-up time from his/her cohort entry was same as for case
Population: Cases \& controls drawn from the GPRD study cohort. Entry into study cohort began January 1, 1993, or at time of GPRD registration if after Jan. 1, 1993. Follow-up ended December 31, 2008, or earlier if respective cancer was diagnosed or if participant left the GPRD for any reason including death. Participants with prior history of cancer excluded.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Incident All-cancer Patients | Number of Other Nervous System Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin | Never (with 2 year lag) | 38 participants |
| Incident All-cancer Patients | Number of Other Nervous System Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin | > 1 year (with 2 year lag) | 0 participants |
| Incident All-cancer Patients | Number of Other Nervous System Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin | > 2 year (with 2 year lag) | 0 participants |
| Incident All-cancer Patients | Number of Other Nervous System Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin | > 3 year (with 2 year lag) | 0 participants |
| Incident All-cancer Patients | Number of Other Nervous System Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin | Never (without 2 year lag) | 36 participants |
| Incident All-cancer Patients | Number of Other Nervous System Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin | > 1 year (without 2 year lag) | 1 participants |
| Incident All-cancer Patients | Number of Other Nervous System Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin | > 2 year (without 2 year lag) | 0 participants |
| Incident All-cancer Patients | Number of Other Nervous System Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin | > 3 year (without 2 year lag) | 0 participants |
| Matched Controls for Incident All-cancer Patients | Number of Other Nervous System Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin | > 3 year (without 2 year lag) | 0 participants |
| Matched Controls for Incident All-cancer Patients | Number of Other Nervous System Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin | Never (with 2 year lag) | 380 participants |
| Matched Controls for Incident All-cancer Patients | Number of Other Nervous System Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin | Never (without 2 year lag) | 379 participants |
| Matched Controls for Incident All-cancer Patients | Number of Other Nervous System Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin | > 1 year (with 2 year lag) | 0 participants |
| Matched Controls for Incident All-cancer Patients | Number of Other Nervous System Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin | > 2 year (without 2 year lag) | 0 participants |
| Matched Controls for Incident All-cancer Patients | Number of Other Nervous System Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin | > 2 year (with 2 year lag) | 0 participants |
| Matched Controls for Incident All-cancer Patients | Number of Other Nervous System Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin | > 1 year (without 2 year lag) | 0 participants |
| Matched Controls for Incident All-cancer Patients | Number of Other Nervous System Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin | > 3 year (with 2 year lag) | 0 participants |
Primary
Number of Other Nervous System (ONS) Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin
Incident ONS cancer. Gabapentin (Gaba.) Exposure Description: With 2 year (yr) lag=Gaba. exposure from cohort entry to 2 yr prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer). Without 2 yr lag=Gaba. exposure from cohort entry to index date. Tertiles (T) with 2 yr lag: T 1 (0.1-30.0 grams \[g\]), T 2 (30.1-189.0 g), and T 3 (189.1-9600.0 g). Tertiles without 2 yr lag: T 1 (0.1-30.0 g), T 2 (30.1-189.0 g), and T 3 (189.1-11610.0 g). Inestimable OR and 95% CI when no gaba.-exposed cancer cases or controls at the exposure level.
Time frame: The case index date was the date of incident other nervous system cancer diagnosis ascertained in the GPRD study cohort 1995-2008. The matched control index date was the date at which the follow-up time from his/her cohort entry was same as for case
Population: Cases \& controls drawn from the GPRD study cohort. Entry into study cohort began January 1, 1993, or at time of GPRD registration if after Jan. 1, 1993. Follow-up ended December 31, 2008, or earlier if respective cancer was diagnosed or if participant left the GPRD for any reason including death. Participants with prior history of cancer excluded.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Incident All-cancer Patients | Number of Other Nervous System (ONS) Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin | Never (with 2 year lag) | 38 participants |
| Incident All-cancer Patients | Number of Other Nervous System (ONS) Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin | Tertile 1 (with 2 year lag) | 0 participants |
| Incident All-cancer Patients | Number of Other Nervous System (ONS) Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin | Tertile 2 (with 2 year lag) | 0 participants |
| Incident All-cancer Patients | Number of Other Nervous System (ONS) Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin | Tertile 3 (with 2 year lag) | 0 participants |
| Incident All-cancer Patients | Number of Other Nervous System (ONS) Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin | Never (without 2 year lag) | 36 participants |
| Incident All-cancer Patients | Number of Other Nervous System (ONS) Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin | Tertile 1 (without 2 year lag) | 0 participants |
| Incident All-cancer Patients | Number of Other Nervous System (ONS) Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin | Tertile 2 (without 2 year lag) | 1 participants |
| Incident All-cancer Patients | Number of Other Nervous System (ONS) Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin | Tertile 3 (without 2 year lag) | 1 participants |
| Matched Controls for Incident All-cancer Patients | Number of Other Nervous System (ONS) Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin | Tertile 3 (without 2 year lag) | 0 participants |
| Matched Controls for Incident All-cancer Patients | Number of Other Nervous System (ONS) Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin | Never (with 2 year lag) | 380 participants |
| Matched Controls for Incident All-cancer Patients | Number of Other Nervous System (ONS) Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin | Never (without 2 year lag) | 379 participants |
| Matched Controls for Incident All-cancer Patients | Number of Other Nervous System (ONS) Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin | Tertile 1 (with 2 year lag) | 0 participants |
| Matched Controls for Incident All-cancer Patients | Number of Other Nervous System (ONS) Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin | Tertile 2 (without 2 year lag) | 1 participants |
| Matched Controls for Incident All-cancer Patients | Number of Other Nervous System (ONS) Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin | Tertile 2 (with 2 year lag) | 0 participants |
| Matched Controls for Incident All-cancer Patients | Number of Other Nervous System (ONS) Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin | Tertile 1 (without 2 year lag) | 0 participants |
| Matched Controls for Incident All-cancer Patients | Number of Other Nervous System (ONS) Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin | Tertile 3 (with 2 year lag) | 0 participants |
p-value: 0.103595% CI: [0.63, 159.9]Conditional Logistic Regression
p-value: 0.379995% CI: [0.18, 95.82]Conditional Logistic Regression
Primary
Number of Other Nervous System (ONS) Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin
Incident ONS cancer. Gabapentin (Gaba.) Exposure Description: With 2 yr lag=Gaba. exposure from cohort entry to 2 yr prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer). Without 2 yr lag=Gaba. exposure from cohort entry to index date. Tertiles (T) with 2 yr lag: T 1 (0.01-1.38 months \[mo.\]), T 2 (1.39-5.56 mo.), and T 3 (5.57-105.82 mo.). Tertiles without 2 yr lag: T 1 (0.01-1.38 mo.), T 2 (1.39-5.72 mo.), and T 3 (5.73-123.70 mo.). Inestimable OR and 95% CI when no gaba.-exposed cancer cases or controls at the exposure level.
Time frame: The case index date was the date of incident other nervous system cancer diagnosis ascertained in the GPRD study cohort 1995-2008. The matched control index date was the date at which the follow-up time from his/her cohort entry was same as for case
Population: Cases \& controls drawn from the GPRD study cohort. Entry into study cohort began January 1, 1993, or at time of GPRD registration if after Jan. 1, 1993. Follow-up ended December 31, 2008, or earlier if respective cancer was diagnosed or if participant left the GPRD for any reason including death. Participants with prior history of cancer excluded.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Incident All-cancer Patients | Number of Other Nervous System (ONS) Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin | Never (with 2 year lag) | 38 participants |
| Incident All-cancer Patients | Number of Other Nervous System (ONS) Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin | Tertile 1 (with 2 year lag) | 0 participants |
| Incident All-cancer Patients | Number of Other Nervous System (ONS) Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin | Tertile 2 (with 2 year lag) | 0 participants |
| Incident All-cancer Patients | Number of Other Nervous System (ONS) Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin | Tertile 3 (with 2 year lag) | 0 participants |
| Incident All-cancer Patients | Number of Other Nervous System (ONS) Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin | Never (without 2 year lag) | 36 participants |
| Incident All-cancer Patients | Number of Other Nervous System (ONS) Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin | Tertile 1 (without 2 year lag) | 0 participants |
| Incident All-cancer Patients | Number of Other Nervous System (ONS) Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin | Tertile 2 (without 2 year lag) | 1 participants |
| Incident All-cancer Patients | Number of Other Nervous System (ONS) Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin | Tertile 3 (without 2 year lag) | 1 participants |
| Matched Controls for Incident All-cancer Patients | Number of Other Nervous System (ONS) Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin | Tertile 3 (without 2 year lag) | 0 participants |
| Matched Controls for Incident All-cancer Patients | Number of Other Nervous System (ONS) Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin | Never (with 2 year lag) | 380 participants |
| Matched Controls for Incident All-cancer Patients | Number of Other Nervous System (ONS) Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin | Never (without 2 year lag) | 379 participants |
| Matched Controls for Incident All-cancer Patients | Number of Other Nervous System (ONS) Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin | Tertile 1 (with 2 year lag) | 0 participants |
| Matched Controls for Incident All-cancer Patients | Number of Other Nervous System (ONS) Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin | Tertile 2 (without 2 year lag) | 1 participants |
| Matched Controls for Incident All-cancer Patients | Number of Other Nervous System (ONS) Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin | Tertile 2 (with 2 year lag) | 0 participants |
| Matched Controls for Incident All-cancer Patients | Number of Other Nervous System (ONS) Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin | Tertile 1 (without 2 year lag) | 0 participants |
| Matched Controls for Incident All-cancer Patients | Number of Other Nervous System (ONS) Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin | Tertile 3 (with 2 year lag) | 0 participants |
p-value: 0.103595% CI: [0.63, 159.9]Conditional Logistic Regression
p-value: 0.379995% CI: [0.18, 95.82]Conditional Logistic Regression
Primary
Number of Other Nervous System (ONS) Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions
Incident ONS cancer. Gabapentin (Gaba.) Exposure Description: With 2 year (yr) lag=Gaba. exposure from cohort entry to 2 yr prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer). Without 2 yr lag=Gaba. exposure from cohort entry to index date. Tertiles (T) with 2 yr lag: T 1 (1-2 prescriptions \[prescrip.\]), T 2 (3-7 prescrip.), T 3 (8-298 prescrip.). Tertiles without 2 yr lag: T 1 (1-2 prescrip.), T 2 (3-7 prescrip.), and T 3 (8-388 prescrip.). Inestimable OR and 95% CI when no gaba.-exposed cancer cases or controls at the exposure level.
Time frame: The case index date was the date of incident other nervous system cancer diagnosis ascertained in the GPRD study cohort 1995-2008. The matched control index date was the date at which the follow-up time from his cohort entry was same as for case.
Population: Cases \& controls drawn from the GPRD study cohort. Entry into study cohort began January 1, 1993, or at time of GPRD registration if after Jan. 1, 1993. Follow-up ended December 31, 2008, or earlier if respective cancer was diagnosed or if participant left the GPRD for any reason including death. Participants with prior history of cancer excluded.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Incident All-cancer Patients | Number of Other Nervous System (ONS) Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions | Never (with 2 year lag) | 38 participants |
| Incident All-cancer Patients | Number of Other Nervous System (ONS) Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions | Tertile 1 (with 2 year lag) | 0 participants |
| Incident All-cancer Patients | Number of Other Nervous System (ONS) Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions | Tertile 2 (with 2 year lag) | 0 participants |
| Incident All-cancer Patients | Number of Other Nervous System (ONS) Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions | Tertile 3 (with 2 year lag) | 0 participants |
| Incident All-cancer Patients | Number of Other Nervous System (ONS) Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions | Never (without 2 year lag) | 36 participants |
| Incident All-cancer Patients | Number of Other Nervous System (ONS) Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions | Tertile 1 (without 2 year lag) | 0 participants |
| Incident All-cancer Patients | Number of Other Nervous System (ONS) Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions | Tertile 2 (without 2 year lag) | 1 participants |
| Incident All-cancer Patients | Number of Other Nervous System (ONS) Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions | Tertile 3 (without 2 year lag) | 1 participants |
| Matched Controls for Incident All-cancer Patients | Number of Other Nervous System (ONS) Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions | Tertile 3 (without 2 year lag) | 0 participants |
| Matched Controls for Incident All-cancer Patients | Number of Other Nervous System (ONS) Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions | Never (with 2 year lag) | 380 participants |
| Matched Controls for Incident All-cancer Patients | Number of Other Nervous System (ONS) Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions | Never (without 2 year lag) | 379 participants |
| Matched Controls for Incident All-cancer Patients | Number of Other Nervous System (ONS) Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions | Tertile 1 (with 2 year lag) | 0 participants |
| Matched Controls for Incident All-cancer Patients | Number of Other Nervous System (ONS) Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions | Tertile 2 (without 2 year lag) | 1 participants |
| Matched Controls for Incident All-cancer Patients | Number of Other Nervous System (ONS) Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions | Tertile 2 (with 2 year lag) | 0 participants |
| Matched Controls for Incident All-cancer Patients | Number of Other Nervous System (ONS) Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions | Tertile 1 (without 2 year lag) | 0 participants |
| Matched Controls for Incident All-cancer Patients | Number of Other Nervous System (ONS) Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions | Tertile 3 (with 2 year lag) | 0 participants |
p-value: 0.103595% CI: [0.63, 159.9]Conditional Logistic Regression
p-value: 0.379995% CI: [0.18, 95.82]Conditional Logistic Regression
Primary
Number of Pancreatic Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin
Incident pancreatic cancer. Gabapentin Exposure Description: With 2 year lag = Gabapentin exposure from cohort entry to 2 years prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer). Without 2 year lag = Gabapentin exposure from cohort entry to index date. Tertile's with 2 year lag: Tertile 1 (0.1 - 30.0 grams), Tertile 2 (30.1 - 189.0 grams), and Tertile 3 (189.1 - 9600.0 grams). Tertile's without 2 year lag: Tertile 1 (0.1 - 30.0 grams), Tertile 2 (30.1 - 189.0 grams), and Tertile 3 (189.1 - 11610.0 grams).
Time frame: The case index date was the date of incident pancreatic cancer diagnosis ascertained in the GPRD study cohort 1995-2008. The matched control index date was the date at which the follow-up time from his/her cohort entry was the same as for the case.
Population: Cases \& controls drawn from the GPRD study cohort. Entry into study cohort began January 1, 1993, or at time of GPRD registration if after Jan. 1, 1993. Follow-up ended December 31, 2008, or earlier if respective cancer was diagnosed or if participant left the GPRD for any reason including death. Participants with prior history of cancer excluded.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Incident All-cancer Patients | Number of Pancreatic Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin | Never (with 2 year lag) | 2135 participants |
| Incident All-cancer Patients | Number of Pancreatic Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin | Tertile 1 (with 2 year lag) | 9 participants |
| Incident All-cancer Patients | Number of Pancreatic Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin | Tertile 2 (with 2 year lag) | 6 participants |
| Incident All-cancer Patients | Number of Pancreatic Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin | Tertile 3 (with 2 year lag) | 5 participants |
| Incident All-cancer Patients | Number of Pancreatic Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin | Never (without 2 year lag) | 2120 participants |
| Incident All-cancer Patients | Number of Pancreatic Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin | Tertile 1 (without 2 year lag) | 15 participants |
| Incident All-cancer Patients | Number of Pancreatic Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin | Tertile 2 (without 2 year lag) | 8 participants |
| Incident All-cancer Patients | Number of Pancreatic Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin | Tertile 3 (without 2 year lag) | 12 participants |
| Matched Controls for Incident All-cancer Patients | Number of Pancreatic Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin | Tertile 3 (without 2 year lag) | 59 participants |
| Matched Controls for Incident All-cancer Patients | Number of Pancreatic Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin | Never (with 2 year lag) | 20296 participants |
| Matched Controls for Incident All-cancer Patients | Number of Pancreatic Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin | Never (without 2 year lag) | 20222 participants |
| Matched Controls for Incident All-cancer Patients | Number of Pancreatic Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin | Tertile 1 (with 2 year lag) | 33 participants |
| Matched Controls for Incident All-cancer Patients | Number of Pancreatic Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin | Tertile 2 (without 2 year lag) | 45 participants |
| Matched Controls for Incident All-cancer Patients | Number of Pancreatic Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin | Tertile 2 (with 2 year lag) | 22 participants |
| Matched Controls for Incident All-cancer Patients | Number of Pancreatic Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin | Tertile 1 (without 2 year lag) | 56 participants |
| Matched Controls for Incident All-cancer Patients | Number of Pancreatic Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin | Tertile 3 (with 2 year lag) | 31 participants |
p-value: 0.024895% CI: [1.12, 5.09]Conditional Logistic Regression
p-value: 0.05295% CI: [0.99, 4.7]Conditional Logistic Regression
p-value: 0.004695% CI: [1.3, 4.2]Conditional Logistic Regression
p-value: 0.019395% CI: [1.12, 3.72]Wilcoxon (Mann-Whitney)
p-value: 0.030995% CI: [1.1, 6.88]Conditional Logistic Regression
p-value: 0.128595% CI: [0.81, 5.51]Conditional Logistic Regression
p-value: 0.125795% CI: [0.85, 3.83]Conditional Logistic Regression
p-value: 0.294495% CI: [0.7, 3.31]Conditional Logistic Regression
p-value: 0.703295% CI: [0.45, 3.21]Conditional Logistic Regression
p-value: 0.992295% CI: [0.37, 2.69]Conditional Logistic Regression
p-value: 0.122795% CI: [0.87, 3.16]Conditional Logistic Regression
p-value: 0.380995% CI: [0.69, 2.61]Conditional Logistic Regression
Primary
Number of Pancreatic Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin
Incident pancreatic cancer. Gabapentin Exposure Description: With 2 year lag = Gabapentin exposure from cohort entry to 2 years prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer). Without 2 year lag = Gabapentin exposure from cohort entry to index date. Tertile's with 2 year lag: Tertile 1 (0.01 - 1.38 months), Tertile 2 (1.39 - 5.56 months), and Tertile 3 (5.57 - 105.82 months). Tertile's without 2 year lag: Tertile 1 (0.01 - 1.38 months), Tertile 2 (1.39 - 5.72 months), and Tertile 3 (5.73 - 123.70 months).
Time frame: The case index date was the date of incident pancreatic cancer diagnosis ascertained in the GPRD study cohort 1995-2008. The matched control index date was the date at which the follow-up time from his/her cohort entry was the same as for the case.
Population: Cases \& controls drawn from the GPRD study cohort. Entry into study cohort began January 1, 1993, or at time of GPRD registration if after Jan. 1, 1993. Follow-up ended December 31, 2008, or earlier if respective cancer was diagnosed or if participant left the GPRD for any reason including death. Participants with prior history of cancer excluded.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Incident All-cancer Patients | Number of Pancreatic Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin | Never (with 2 year lag) | 2135 participants |
| Incident All-cancer Patients | Number of Pancreatic Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin | Tertile 1 (with 2 year lag) | 11 participants |
| Incident All-cancer Patients | Number of Pancreatic Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin | Tertile 2 (with 2 year lag) | 2 participants |
| Incident All-cancer Patients | Number of Pancreatic Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin | Tertile 3 (with 2 year lag) | 7 participants |
| Incident All-cancer Patients | Number of Pancreatic Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin | Never (without 2 year lag) | 2120 participants |
| Incident All-cancer Patients | Number of Pancreatic Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin | Tertile 1 (without 2 year lag) | 15 participants |
| Incident All-cancer Patients | Number of Pancreatic Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin | Tertile 2 (without 2 year lag) | 5 participants |
| Incident All-cancer Patients | Number of Pancreatic Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin | Tertile 3 (without 2 year lag) | 15 participants |
| Matched Controls for Incident All-cancer Patients | Number of Pancreatic Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin | Tertile 3 (without 2 year lag) | 64 participants |
| Matched Controls for Incident All-cancer Patients | Number of Pancreatic Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin | Never (with 2 year lag) | 20296 participants |
| Matched Controls for Incident All-cancer Patients | Number of Pancreatic Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin | Never (without 2 year lag) | 20222 participants |
| Matched Controls for Incident All-cancer Patients | Number of Pancreatic Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin | Tertile 1 (with 2 year lag) | 28 participants |
| Matched Controls for Incident All-cancer Patients | Number of Pancreatic Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin | Tertile 2 (without 2 year lag) | 43 participants |
| Matched Controls for Incident All-cancer Patients | Number of Pancreatic Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin | Tertile 2 (with 2 year lag) | 27 participants |
| Matched Controls for Incident All-cancer Patients | Number of Pancreatic Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin | Tertile 1 (without 2 year lag) | 53 participants |
| Matched Controls for Incident All-cancer Patients | Number of Pancreatic Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin | Tertile 3 (with 2 year lag) | 31 participants |
p-value: 0.000595% CI: [1.75, 7.46]Conditional Logistic Regression
p-value: 0.001995% CI: [1.55, 6.83]Conditional Logistic Regression
p-value: 0.002495% CI: [1.39, 4.55]Conditional Logistic Regression
p-value: 0.011595% CI: [1.19, 4]Wilcoxon (Mann-Whitney)
p-value: 0.628195% CI: [0.17, 2.96]Conditional Logistic Regression
p-value: 0.510395% CI: [0.14, 2.62]Conditional Logistic Regression
p-value: 0.773395% CI: [0.45, 2.9]Conditional Logistic Regression
p-value: 0.83795% CI: [0.43, 2.81]Conditional Logistic Regression
p-value: 0.19895% CI: [0.75, 4.1]Conditional Logistic Regression
p-value: 0.539195% CI: [0.54, 3.21]Conditional Logistic Regression
p-value: 0.022495% CI: [1.1, 3.53]Conditional Logistic Regression
p-value: 0.181595% CI: [0.82, 2.77]Conditional Logistic Regression
Primary
Number of Pancreatic Cancer Cases and Matched Controls With the Indicated Exposure to Gabapentin
Incident pancreatic cancer. Gabapentin Exposure Description: With 2 year lag = Gabapentin prescription from cohort entry to 2 years prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer). Without 2 year lag = Gabapentin prescription from cohort entry to index date.
Time frame: The case index date was the date of incident pancreatic cancer diagnosis ascertained in the GPRD study cohort 1995-2008. The matched control index date was the date at which the follow-up time from his/her cohort entry was the same as for the case.
Population: Cases \& controls drawn from the GPRD study cohort. Entry into study cohort began January 1, 1993, or at time of GPRD registration if after Jan. 1, 1993. Follow-up ended December 31, 2008, or earlier if respective cancer was diagnosed or if participant left the GPRD for any reason including death. Participants with prior history of cancer excluded.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Incident All-cancer Patients | Number of Pancreatic Cancer Cases and Matched Controls With the Indicated Exposure to Gabapentin | Ever (without 2 year lag) | 35 participants |
| Incident All-cancer Patients | Number of Pancreatic Cancer Cases and Matched Controls With the Indicated Exposure to Gabapentin | Never (with 2 year lag) | 2135 participants |
| Incident All-cancer Patients | Number of Pancreatic Cancer Cases and Matched Controls With the Indicated Exposure to Gabapentin | Never (without 2 year lag) | 2120 participants |
| Incident All-cancer Patients | Number of Pancreatic Cancer Cases and Matched Controls With the Indicated Exposure to Gabapentin | Ever (with 2 year lag) | 20 participants |
| Matched Controls for Incident All-cancer Patients | Number of Pancreatic Cancer Cases and Matched Controls With the Indicated Exposure to Gabapentin | Never (without 2 year lag) | 20222 participants |
| Matched Controls for Incident All-cancer Patients | Number of Pancreatic Cancer Cases and Matched Controls With the Indicated Exposure to Gabapentin | Never (with 2 year lag) | 20296 participants |
| Matched Controls for Incident All-cancer Patients | Number of Pancreatic Cancer Cases and Matched Controls With the Indicated Exposure to Gabapentin | Ever (without 2 year lag) | 160 participants |
| Matched Controls for Incident All-cancer Patients | Number of Pancreatic Cancer Cases and Matched Controls With the Indicated Exposure to Gabapentin | Ever (with 2 year lag) | 86 participants |
p-value: 0.006695% CI: [1.21, 3.32]Conditional Logistic Regression
p-value: 0.049495% CI: [1, 2.82]Conditional Logistic Regression
p-value: 0.000695% CI: [1.33, 2.82]Conditional Logistic Regression
p-value: 0.013895% CI: [1.11, 2.41]Conditional Logistic Regression
Primary
Number of Pancreatic Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin
Incident pancreatic cancer. Gabapentin Exposure Description: With 2 year lag = Gabapentin exposure from cohort entry to 2 years prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer). Without 2 year lag = Gabapentin exposure from cohort entry to index date.
Time frame: The case index date was the date of incident pancreatic cancer diagnosis ascertained in the GPRD study cohort 1995-2008. The matched control index date was the date at which the follow-up time from his/her cohort entry was the same as for the case
Population: Cases \& controls drawn from the GPRD study cohort. Entry into study cohort began January 1, 1993, or at time of GPRD registration if after Jan. 1, 1993. Follow-up ended December 31, 2008, or earlier if respective cancer was diagnosed or if participant left the GPRD for any reason including death. Participants with prior history of cancer excluded.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Incident All-cancer Patients | Number of Pancreatic Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin | Never (with 2 year lag) | 2135 participants |
| Incident All-cancer Patients | Number of Pancreatic Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin | > 1 year (with 2 year lag) | 5 participants |
| Incident All-cancer Patients | Number of Pancreatic Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin | > 2 year (with 2 year lag) | 2 participants |
| Incident All-cancer Patients | Number of Pancreatic Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin | > 3 year (with 2 year lag) | 1 participants |
| Incident All-cancer Patients | Number of Pancreatic Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin | Never (without 2 year lag) | 2120 participants |
| Incident All-cancer Patients | Number of Pancreatic Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin | > 1 year (without 2 year lag) | 7 participants |
| Incident All-cancer Patients | Number of Pancreatic Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin | > 2 year (without 2 year lag) | 2 participants |
| Incident All-cancer Patients | Number of Pancreatic Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin | > 3 year (without 2 year lag) | 1 participants |
| Matched Controls for Incident All-cancer Patients | Number of Pancreatic Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin | > 3 year (without 2 year lag) | 6 participants |
| Matched Controls for Incident All-cancer Patients | Number of Pancreatic Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin | Never (with 2 year lag) | 20296 participants |
| Matched Controls for Incident All-cancer Patients | Number of Pancreatic Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin | Never (without 2 year lag) | 20222 participants |
| Matched Controls for Incident All-cancer Patients | Number of Pancreatic Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin | > 1 year (with 2 year lag) | 18 participants |
| Matched Controls for Incident All-cancer Patients | Number of Pancreatic Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin | > 2 year (without 2 year lag) | 23 participants |
| Matched Controls for Incident All-cancer Patients | Number of Pancreatic Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin | > 2 year (with 2 year lag) | 6 participants |
| Matched Controls for Incident All-cancer Patients | Number of Pancreatic Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin | > 1 year (without 2 year lag) | 46 participants |
| Matched Controls for Incident All-cancer Patients | Number of Pancreatic Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin | > 3 year (with 2 year lag) | 2 participants |
Primary
Number of Pancreatic Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions
Incident pancreatic cancer. Gabapentin Exposure Description: With 2 year lag = Gabapentin exposure from cohort entry to 2 years prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer). Without 2 year lag = Gabapentin exposure from cohort entry to index date. Tertile's with 2 year lag: Tertile 1 (1-2 prescriptions), Tertile 2 (3-7 prescriptions), Tertile 3 (8-298 prescriptions). Tertiles without 2 year lag: Tertile 1 (1-2 prescriptions), Tertile 2 (3-7 prescriptions), and Tertile 3 (8-388 prescriptions).
Time frame: The case index date was the date of incident pancreatic cancer diagnosis ascertained in the GPRD study cohort 1995-2008. The matched control index date was the date at which the follow-up time from his/her cohort entry was the same as for the case.
Population: Cases \& controls drawn from the GPRD study cohort. Entry into study cohort began January 1, 1993, or at time of GPRD registration if after Jan. 1, 1993. Follow-up ended December 31, 2008, or earlier if respective cancer was diagnosed or if participant left the GPRD for any reason including death. Participants with prior history of cancer excluded.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Incident All-cancer Patients | Number of Pancreatic Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions | Never (with 2 year lag) | 2135 participants |
| Incident All-cancer Patients | Number of Pancreatic Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions | Tertile 1 (with 2 year lag) | 12 participants |
| Incident All-cancer Patients | Number of Pancreatic Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions | Tertile 2 (with 2 year lag) | 2 participants |
| Incident All-cancer Patients | Number of Pancreatic Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions | Tertile 3 (with 2 year lag) | 6 participants |
| Incident All-cancer Patients | Number of Pancreatic Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions | Never (without 2 year lag) | 2120 participants |
| Incident All-cancer Patients | Number of Pancreatic Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions | Tertile 1 (without 2 year lag) | 17 participants |
| Incident All-cancer Patients | Number of Pancreatic Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions | Tertile 2 (without 2 year lag) | 4 participants |
| Incident All-cancer Patients | Number of Pancreatic Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions | Tertile 3 (without 2 year lag) | 14 participants |
| Matched Controls for Incident All-cancer Patients | Number of Pancreatic Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions | Tertile 3 (without 2 year lag) | 68 participants |
| Matched Controls for Incident All-cancer Patients | Number of Pancreatic Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions | Never (with 2 year lag) | 20296 participants |
| Matched Controls for Incident All-cancer Patients | Number of Pancreatic Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions | Never (without 2 year lag) | 20222 participants |
| Matched Controls for Incident All-cancer Patients | Number of Pancreatic Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions | Tertile 1 (with 2 year lag) | 34 participants |
| Matched Controls for Incident All-cancer Patients | Number of Pancreatic Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions | Tertile 2 (without 2 year lag) | 30 participants |
| Matched Controls for Incident All-cancer Patients | Number of Pancreatic Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions | Tertile 2 (with 2 year lag) | 22 participants |
| Matched Controls for Incident All-cancer Patients | Number of Pancreatic Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions | Tertile 1 (without 2 year lag) | 62 participants |
| Matched Controls for Incident All-cancer Patients | Number of Pancreatic Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions | Tertile 3 (with 2 year lag) | 30 participants |
p-value: 0.000695% CI: [1.66, 6.53]Conditional Logistic Regression
p-value: 0.00295% CI: [1.5, 6.05]Conditional Logistic Regression
p-value: 0.001395% CI: [1.43, 4.34]Conditional Logistic Regression
p-value: 0.00895% CI: [1.22, 3.8]Conditional Logistic Regression
p-value: 0.816595% CI: [0.2, 3.61]Conditional Logistic Regression
p-value: 0.662495% CI: [0.17, 3.12]Conditional Logistic Regression
p-value: 0.631695% CI: [0.45, 3.68]Conditional Logistic Regression
p-value: 0.90695% CI: [0.35, 3.22]Conditional Logistic Regression
p-value: 0.373195% CI: [0.61, 3.74]Conditional Logistic Regression
p-value: 0.826695% CI: [0.43, 2.87]Conditional Logistic Regression
p-value: 0.071295% CI: [0.95, 3.13]Conditional Logistic Regression
p-value: 0.267495% CI: [0.77, 2.6]Conditional Logistic Regression
Primary
Number of Penile Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin
Incident penile cancer. Gabapentin (Gaba.) Exposure Description: With 2 year (yr) lag=Gaba. exposure from cohort entry to 2 yr prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer). Without 2 yr lag=Gaba. exposure from cohort entry to index date. Tertiles (T) with 2 yr lag: T 1 (0.1-30.0 grams \[g\]), T 2 (30.1-189.0 g), and T 3 (189.1-9600.0 g). Tertiles without 2 yr lag: T 1 (0.1-30.0 g), T 2 (30.1-189.0 g), and T 3 (189.1-11610.0 g). Inestimable OR and 95% CI when no gaba.-exposed cancer cases or controls at the exposure level.
Time frame: The case index date was the date of incident penile cancer diagnosis ascertained in the GPRD study cohort 1995-2008. The matched control index date was the date at which the follow-up time from his/her cohort entry was the same as that for the case.
Population: Cases \& controls drawn from the GPRD study cohort. Entry into study cohort began January 1, 1993, or at time of GPRD registration if after Jan. 1, 1993. Follow-up ended December 31, 2008, or earlier if respective cancer was diagnosed or if participant left the GPRD for any reason including death. Participants with prior history of cancer excluded.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Incident All-cancer Patients | Number of Penile Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin | Never (without 2 year lag) | 147 participants |
| Incident All-cancer Patients | Number of Penile Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin | Tertile 2 (with 2 year lag) | 0 participants |
| Incident All-cancer Patients | Number of Penile Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin | Tertile 1 (without 2 year lag) | 1 participants |
| Incident All-cancer Patients | Number of Penile Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin | Tertile 1 (with 2 year lag) | 1 participants |
| Incident All-cancer Patients | Number of Penile Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin | Tertile 2 (without 2 year lag) | 0 participants |
| Incident All-cancer Patients | Number of Penile Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin | Tertile 3 (with 2 year lag) | 0 participants |
| Incident All-cancer Patients | Number of Penile Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin | Tertile 3 (without 2 year lag) | 0 participants |
| Incident All-cancer Patients | Number of Penile Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin | Never (with 2 year lag) | 147 participants |
| Matched Controls for Incident All-cancer Patients | Number of Penile Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin | Tertile 3 (without 2 year lag) | 3 participants |
| Matched Controls for Incident All-cancer Patients | Number of Penile Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin | Tertile 1 (with 2 year lag) | 1 participants |
| Matched Controls for Incident All-cancer Patients | Number of Penile Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin | Tertile 2 (with 2 year lag) | 0 participants |
| Matched Controls for Incident All-cancer Patients | Number of Penile Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin | Tertile 3 (with 2 year lag) | 1 participants |
| Matched Controls for Incident All-cancer Patients | Number of Penile Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin | Never (without 2 year lag) | 1390 participants |
| Matched Controls for Incident All-cancer Patients | Number of Penile Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin | Tertile 1 (without 2 year lag) | 1 participants |
| Matched Controls for Incident All-cancer Patients | Number of Penile Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin | Tertile 2 (without 2 year lag) | 2 participants |
| Matched Controls for Incident All-cancer Patients | Number of Penile Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin | Never (with 2 year lag) | 1394 participants |
p-value: 0.203895% CI: [0.37, 108.8]Conditional Logistic Regression
p-value: 0.286695% CI: [0.28, 77.51]Conditional Logistic Regression
p-value: 0.203895% CI: [0.37, 108.8]Conditional Logistic Regression
p-value: 0.111895% CI: [0.5, 839]Conditional Logistic Regression
Primary
Number of Penile Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin
Incident penile cancer. Gabapentin (Gaba.) Exposure Description: With 2 year (yr) lag=Gaba. exposure from cohort entry to 2 yr prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer). Without 2 yr lag=Gaba. exposure from cohort entry to index date. Tertiles (T) with 2 yr lag: T 1 (0.01-1.38 months \[mo.\]), T 2 (1.39-5.56 mo.), and T 3 (5.57-105.82 mo.). Tertiles without 2 yr lag: T 1 (0.01-1.38 mo.), T 2 (1.39-5.72 mo.), and T 3 (5.73-123.70 mo.). Inestimable OR and 95% CI when no gaba.-exposed cancer cases or controls at the exposure level.
Time frame: The case index date was the date of incident penile cancer diagnosis ascertained in the GPRD study cohort 1995-2008. The matched control index date was the date at which the follow-up time from his/her cohort entry was the same as that for the case.
Population: Cases \& controls drawn from the GPRD study cohort. Entry into study cohort began January 1, 1993, or at time of GPRD registration if after Jan. 1, 1993. Follow-up ended December 31, 2008, or earlier if respective cancer was diagnosed or if participant left the GPRD for any reason including death. Participants with prior history of cancer excluded.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Incident All-cancer Patients | Number of Penile Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin | Never (with 2 year lag) | 147 participants |
| Incident All-cancer Patients | Number of Penile Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin | Tertile 1 (with 2 year lag) | 1 participants |
| Incident All-cancer Patients | Number of Penile Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin | Tertile 2 (with 2 year lag) | 0 participants |
| Incident All-cancer Patients | Number of Penile Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin | Tertile 3 (with 2 year lag) | 0 participants |
| Incident All-cancer Patients | Number of Penile Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin | Never (without 2 year lag) | 147 participants |
| Incident All-cancer Patients | Number of Penile Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin | Tertile 1 (without 2 year lag) | 1 participants |
| Incident All-cancer Patients | Number of Penile Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin | Tertile 2 (without 2 year lag) | 0 participants |
| Incident All-cancer Patients | Number of Penile Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin | Tertile 3 (without 2 year lag) | 0 participants |
| Matched Controls for Incident All-cancer Patients | Number of Penile Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin | Tertile 3 (without 2 year lag) | 2 participants |
| Matched Controls for Incident All-cancer Patients | Number of Penile Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin | Never (with 2 year lag) | 1394 participants |
| Matched Controls for Incident All-cancer Patients | Number of Penile Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin | Never (without 2 year lag) | 1390 participants |
| Matched Controls for Incident All-cancer Patients | Number of Penile Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin | Tertile 1 (with 2 year lag) | 1 participants |
| Matched Controls for Incident All-cancer Patients | Number of Penile Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin | Tertile 2 (without 2 year lag) | 3 participants |
| Matched Controls for Incident All-cancer Patients | Number of Penile Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin | Tertile 2 (with 2 year lag) | 0 participants |
| Matched Controls for Incident All-cancer Patients | Number of Penile Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin | Tertile 1 (without 2 year lag) | 1 participants |
| Matched Controls for Incident All-cancer Patients | Number of Penile Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin | Tertile 3 (with 2 year lag) | 1 participants |
p-value: 0.203895% CI: [0.37, 108.8]Conditional Logistic Regression
p-value: 0.286695% CI: [0.28, 77.51]Conditional Logistic Regression
p-value: 0.203895% CI: [0.37, 108.8]Conditional Logistic Regression
p-value: 0.111895% CI: [0.5, 839]Conditional Logistic Regression
Primary
Number of Penile Cancer Cases and Matched Controls With the Indicated Exposure to Gabapentin
Incident penile cancer. Gabapentin Exposure Description: With 2 year lag = Gabapentin prescription from cohort entry to 2 years prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer). Without 2 year lag = Gabapentin prescription from cohort entry to index date.
Time frame: The case index date was the date of incident penile cancer diagnosis ascertained in the GPRD study cohort 1995-2008. The matched control index date was the date at which the follow-up time from his/her cohort entry was the same as that for the case.
Population: Cases \& controls drawn from the GPRD study cohort. Entry into study cohort began January 1, 1993, or at time of GPRD registration if after Jan. 1, 1993. Follow-up ended December 31, 2008, or earlier if respective cancer was diagnosed or if participant left the GPRD for any reason including death. Participants with prior history of cancer excluded.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Incident All-cancer Patients | Number of Penile Cancer Cases and Matched Controls With the Indicated Exposure to Gabapentin | Ever (with 2 year lag) | 1 participants |
| Incident All-cancer Patients | Number of Penile Cancer Cases and Matched Controls With the Indicated Exposure to Gabapentin | Never (with 2 year lag) | 147 participants |
| Incident All-cancer Patients | Number of Penile Cancer Cases and Matched Controls With the Indicated Exposure to Gabapentin | Ever (without 2 year lag) | 1 participants |
| Incident All-cancer Patients | Number of Penile Cancer Cases and Matched Controls With the Indicated Exposure to Gabapentin | Never (without 2 year lag) | 147 participants |
| Matched Controls for Incident All-cancer Patients | Number of Penile Cancer Cases and Matched Controls With the Indicated Exposure to Gabapentin | Never (without 2 year lag) | 1390 participants |
| Matched Controls for Incident All-cancer Patients | Number of Penile Cancer Cases and Matched Controls With the Indicated Exposure to Gabapentin | Ever (with 2 year lag) | 2 participants |
| Matched Controls for Incident All-cancer Patients | Number of Penile Cancer Cases and Matched Controls With the Indicated Exposure to Gabapentin | Ever (without 2 year lag) | 6 participants |
| Matched Controls for Incident All-cancer Patients | Number of Penile Cancer Cases and Matched Controls With the Indicated Exposure to Gabapentin | Never (with 2 year lag) | 1394 participants |
p-value: 0.308295% CI: [0.31, 41.71]Conditional Logistic Regression
p-value: 0.399995% CI: [0.24, 34.69]Conditional Logistic Regression
p-value: 0.750995% CI: [0.16, 12.52]Conditional Logistic Regression
p-value: 0.630395% CI: [0.18, 17.07]Conditional Logistic Regression
Primary
Number of Penile Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin
Incident penile cancer. Gabapentin Exposure Description: With 2 year lag = Gabapentin exposure from cohort entry to 2 years prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer). Without 2 year lag = Gabapentin exposure from cohort entry to index date.
Time frame: The case index date was the date of incident penile cancer diagnosis ascertained in the GPRD study cohort 1995-2008. The matched control index date was the date at which the follow-up time from his/her cohort entry was the same as that for the case.
Population: Cases \& controls drawn from the GPRD study cohort. Entry into study cohort began January 1, 1993, or at time of GPRD registration if after Jan. 1, 1993. Follow-up ended December 31, 2008, or earlier if respective cancer was diagnosed or if participant left the GPRD for any reason including death. Participants with prior history of cancer excluded.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Incident All-cancer Patients | Number of Penile Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin | Never (with 2 year lag) | 147 participants |
| Incident All-cancer Patients | Number of Penile Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin | > 1 year (with 2 year lag) | 0 participants |
| Incident All-cancer Patients | Number of Penile Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin | > 2 year (with 2 year lag) | 0 participants |
| Incident All-cancer Patients | Number of Penile Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin | > 3 year (with 2 year lag) | 0 participants |
| Incident All-cancer Patients | Number of Penile Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin | Never (without 2 year lag) | 147 participants |
| Incident All-cancer Patients | Number of Penile Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin | > 1 year (without 2 year lag) | 0 participants |
| Incident All-cancer Patients | Number of Penile Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin | > 2 year (without 2 year lag) | 0 participants |
| Incident All-cancer Patients | Number of Penile Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin | > 3 year (without 2 year lag) | 0 participants |
| Matched Controls for Incident All-cancer Patients | Number of Penile Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin | > 3 year (without 2 year lag) | 1 participants |
| Matched Controls for Incident All-cancer Patients | Number of Penile Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin | Never (with 2 year lag) | 1394 participants |
| Matched Controls for Incident All-cancer Patients | Number of Penile Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin | Never (without 2 year lag) | 1390 participants |
| Matched Controls for Incident All-cancer Patients | Number of Penile Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin | > 1 year (with 2 year lag) | 1 participants |
| Matched Controls for Incident All-cancer Patients | Number of Penile Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin | > 2 year (without 2 year lag) | 1 participants |
| Matched Controls for Incident All-cancer Patients | Number of Penile Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin | > 2 year (with 2 year lag) | 0 participants |
| Matched Controls for Incident All-cancer Patients | Number of Penile Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin | > 1 year (without 2 year lag) | 1 participants |
| Matched Controls for Incident All-cancer Patients | Number of Penile Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin | > 3 year (with 2 year lag) | 0 participants |
Primary
Number of Penile Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions
Incident penile cancer. Gabapentin (Gaba.) Exposure Description: With 2 year (yr) lag=Gaba. exposure from cohort entry to 2 yr prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer). Without 2 yr lag=Gaba. exposure from cohort entry to index date. Tertiles (T) with 2 yr lag: T 1 (1-2 prescriptions \[prescrip.\]), T 2 (3-7 prescrip.), T 3 (8-298 prescrip.). Tertiles without 2 yr lag: T 1 (1-2 prescrip.), T 2 (3-7 prescrip.), and T 3 (8-388 prescrip.). Inestimable OR/95% CI when no gaba.-exposed cancer cases or controls at the exposure level.
Time frame: The case index date was the date of incident penile cancer diagnosis ascertained in the GPRD study cohort 1995-2008. The matched control index date was the date at which the follow-up time from his/her cohort entry was the same as that for the case.
Population: Cases \& controls drawn from the GPRD study cohort. Entry into study cohort began January 1, 1993, or at time of GPRD registration if after Jan. 1, 1993. Follow-up ended December 31, 2008, or earlier if respective cancer was diagnosed or if participant left the GPRD for any reason including death. Participants with prior history of cancer excluded.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Incident All-cancer Patients | Number of Penile Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions | Never (with 2 year lag) | 147 participants |
| Incident All-cancer Patients | Number of Penile Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions | Tertile 1 (with 2 year lag) | 1 participants |
| Incident All-cancer Patients | Number of Penile Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions | Tertile 2 (with 2 year lag) | 0 participants |
| Incident All-cancer Patients | Number of Penile Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions | Tertile 3 (with 2 year lag) | 0 participants |
| Incident All-cancer Patients | Number of Penile Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions | Never (without 2 year lag) | 147 participants |
| Incident All-cancer Patients | Number of Penile Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions | Tertile 1 (without 2 year lag) | 1 participants |
| Incident All-cancer Patients | Number of Penile Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions | Tertile 2 (without 2 year lag) | 0 participants |
| Incident All-cancer Patients | Number of Penile Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions | Tertile 3 (without 2 year lag) | 0 participants |
| Matched Controls for Incident All-cancer Patients | Number of Penile Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions | Tertile 3 (without 2 year lag) | 2 participants |
| Matched Controls for Incident All-cancer Patients | Number of Penile Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions | Never (with 2 year lag) | 1394 participants |
| Matched Controls for Incident All-cancer Patients | Number of Penile Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions | Never (without 2 year lag) | 1390 participants |
| Matched Controls for Incident All-cancer Patients | Number of Penile Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions | Tertile 1 (with 2 year lag) | 1 participants |
| Matched Controls for Incident All-cancer Patients | Number of Penile Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions | Tertile 2 (without 2 year lag) | 3 participants |
| Matched Controls for Incident All-cancer Patients | Number of Penile Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions | Tertile 2 (with 2 year lag) | 0 participants |
| Matched Controls for Incident All-cancer Patients | Number of Penile Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions | Tertile 1 (without 2 year lag) | 1 participants |
| Matched Controls for Incident All-cancer Patients | Number of Penile Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions | Tertile 3 (with 2 year lag) | 1 participants |
p-value: 0.203895% CI: [0.37, 108.8]Conditional Logistic Regression
p-value: 0.286695% CI: [0.28, 77.51]Conditional Logistic Regression
p-value: 0.203895% CI: [0.37, 108.8]Conditional Logistic Regression
p-value: 0.111895% CI: [0.5, 839]Conditional Logistic Regression
Primary
Number of Renal Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin
Incident renal cancer. Gabapentin Exposure Description: With 2 year lag = Gabapentin exposure from cohort entry to 2 years prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer). Without 2 year lag = Gabapentin exposure from cohort entry to index date. Tertile's with 2 year lag: Tertile 1 (0.1 - 30.0 grams), Tertile 2 (30.1 - 189.0 grams), and Tertile 3 (189.1 - 9600.0 grams). Tertile's without 2 year lag: Tertile 1 (0.1 - 30.0 grams), Tertile 2 (30.1 - 189.0 grams), and Tertile 3 (189.1 - 11610.0 grams).
Time frame: The case index date was the date of incident renal cancer diagnosis ascertained in the GPRD study cohort 1995-2008. The matched control index date was the date at which the follow-up time from his/her cohort entry was the same as that for the case.
Population: Cases \& controls drawn from the GPRD study cohort. Entry into study cohort began January 1, 1993, or at time of GPRD registration if after Jan. 1, 1993. Follow-up ended December 31, 2008, or earlier if respective cancer was diagnosed or if participant left the GPRD for any reason including death. Participants with prior history of cancer excluded.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Incident All-cancer Patients | Number of Renal Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin | Tertile 1 (with 2 year lag) | 4 participants |
| Incident All-cancer Patients | Number of Renal Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin | Tertile 2 (with 2 year lag) | 3 participants |
| Incident All-cancer Patients | Number of Renal Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin | Tertile 3 (with 2 year lag) | 2 participants |
| Incident All-cancer Patients | Number of Renal Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin | Never (without 2 year lag) | 1257 participants |
| Incident All-cancer Patients | Number of Renal Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin | Tertile 1 (without 2 year lag) | 5 participants |
| Incident All-cancer Patients | Number of Renal Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin | Tertile 2 (without 2 year lag) | 6 participants |
| Incident All-cancer Patients | Number of Renal Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin | Tertile 3 (without 2 year lag) | 4 participants |
| Incident All-cancer Patients | Number of Renal Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin | Never (with 2 year lag) | 1263 participants |
| Matched Controls for Incident All-cancer Patients | Number of Renal Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin | Never (with 2 year lag) | 12114 participants |
| Matched Controls for Incident All-cancer Patients | Number of Renal Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin | Tertile 1 (with 2 year lag) | 15 participants |
| Matched Controls for Incident All-cancer Patients | Number of Renal Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin | Tertile 1 (without 2 year lag) | 32 participants |
| Matched Controls for Incident All-cancer Patients | Number of Renal Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin | Tertile 2 (with 2 year lag) | 19 participants |
| Matched Controls for Incident All-cancer Patients | Number of Renal Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin | Tertile 3 (without 2 year lag) | 35 participants |
| Matched Controls for Incident All-cancer Patients | Number of Renal Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin | Tertile 3 (with 2 year lag) | 19 participants |
| Matched Controls for Incident All-cancer Patients | Number of Renal Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin | Tertile 2 (without 2 year lag) | 40 participants |
| Matched Controls for Incident All-cancer Patients | Number of Renal Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin | Never (without 2 year lag) | 12060 participants |
p-value: 0.084395% CI: [0.88, 7.96]Conditional Logistic Regression
p-value: 0.08195% CI: [0.88, 8.28]Conditional Logistic Regression
p-value: 0.458395% CI: [0.55, 3.7]Conditional Logistic Regression
p-value: 0.462295% CI: [0.55, 3.73]Conditional Logistic Regression
p-value: 0.551295% CI: [0.43, 4.95]Conditional Logistic Regression
p-value: 0.927795% CI: [0.31, 3.67]Conditional Logistic Regression
p-value: 0.640295% CI: [0.51, 2.95]Conditional Logistic Regression
p-value: 0.925695% CI: [0.4, 2.32]Conditional Logistic Regression
p-value: 0.951495% CI: [0.24, 4.5]Conditional Logistic Regression
p-value: 0.754395% CI: [0.18, 3.44]Conditional Logistic Regression
p-value: 0.878195% CI: [0.38, 3.07]Conditional Logistic Regression
p-value: 0.742995% CI: [0.29, 2.4]Conditional Logistic Regression
Primary
Number of Renal Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin
Incident renal cancer. Gabapentin Exposure Description: With 2 year lag = Gabapentin exposure from cohort entry to 2 years prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer). Without 2 year lag = Gabapentin exposure from cohort entry to index date. Tertile's with 2 year lag: Tertile 1 (0.01 - 1.38 months), Tertile 2 (1.39 - 5.56 months), and Tertile 3 (5.57 - 105.82 months). Tertile's without 2 year lag: Tertile 1 (0.01 - 1.38 months), Tertile 2 (1.39 - 5.72 months), and Tertile 3 (5.73 - 123.70 months).
Time frame: The case index date was the date of incident renal cancer diagnosis ascertained in the GPRD study cohort 1995-2008. The matched control index date was the date at which the follow-up time from his/her cohort entry was the same as that for the case.
Population: Cases \& controls drawn from the GPRD study cohort. Entry into study cohort began January 1, 1993, or at time of GPRD registration if after Jan. 1, 1993. Follow-up ended December 31, 2008, or earlier if respective cancer was diagnosed or if participant left the GPRD for any reason including death. Participants with prior history of cancer excluded.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Incident All-cancer Patients | Number of Renal Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin | Never (without 2 year lag) | 1257 participants |
| Incident All-cancer Patients | Number of Renal Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin | Tertile 2 (with 2 year lag) | 3 participants |
| Incident All-cancer Patients | Number of Renal Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin | Tertile 1 (without 2 year lag) | 5 participants |
| Incident All-cancer Patients | Number of Renal Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin | Never (with 2 year lag) | 1263 participants |
| Incident All-cancer Patients | Number of Renal Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin | Tertile 2 (without 2 year lag) | 4 participants |
| Incident All-cancer Patients | Number of Renal Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin | Tertile 3 (with 2 year lag) | 3 participants |
| Incident All-cancer Patients | Number of Renal Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin | Tertile 3 (without 2 year lag) | 6 participants |
| Incident All-cancer Patients | Number of Renal Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin | Tertile 1 (with 2 year lag) | 3 participants |
| Matched Controls for Incident All-cancer Patients | Number of Renal Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin | Tertile 3 (without 2 year lag) | 31 participants |
| Matched Controls for Incident All-cancer Patients | Number of Renal Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin | Never (with 2 year lag) | 12114 participants |
| Matched Controls for Incident All-cancer Patients | Number of Renal Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin | Tertile 2 (with 2 year lag) | 22 participants |
| Matched Controls for Incident All-cancer Patients | Number of Renal Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin | Tertile 3 (with 2 year lag) | 15 participants |
| Matched Controls for Incident All-cancer Patients | Number of Renal Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin | Never (without 2 year lag) | 12060 participants |
| Matched Controls for Incident All-cancer Patients | Number of Renal Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin | Tertile 1 (without 2 year lag) | 32 participants |
| Matched Controls for Incident All-cancer Patients | Number of Renal Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin | Tertile 2 (without 2 year lag) | 44 participants |
| Matched Controls for Incident All-cancer Patients | Number of Renal Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin | Tertile 1 (with 2 year lag) | 16 participants |
p-value: 0.312395% CI: [0.55, 6.59]Conditional Logistic Regression
p-value: 0.395195% CI: [0.49, 6.15]Conditional Logistic Regression
p-value: 0.438895% CI: [0.56, 3.75]Conditional Logistic Regression
p-value: 0.553595% CI: [0.51, 3.47]Conditional Logistic Regression
p-value: 0.633295% CI: [0.4, 4.48]Conditional Logistic Regression
p-value: 0.874395% CI: [0.32, 3.75]Conditional Logistic Regression
p-value: 0.613295% CI: [0.27, 2.15]Conditional Logistic Regression
p-value: 0.382195% CI: [0.22, 1.78]Conditional Logistic Regression
p-value: 0.359195% CI: [0.51, 6.28]Conditional Logistic Regression
p-value: 0.689995% CI: [0.37, 4.58]Conditional Logistic Regression
p-value: 0.203195% CI: [0.73, 4.3]Conditional Logistic Regression
p-value: 0.493295% CI: [0.56, 3.37]Conditional Logistic Regression
Primary
Number of Renal Cancer Cases and Matched Controls With the Indicated Exposure to Gabapentin
Incident renal cancer. Gabapentin Exposure Description: With 2 year lag = Gabapentin prescription from cohort entry to 2 years prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer). Without 2 year lag = Gabapentin prescription from cohort entry to index date.
Time frame: The case index date was the date of incident pancreatic cancer diagnosis ascertained in the GPRD study cohort 1995-2008. The matched control index date was the date at which the follow-up time from his/her cohort entry was the same as for the case.
Population: Cases \& controls drawn from the GPRD study cohort. Entry into study cohort began January 1, 1993, or at time of GPRD registration if after Jan. 1, 1993. Follow-up ended December 31, 2008, or earlier if respective cancer was diagnosed or if participant left the GPRD for any reason including death. Participants with prior history of cancer excluded.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Incident All-cancer Patients | Number of Renal Cancer Cases and Matched Controls With the Indicated Exposure to Gabapentin | Ever (with 2 year lag) | 9 participants |
| Incident All-cancer Patients | Number of Renal Cancer Cases and Matched Controls With the Indicated Exposure to Gabapentin | Never (with 2 year lag) | 1263 participants |
| Incident All-cancer Patients | Number of Renal Cancer Cases and Matched Controls With the Indicated Exposure to Gabapentin | Ever (without 2 year lag) | 15 participants |
| Incident All-cancer Patients | Number of Renal Cancer Cases and Matched Controls With the Indicated Exposure to Gabapentin | Never (without 2 year lag) | 1257 participants |
| Matched Controls for Incident All-cancer Patients | Number of Renal Cancer Cases and Matched Controls With the Indicated Exposure to Gabapentin | Never (without 2 year lag) | 12060 participants |
| Matched Controls for Incident All-cancer Patients | Number of Renal Cancer Cases and Matched Controls With the Indicated Exposure to Gabapentin | Ever (with 2 year lag) | 53 participants |
| Matched Controls for Incident All-cancer Patients | Number of Renal Cancer Cases and Matched Controls With the Indicated Exposure to Gabapentin | Ever (without 2 year lag) | 107 participants |
| Matched Controls for Incident All-cancer Patients | Number of Renal Cancer Cases and Matched Controls With the Indicated Exposure to Gabapentin | Never (with 2 year lag) | 12114 participants |
p-value: 0.175795% CI: [0.8, 3.34]Conditional Logistic Regression
p-value: 0.440595% CI: [0.64, 2.75]Conditional Logistic Regression
p-value: 0.44295% CI: [0.71, 2.16]Conditional Logistic Regression
p-value: 0.903495% CI: [0.59, 1.82]Conditional Logistic Regression
Primary
Number of Renal Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin
Incident renal cancer. Gabapentin Exposure Description: With 2 year lag = Gabapentin exposure from cohort entry to 2 years prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer). Without 2 year lag = Gabapentin exposure from cohort entry to index date.
Time frame: The case index date was the date of incident renal cancer diagnosis ascertained in the GPRD study cohort 1995-2008. The matched control index date was the date at which the follow-up time from his/her cohort entry was the same as that for the case.
Population: Cases \& controls drawn from the GPRD study cohort. Entry into study cohort began January 1, 1993, or at time of GPRD registration if after Jan. 1, 1993. Follow-up ended December 31, 2008, or earlier if respective cancer was diagnosed or if participant left the GPRD for any reason including death. Participants with prior history of cancer excluded.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Incident All-cancer Patients | Number of Renal Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin | Never (with 2 year lag) | 1263 participants |
| Incident All-cancer Patients | Number of Renal Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin | Never (without 2 year lag) | 1257 participants |
| Incident All-cancer Patients | Number of Renal Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin | > 2 year (with 2 year lag) | 0 participants |
| Incident All-cancer Patients | Number of Renal Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin | > 1 year (with 2 year lag) | 2 participants |
| Incident All-cancer Patients | Number of Renal Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin | > 2 year (without 2 year lag) | 4 participants |
| Incident All-cancer Patients | Number of Renal Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin | > 3 year (with 2 year lag) | 0 participants |
| Incident All-cancer Patients | Number of Renal Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin | > 3 year (without 2 year lag) | 2 participants |
| Incident All-cancer Patients | Number of Renal Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin | > 1 year (without 2 year lag) | 4 participants |
| Matched Controls for Incident All-cancer Patients | Number of Renal Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin | > 3 year (without 2 year lag) | 3 participants |
| Matched Controls for Incident All-cancer Patients | Number of Renal Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin | Never (with 2 year lag) | 12114 participants |
| Matched Controls for Incident All-cancer Patients | Number of Renal Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin | > 1 year (with 2 year lag) | 6 participants |
| Matched Controls for Incident All-cancer Patients | Number of Renal Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin | > 2 year (with 2 year lag) | 2 participants |
| Matched Controls for Incident All-cancer Patients | Number of Renal Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin | > 3 year (with 2 year lag) | 1 participants |
| Matched Controls for Incident All-cancer Patients | Number of Renal Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin | Never (without 2 year lag) | 12060 participants |
| Matched Controls for Incident All-cancer Patients | Number of Renal Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin | > 1 year (without 2 year lag) | 16 participants |
| Matched Controls for Incident All-cancer Patients | Number of Renal Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin | > 2 year (without 2 year lag) | 7 participants |
Primary
Number of Renal Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions
Incident renal cancer. Gabapentin Exposure Description: With 2 year lag = Gabapentin exposure from cohort entry to 2 years prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer). Without 2 year lag = Gabapentin exposure from cohort entry to index date. Tertile's with 2 year lag: Tertile 1 (1-2 prescriptions), Tertile 2 (3-7 prescriptions), Tertile 3 (8-298 prescriptions). Tertiles without 2 year lag: Tertile 1 (1-2 prescriptions), Tertile 2 (3-7 prescriptions), and Tertile 3 (8-388 prescriptions).
Time frame: The case index date was the date of incident renal cancer diagnosis ascertained in the GPRD study cohort 1995-2008. The matched control index date was the date at which the follow-up time from his/her cohort entry was the same as that for the case.
Population: Cases \& controls drawn from the GPRD study cohort. Entry into study cohort began January 1, 1993, or at time of GPRD registration if after Jan. 1, 1993. Follow-up ended December 31, 2008, or earlier if respective cancer was diagnosed or if participant left the GPRD for any reason including death. Participants with prior history of cancer excluded.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Incident All-cancer Patients | Number of Renal Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions | Never (with 2 year lag) | 1263 participants |
| Incident All-cancer Patients | Number of Renal Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions | Tertile 1 (with 2 year lag) | 4 participants |
| Incident All-cancer Patients | Number of Renal Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions | Tertile 2 (with 2 year lag) | 2 participants |
| Incident All-cancer Patients | Number of Renal Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions | Tertile 3 (with 2 year lag) | 3 participants |
| Incident All-cancer Patients | Number of Renal Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions | Never (without 2 year lag) | 1257 participants |
| Incident All-cancer Patients | Number of Renal Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions | Tertile 1 (without 2 year lag) | 6 participants |
| Incident All-cancer Patients | Number of Renal Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions | Tertile 2 (without 2 year lag) | 3 participants |
| Incident All-cancer Patients | Number of Renal Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions | Tertile 3 (without 2 year lag) | 6 participants |
| Matched Controls for Incident All-cancer Patients | Number of Renal Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions | Tertile 3 (without 2 year lag) | 32 participants |
| Matched Controls for Incident All-cancer Patients | Number of Renal Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions | Never (with 2 year lag) | 12114 participants |
| Matched Controls for Incident All-cancer Patients | Number of Renal Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions | Never (without 2 year lag) | 12060 participants |
| Matched Controls for Incident All-cancer Patients | Number of Renal Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions | Tertile 1 (with 2 year lag) | 21 participants |
| Matched Controls for Incident All-cancer Patients | Number of Renal Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions | Tertile 2 (without 2 year lag) | 29 participants |
| Matched Controls for Incident All-cancer Patients | Number of Renal Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions | Tertile 2 (with 2 year lag) | 15 participants |
| Matched Controls for Incident All-cancer Patients | Number of Renal Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions | Tertile 1 (without 2 year lag) | 46 participants |
| Matched Controls for Incident All-cancer Patients | Number of Renal Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions | Tertile 3 (with 2 year lag) | 17 participants |
p-value: 0.239595% CI: [0.65, 5.6]Conditional Logistic Regression
p-value: 0.376495% CI: [0.55, 4.93]Conditional Logistic Regression
p-value: 0.759995% CI: [0.48, 2.71]Conditional Logistic Regression
p-value: 0.950295% CI: [0.43, 2.46]Conditional Logistic Regression
p-value: 0.716495% CI: [0.3, 5.75]Conditional Logistic Regression
p-value: 0.934595% CI: [0.24, 4.73]Conditional Logistic Regression
p-value: 0.883395% CI: [0.28, 3.02]Conditional Logistic Regression
p-value: 0.617895% CI: [0.22, 2.46]Conditional Logistic Regression
p-value: 0.455695% CI: [0.46, 5.53]Conditional Logistic Regression
p-value: 0.747895% CI: [0.35, 4.29]Conditional Logistic Regression
p-value: 0.23595% CI: [0.71, 4.13]Conditional Logistic Regression
p-value: 0.542895% CI: [0.54, 3.24]Conditional Logistic Regression
Primary
Number of Stomach Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin
Incident stomach cancer. Gabapentin (Gaba.) Exposure Description: With 2 year (yr) lag=Gabapentin exposure from cohort entry to 2 years prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer). Without 2 yr lag=Gaba. exposure from cohort entry to index date. Tertiles (T) with 2 yr lag: T 1 (0.1-30.0 grams \[g\]), T 2 (30.1-189.0 g), and T 3 (189.1-9600.0 g). Tertiles without 2 yr lag: T 1 (0.1-30.0 g), T 2 (30.1-189.0 g), and T 3 (189.1-11610.0 g). Inestimable OR and 95% CI when no gaba.-exposed cancer cases or controls at the exposure level.
Time frame: The case index date was the date of incident stomach cancer diagnosis ascertained in the GPRD study cohort 1995-2008. The matched control index date was the date at which the follow-up time from his/her cohort entry was the same as that for the case
Population: Cases \& controls drawn from the GPRD study cohort. Entry into study cohort began January 1, 1993, or at time of GPRD registration if after Jan. 1, 1993. Follow-up ended December 31, 2008, or earlier if respective cancer was diagnosed or if participant left the GPRD for any reason including death. Participants with prior history of cancer excluded.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Incident All-cancer Patients | Number of Stomach Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin | Never (with 2 year lag) | 1872 participants |
| Incident All-cancer Patients | Number of Stomach Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin | Tertile 1 (with 2 year lag) | 0 participants |
| Incident All-cancer Patients | Number of Stomach Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin | Tertile 2 (with 2 year lag) | 3 participants |
| Incident All-cancer Patients | Number of Stomach Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin | Tertile 3 (with 2 year lag) | 2 participants |
| Incident All-cancer Patients | Number of Stomach Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin | Never (without 2 year lag) | 1864 participants |
| Incident All-cancer Patients | Number of Stomach Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin | Tertile 1 (without 2 year lag) | 3 participants |
| Incident All-cancer Patients | Number of Stomach Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin | Tertile 2 (without 2 year lag) | 6 participants |
| Incident All-cancer Patients | Number of Stomach Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin | Tertile 3 (without 2 year lag) | 4 participants |
| Matched Controls for Incident All-cancer Patients | Number of Stomach Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin | Tertile 3 (without 2 year lag) | 43 participants |
| Matched Controls for Incident All-cancer Patients | Number of Stomach Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin | Never (with 2 year lag) | 17783 participants |
| Matched Controls for Incident All-cancer Patients | Number of Stomach Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin | Never (without 2 year lag) | 17733 participants |
| Matched Controls for Incident All-cancer Patients | Number of Stomach Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin | Tertile 1 (with 2 year lag) | 22 participants |
| Matched Controls for Incident All-cancer Patients | Number of Stomach Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin | Tertile 2 (without 2 year lag) | 31 participants |
| Matched Controls for Incident All-cancer Patients | Number of Stomach Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin | Tertile 2 (with 2 year lag) | 21 participants |
| Matched Controls for Incident All-cancer Patients | Number of Stomach Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin | Tertile 1 (without 2 year lag) | 46 participants |
| Matched Controls for Incident All-cancer Patients | Number of Stomach Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin | Tertile 3 (with 2 year lag) | 27 participants |
p-value: 0.43195% CI: [0.19, 2.01]Conditional Logistic Regression
p-value: 0.322695% CI: [0.17, 1.79]Conditional Logistic Regression
p-value: 0.620695% CI: [0.4, 4.59]Conditional Logistic Regression
p-value: 0.855795% CI: [0.33, 3.84]Conditional Logistic Regression
p-value: 0.149895% CI: [0.79, 4.62]Unadjusted Odds Ratio
p-value: 0.264595% CI: [0.68, 4.07]Conditional Logistic Regression
p-value: 0.572895% CI: [0.16, 2.79]Conditional Logistic Regression
p-value: 0.372795% CI: [0.12, 2.21]Conditional Logistic Regression
p-value: 0.774395% CI: [0.31, 2.4]Conditional Logistic Regression
p-value: 0.477595% CI: [0.24, 1.94]Conditional Logistic Regression
Primary
Number of Stomach Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin
Incident stomach cancer. Gabapentin (Gaba.) Exposure Description: With 2 year (yr) lag=Gaba. exposure from cohort entry to 2 yr prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer). Without 2 yr lag=Gaba. exposure from cohort entry to index date. Tertiles (T) with 2 yr lag: T 1 (0.01-1.38 months \[mo.\]), T 2 (1.3-5.56 mo.), and T 3 (5.57-105.82 mo.). Tertiles without 2 yr lag: T 1 (0.01-1.38 m.), T 2 (1.39-5.72 mo.), and T 3 (5.73-123.70 mo.). Inestimable OR and 95% CI when no gaba.-exposed cancer cases or controls at the exposure level.
Time frame: The case index date was the date of incident stomach cancer diagnosis ascertained in the GPRD study cohort 1995-2008. The matched control index date was the date at which the follow-up time from his/her cohort entry was the same as that for the case
Population: Cases \& controls drawn from the GPRD study cohort. Entry into study cohort began January 1, 1993, or at time of GPRD registration if after Jan. 1, 1993. Follow-up ended December 31, 2008, or earlier if respective cancer was diagnosed or if participant left the GPRD for any reason including death. Participants with prior history of cancer excluded.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Incident All-cancer Patients | Number of Stomach Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin | Never (with 2 year lag) | 1872 participants |
| Incident All-cancer Patients | Number of Stomach Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin | Tertile 1 (with 2 year lag) | 0 participants |
| Incident All-cancer Patients | Number of Stomach Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin | Tertile 2 (with 2 year lag) | 2 participants |
| Incident All-cancer Patients | Number of Stomach Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin | Tertile 3 (with 2 year lag) | 3 participants |
| Incident All-cancer Patients | Number of Stomach Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin | Never (without 2 year lag) | 1864 participants |
| Incident All-cancer Patients | Number of Stomach Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin | Tertile 1 (without 2 year lag) | 4 participants |
| Incident All-cancer Patients | Number of Stomach Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin | Tertile 2 (without 2 year lag) | 4 participants |
| Incident All-cancer Patients | Number of Stomach Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin | Tertile 3 (without 2 year lag) | 5 participants |
| Matched Controls for Incident All-cancer Patients | Number of Stomach Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin | Tertile 3 (without 2 year lag) | 46 participants |
| Matched Controls for Incident All-cancer Patients | Number of Stomach Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin | Never (with 2 year lag) | 17783 participants |
| Matched Controls for Incident All-cancer Patients | Number of Stomach Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin | Never (without 2 year lag) | 17733 participants |
| Matched Controls for Incident All-cancer Patients | Number of Stomach Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin | Tertile 1 (with 2 year lag) | 24 participants |
| Matched Controls for Incident All-cancer Patients | Number of Stomach Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin | Tertile 2 (without 2 year lag) | 30 participants |
| Matched Controls for Incident All-cancer Patients | Number of Stomach Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin | Tertile 2 (with 2 year lag) | 14 participants |
| Matched Controls for Incident All-cancer Patients | Number of Stomach Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin | Tertile 1 (without 2 year lag) | 44 participants |
| Matched Controls for Incident All-cancer Patients | Number of Stomach Cancer Cases and Matched Controls With the Indicated Duration of Exposure to Gabapentin | Tertile 3 (with 2 year lag) | 32 participants |
p-value: 0.789195% CI: [0.31, 2.43]Conditional Logistic Regression
p-value: 0.621695% CI: [0.27, 2.17]Conditional Logistic Regression
p-value: 0.689395% CI: [0.31, 5.96]Conditional Logistic Regression
p-value: 0.927395% CI: [0.24, 4.84]Conditional Logistic Regression
p-value: 0.59895% CI: [0.47, 3.78]Conditional Logistic Regression
p-value: 0.857295% CI: [0.38, 3.18]Conditional Logistic Regression
p-value: 0.780795% CI: [0.26, 2.77]Conditional Logistic Regression
p-value: 0.557995% CI: [0.21, 2.32]Conditional Logistic Regression
p-value: 0.993295% CI: [0.4, 2.53]Conditional Logistic Regression
p-value: 0.690195% CI: [0.32, 2.11]Conditional Logistic Regression
Primary
Number of Stomach Cancer Cases and Matched Controls With the Indicated Exposure to Gabapentin
Incident stomach cancer. Gabapentin Exposure Description: With 2 year lag = Gabapentin prescription from cohort entry to 2 years prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer). Without 2 year lag = Gabapentin prescription from cohort entry to index date.
Time frame: The case index date was the date of incident stomach cancer diagnosis ascertained in the GPRD study cohort 1995-2008. The matched control index date was the date at which the follow-up time from his/her cohort entry was the same as that for the case
Population: Cases \& controls drawn from the GPRD study cohort. Entry into study cohort began January 1, 1993, or at time of GPRD registration if after Jan. 1, 1993. Follow-up ended December 31, 2008, or earlier if respective cancer was diagnosed or if participant left the GPRD for any reason including death. Participants with prior history of cancer excluded.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Incident All-cancer Patients | Number of Stomach Cancer Cases and Matched Controls With the Indicated Exposure to Gabapentin | Ever (without 2 year lag) | 13 participants |
| Incident All-cancer Patients | Number of Stomach Cancer Cases and Matched Controls With the Indicated Exposure to Gabapentin | Ever (with 2 year lag) | 5 participants |
| Incident All-cancer Patients | Number of Stomach Cancer Cases and Matched Controls With the Indicated Exposure to Gabapentin | Never (without 2 year lag) | 1864 participants |
| Incident All-cancer Patients | Number of Stomach Cancer Cases and Matched Controls With the Indicated Exposure to Gabapentin | Never (with 2 year lag) | 1872 participants |
| Matched Controls for Incident All-cancer Patients | Number of Stomach Cancer Cases and Matched Controls With the Indicated Exposure to Gabapentin | Never (without 2 year lag) | 17733 participants |
| Matched Controls for Incident All-cancer Patients | Number of Stomach Cancer Cases and Matched Controls With the Indicated Exposure to Gabapentin | Ever (with 2 year lag) | 70 participants |
| Matched Controls for Incident All-cancer Patients | Number of Stomach Cancer Cases and Matched Controls With the Indicated Exposure to Gabapentin | Ever (without 2 year lag) | 20 participants |
| Matched Controls for Incident All-cancer Patients | Number of Stomach Cancer Cases and Matched Controls With the Indicated Exposure to Gabapentin | Never (with 2 year lag) | 17783 participants |
p-value: 0.359795% CI: [0.26, 1.62]Conditional Logistic Regression
p-value: 0.184595% CI: [0.21, 1.34]Conditional Logistic Regression
p-value: 0.914295% CI: [0.58, 1.84]Conditional Logistic Regression
p-value: 0.652495% CI: [0.49, 1.57]Conditional Logistic Regression
Primary
Number of Stomach Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin
Incident stomach cancer. Gabapentin Exposure Description: With 2 year lag = Gabapentin exposure from cohort entry to 2 years prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer). Without 2 year lag = Gabapentin exposure from cohort entry to index date.
Time frame: The case index date was the date of incident stomach cancer diagnosis ascertained in the GPRD study cohort 1995-2008. The matched control index date was the date at which the follow-up time from his/her cohort entry was the same as that for the case
Population: Cases \& controls drawn from the GPRD study cohort. Entry into study cohort began January 1, 1993, or at time of GPRD registration if after Jan. 1, 1993. Follow-up ended December 31, 2008, or earlier if respective cancer was diagnosed or if participant left the GPRD for any reason including death. Participants with prior history of cancer excluded.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Incident All-cancer Patients | Number of Stomach Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin | Never (with 2 year lag) | 1872 participants |
| Incident All-cancer Patients | Number of Stomach Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin | > 1 year (with 2 year lag) | 2 participants |
| Incident All-cancer Patients | Number of Stomach Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin | > 2 year (with 2 year lag) | 1 participants |
| Incident All-cancer Patients | Number of Stomach Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin | > 3 year (with 2 year lag) | 1 participants |
| Incident All-cancer Patients | Number of Stomach Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin | Never (without 2 year lag) | 1864 participants |
| Incident All-cancer Patients | Number of Stomach Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin | > 1 year (without 2 year lag) | 3 participants |
| Incident All-cancer Patients | Number of Stomach Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin | > 2 year (without 2 year lag) | 2 participants |
| Incident All-cancer Patients | Number of Stomach Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin | > 3 year (without 2 year lag) | 1 participants |
| Matched Controls for Incident All-cancer Patients | Number of Stomach Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin | > 3 year (without 2 year lag) | 11 participants |
| Matched Controls for Incident All-cancer Patients | Number of Stomach Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin | Never (with 2 year lag) | 17783 participants |
| Matched Controls for Incident All-cancer Patients | Number of Stomach Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin | Never (without 2 year lag) | 17733 participants |
| Matched Controls for Incident All-cancer Patients | Number of Stomach Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin | > 1 year (with 2 year lag) | 15 participants |
| Matched Controls for Incident All-cancer Patients | Number of Stomach Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin | > 2 year (without 2 year lag) | 19 participants |
| Matched Controls for Incident All-cancer Patients | Number of Stomach Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin | > 2 year (with 2 year lag) | 8 participants |
| Matched Controls for Incident All-cancer Patients | Number of Stomach Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin | > 1 year (without 2 year lag) | 33 participants |
| Matched Controls for Incident All-cancer Patients | Number of Stomach Cancer Cases and Matched Controls With the Indicated Long Duration of Exposure to Gabapentin | > 3 year (with 2 year lag) | 4 participants |
Primary
Number of Stomach Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions
Incident stomach cancer. Gabapentin (Gaba.) Exposure Description: With 2 year (yr) lag=Gaba. exposure from cohort entry to 2 yr prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer). Without 2 yr lag=Gaba. exposure from cohort entry to index date. Tertiles (T) with 2 yr lag: T 1 (1-2 prescriptions \[prescrip\]), T 2 (3-7 prescrip), T 3 (8-298 prescrip). Tertiles without 2 yr lag: T 1 (1-2 prescrip), T 2 (3-7 prescrip), and T 3 (8-388 prescrip). Inestimable OR and 95% CI when no gaba.-exposed cancer cases or controls at the exposure level.
Time frame: The case index date was the date of incident stomach cancer diagnosis ascertained in the GPRD study cohort 1995-2008. The matched control index date was the date at which the follow-up time from his/her cohort entry was the same as that for the case
Population: Cases \& controls drawn from the GPRD study cohort. Entry into study cohort began January 1, 1993, or at time of GPRD registration if after Jan. 1, 1993. Follow-up ended December 31, 2008, or earlier if respective cancer was diagnosed or if participant left the GPRD for any reason including death. Participants with prior history of cancer excluded.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Incident All-cancer Patients | Number of Stomach Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions | Never (with 2 year lag) | 1872 participants |
| Incident All-cancer Patients | Number of Stomach Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions | Tertile 1 (with 2 year lag) | 0 participants |
| Incident All-cancer Patients | Number of Stomach Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions | Tertile 2 (with 2 year lag) | 2 participants |
| Incident All-cancer Patients | Number of Stomach Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions | Tertile 3 (with 2 year lag) | 3 participants |
| Incident All-cancer Patients | Number of Stomach Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions | Never (without 2 year lag) | 1864 participants |
| Incident All-cancer Patients | Number of Stomach Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions | Tertile 1 (without 2 year lag) | 3 participants |
| Incident All-cancer Patients | Number of Stomach Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions | Tertile 2 (without 2 year lag) | 7 participants |
| Incident All-cancer Patients | Number of Stomach Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions | Tertile 3 (without 2 year lag) | 3 participants |
| Matched Controls for Incident All-cancer Patients | Number of Stomach Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions | Tertile 3 (without 2 year lag) | 46 participants |
| Matched Controls for Incident All-cancer Patients | Number of Stomach Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions | Never (with 2 year lag) | 17783 participants |
| Matched Controls for Incident All-cancer Patients | Number of Stomach Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions | Never (without 2 year lag) | 17733 participants |
| Matched Controls for Incident All-cancer Patients | Number of Stomach Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions | Tertile 1 (with 2 year lag) | 29 participants |
| Matched Controls for Incident All-cancer Patients | Number of Stomach Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions | Tertile 2 (without 2 year lag) | 19 participants |
| Matched Controls for Incident All-cancer Patients | Number of Stomach Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions | Tertile 2 (with 2 year lag) | 10 participants |
| Matched Controls for Incident All-cancer Patients | Number of Stomach Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions | Tertile 1 (without 2 year lag) | 55 participants |
| Matched Controls for Incident All-cancer Patients | Number of Stomach Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions | Tertile 3 (with 2 year lag) | 31 participants |
p-value: 0.287595% CI: [0.17, 1.7]Conditional Logistic Regression
p-value: 0.204295% CI: [0.15, 1.51]Conditional Logistic Regression
p-value: 0.473395% CI: [0.38, 8.06]Conditional Logistic Regression
p-value: 0.786795% CI: [0.26, 5.85]Conditional Logistic Regression
p-value: 0.004995% CI: [1.47, 8.5]Conditional Logistic Regression
p-value: 0.021895% CI: [1.17, 7.08]Conditional Logistic Regression
p-value: 0.84995% CI: [0.27, 2.92]Conditional Logistic Regression
p-value: 0.626395% CI: [0.22, 2.46]Conditional Logistic Regression
p-value: 0.412295% CI: [0.19, 1.97]Conditional Logistic Regression
p-value: 0.264295% CI: [0.16, 1.66]Conditional Logistic Regression